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Summary 
Current methods for obtaining fetal cells for prenatal diagnosis are invasive and 
carry a small but definitive risk of fetal loss.  Recovery of first trimester fetal 
erythroblasts (NRBCs) in maternal blood represents an attractive and promising 
alternative for early non-invasive prenatal diagnosis.  However, these cells are 
rare and it is technically challenging in recovering them from maternal blood due 
to the lack of a fetal specific surface marker that could be used to isolate fetal 
NRBCs from adult RBCs. 
 
This thesis investigated the membrane protein profiles of first trimester primitive 
fetal NRBCs and adult RBCs using proteomic approaches and 
immunocytochemical screening with an aim to identify unique surface marker(s).  
To enhance the recovery of membrane proteome from a limited amount of fetal 
NRBC sample, an efficient proteomic strategy was developed for membrane 
proteome analysis, that is, sequential use of organic solvents methanol (MeOH) 
and 2,2,2-trifluoroethanol (TFE) to recover both hydrophilic and hydrophobic 
peptides and identification of proteins using two-dimensional liquid 
chromatography coupled with matrix-assisted laser desorption/ionisation-time of 
flight/time of flight tandem mass spectrometry (2-D LC-MALDI-TOF/TOF-MS).  
The use of this strategy to analyse fetal NRBC membrane enabled us to present 
its first relatively comprehensive membrane proteome, and to identify twenty-
three unique fetal NRBC membrane proteins when compared with adult RBC 
membrane proteome.  In addition, three differentially/uniquely expressed surface 
antigens were identified using immunocytochemical screening. 
 
Of the twenty-six potentially useful markers, surface antigen CD147 was tested 
and demonstrated to be a very useful target for the separation of fetal NRBCs 
 X
from adult RBCs in model mixture, by either immunomagnetic cell sorting or 
fluorescence-activate cell sorting.  I envisage that CD147, and/or other potential 
targets after further investigation, would be useful for the development of an 
efficient protocol to isolate fetal NRBCs from maternal blood in the first trimester 
of pregnancy, for early non-invasive prenatal diagnosis. 
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Chapter 1 Introduction 
 
1.1 Overview 
Current prenatal diagnosis of genetic birth defects such as aneuploidies and 
monogenic disorders requires invasive diagnosis by amniocentesis, chorionic 
villus sampling (CVS) and fetal blood sampling (FBS).  These procedures carry a 
1-4% risk of fetal loss (Buscaglia et al., 1996; Lippman et al., 1992; Rhoads et al., 
1989; Tabor et al., 1986; Wald et al., 1998) and 1 in 5 at-risk women (>35 years 
old) would decline the invasive tests (Cuckle 1996; Kocun et al., 2000).  Thus the 
importance of developing non-invasive prenatal diagnosis is significant. 
 
Detection of cell-free fetal DNA in maternal plasma and serum (Lo et al., 1997) 
and enrichment of fetal cells from maternal blood (Bianchi 1997, 1999; Choolani 
et al., 2003) offer an alternative source of fetal DNA for non-invasive prenatal 
diagnosis.  The relatively high concentration of cell-free fetal DNA (Lo et al., 
1997; Lo et al., 1998b) and its rapid clearance after delivery (Lo et al., 1999a) are 
very useful to determine fetal gender in pregnancies as early as 5 gestational 
weeks (Guibert et al., 2003; Ho et al., 2003; Honda et al., 2002) and single gene 
disorders such as RhD status (Lo et al., 1998c; Zhong et al., 2000a) and β-
thalassaemia (Chiu et al., 2002b).  The determination of RhD status using cell-
free fetal DNA in maternal plasma is routine clinical application by the 
International Blood Group Reference Laboratory (IBGRL, UK).  However, 
maternal DNA masks maternally-inherited fetal DNA and thus only paternally-




On the other hand, fetal cells in the maternal blood contain the full complement of 
fetal genes.  Theoretically, all fetal aneuploidies and single gene disorders could 
be detected by analysing these cells.  Since trophoblasts were first found in the 
maternal circulation (Schmorl 1893), other types of fetal cells such as leukocytes 
(Walknowska et al., 1969), progenitor and stem cells (Campagnoli et al., 2001b; 
Little et al., 1997; O'Donoghue et al., 2003) and fetal nucleated red blood cells 
(NRBCs) have been demonstrated to be present in the maternal circulation.  Of 
these cells, fetal NRBCs are considered as an ideal candidate for non-invasive 
detection of aneuploidies and monogenic disorders (Ho et al., 2003), as they are 
short-lived, morphologically distinct from maternal blood cells and have a highly 
specific fetal cell marker useful for their identification (Choolani et al., 2001). 
 
The potential value of fetal NRBCs for non-invasive prenatal diagnosis has led to 
many attempts to enrich these cells from maternal blood (Bianchi et al., 1990; 
Bianchi 1997, 1999; Ganshirt et al., 1994a; Hahn et al., 1998; Holzgreve et al., 
1992; Wachtel et al., 1991).  Attempts using either fluorescence-activated cell 
sorting (FACS) or magnetic-activated cell sorting (MACS) represent the 
commonest and most successful approaches for the enrichment of fetal NRBCs 
from maternal blood.  Both of them usually use density gradient centrifugation to 
remove the bulk of maternal red blood cells (RBCs) followed by an antibody-
based cell separation.  The use of enriched fetal NRBCs could give a 100% 
accuracy in the determination of fetal gender (Bianchi et al., 1993) and 
aneuploidies (Ganshirt-Ahlert et al., 1993).  These initial promising results led to a 
large-scale clinical study called National Institutes of Health Fetal Cell Study 
(NIFTY) (Bianchi et al., 1999).  In this study, either FACS with anti-haemoglobin F 
(HbF) or MACS with anti-CD71 was used to enrich fetal NRBCs from maternal 
blood samples by four participating centres.  The overall sensitivity and false-
positive rate for detection of aneuploidies from the analysis of enriched fetal 
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NRBCs were 74.4% and 0.6-4.1% respectively, which indicated that it could be 
used as a screening tool but not yet for clinical diagnostic application.  Other 
efforts were made to use a more optimal density gradient centrifugation (Samura 
et al., 2000; Sekizawa et al., 1999) or to couple with laser capture 
micromanipulation to isolate fetal cells (Di Naro et al., 2000).  However, the 
complexity of enrichment step would not only cause a significant loss of target 
cells (Huber et al., 1996) but also increase the burden of procedure, rendering 
them to be very time-consuming and cost-ineffective, and thus of little clinical 
value. 
 
The difficulty in current enrichment of fetal NRBCs is due to the rarity of fetal cells 
in maternal blood (Bianchi et al., 1997; Krabchi et al., 2001) and the lack of 
surface markers that could be used to separate fetal NRBCs from adult RBCs.  
The targeting intracellular antigen HbF makes the purification steps subject to 
more cell loss as the fragile fetal NRBCs need to be permeabilised (Huie et al., 
2001); and the use of anti-CD71, which targets surface antigen but is not highly 
specific to fetal NRBCs, does not yield satisfactory results as shown in the NIFTY 
trial.  Moreover, only about 68% of primitive fetal NRBCs express CD71 and the 
expression is weak compared to that of definitive fetal NRBCs (Choolani et al., 
2003), rendering much difficulty in enrichment of primitive fetal NRBCs from 
maternal blood of first trimester pregnancy.  In this thesis, I aimed to identify the 
differential expression of membrane proteins between primitive fetal NRBCs and 
adult RBCs, which can be potentially useful for the development of an efficient 
protocol to enrich primitive fetal NRBCs from maternal blood. 
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1.2 Current methods of prenatal diagnosis 
Currently, there are four prenatal diagnostic methods used to diagnose fetal 
structural, chromosomal and genetic abnormalities.  Ultrasonography is the only 
non-invasive method, and can assess and evaluate gestational age, fetal 
position, growth, development, and many structural birth defects.  When 
performed by highly experienced operators, ultrasonography can detect fetal 
structural abnormalities with up to 96% accuracy (Andrews et al., 1994; Carrera 
et al., 1995; Markov et al., 2006).  However, the use of ultrasonography for the 
detection of chromosomal and genetic abnormalities has relatively low sensitivity 
and specificity (DeVore 2001; Queisser-Luft et al., 1998).  For the major 
chromosomal abnormality of Down syndrome, ultrasonography can only detect 
about 53% of the affected pregnancies (Smith-Bindman et al., 2007).  The other 
three methods (amniocentesis, CVS and FBS) are often used to detect fetal 
chromosomal and genetic abnormalities.  They are highly accurate and reliable 
for diagnosis of fetal chromosomal and genetic abnormalities, but carry a 1-4% 
risk of fetal loss. 
 
Amniocentesis.  Amniotic fluid contains hormones, enzymes and amniocytes.  
The procedure to obtain amniotic fluid is often performed in the second trimester 
of pregnancy (15-18 gestational weeks) for at-risk pregnant women.  In this 
procedure, a thin needle is inserted through abdomen and uterus into amniotic 
sac with ultrasonic guidance and 10-20 ml of amniotic fluid is withdrawn.  The 
levels of hormones (e.g. α-fetoprotein) in the supernatant of amniotic fluid can be 
measured directly for screening various abnormalities such as anencephaly, 
spina bifida and omphalocele (Szabo et al., 1990).  The enzymes and some 
metabolites can be used to detect fetal abnormality as well, but this has been 
largely replaced by molecular testing to achieve higher accuracy.  The cells in 
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amniotic fluid can be cultured and used for analysis of chromosomal 
abnormalities and genetic disorders.  The test results will be obtained within 2-3 
weeks. 
 
Recent use of quantitative fluorescent polymerase chain reaction (QF-PCR) 
assays (Adinolfi et al., 1997; Bili et al., 2002; Cirigliano et al., 2001) and 
fluorescence in situ hybridisation (FISH) (Eiben et al., 1998) to analyse 
uncultured amniocytes have allowed not only fast, but accurate detection of 
chromosomal aneuploidies and genetic disorders.  The results can be obtained 
within hours.  Use of real-time PCR technique to analyse uncultured amniocytes 
has also been demonstrated to be fast, reliable and specific for the diagnosis of 
aneuploidies (Hu et al., 2004). 
 
Chorionic villus sampling.  CVS is performed earlier in pregnancy (10-12 
gestational weeks) as compared with amniocentesis.  Placental villi which protect 
the fetus may be obtained through transcervical or transabdominal access to the 
placenta with ultrasonic guidance.  Large amounts of fetal DNA can be isolated 
from the villi and genetic analysis can be done within 24-48 hours.  This quick 
results and its use at earlier gestational age provide more time for counselling 
and decision-making, and if termination of pregnancy is elected, it can be 
performed much safer at this early stage (Weatherall 1991).  There is no 
difference in fetal loss rates after transcervical or transabdominal CVS (Jackson 
et al., 1992).  However, the risk of miscarriage and other complications after CVS 
is slightly higher than the risk after midtrimester amniocentesis (Caughey et al., 
2006; Lippman et al., 1992; Mujezinovic et al., 2007). 
 
Transabdominal fetal blood sampling.  This method is also called percutaneous 
umbilical blood sampling (PUBS) and is usually performed after 20 gestational 
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weeks.  A needle is inserted into the umbilical vein and fetal blood is drawn.  The 
procedure presents the highest risk of miscarriage and is usually recommended 
only when diagnostic information can not be gathered via other tests or the 
results of those tests are inconclusive.  For example, it may be useful to further 
evaluate chromosomal mosaicism discovered after CVS or amniocentesis is 
performed (ACOG 2007).  
 
1.3 Disadvantages of current prenatal diagnostic tests 
These relate to reliability, safety, accuracy of the procedures, and timing of 
availability of results. 
 
Ultrasonography.  The ultrasonography scanning is the only non-invasive 
diagnostic method and preferred by many women.  However, whether the 
specificity and sensitivity are high enough as a diagnostic method largely 
depends on expertises of operators and the nature of the abnormalities. In 
addition, although significant progress has been made in the ability to detect fetal 
anomalies by ultrasound, some fetal anomalies cannot be detected during early 
pregnancy (Achiron et al., 1991).  Furthermore, this method is mainly limited to 
the detection of structural defects, and used often in conjunction with maternal 
serum α-fetoprotein screening for prenatal screening. 
 
Amniocentesis.  The second trimester amniocentesis is considered as the “gold 
standard” for prenatal diagnosis, but it involves 0.5-1.0% risk of miscarriage 
(Wilson 2000), fetal injury, and maternal complications such as Rh sensitisation 
and chorioamnionitis.  In addition, the procedure is performed at relatively late 
gestational age and the results may not be available until 18 weeks.  Thus, 
termination of pregnancy, when indicated, may not be as safe as that in the first 
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trimester.  The concept of the procedure (e.g., a needle in the abdomen) can be 
very distressing to some women with needle anxiety.  Early amniocentesis, which 
is performed at 10-12 gestational weeks, would provide results earlier.  However, 
higher risks are involved, that include increased risk of fetal loss, a higher rate of 
amniotic fluid leakage, a higher incidence of cell culture failure as well as 
orthopaedic and respiratory problems among children (Himes 1999).  It generally 
takes longer to receive test results because fewer cells are present to initiate the 
cell culture for early amniocentesis.  The Canadian Early and Mid-trimester 
Amniocentesis Trial (CEMAT) Group (Winsor et al., 1999) found the risk of 
miscarriage to be 2.6% for early amniocentesis as compared to 0.8% for the 
second trimester amniocentesis, and the risk of limb-defects after early 
amniocentesis was higher as well (1.3% vs. 0.1%). 
 
Chorion Villi Sampling.  Potential risks associated with this test include 
miscarriage and pregnancy complications.  The risk of fetal loss is slightly higher 
for CVS than amniocentesis in the second trimester and less than early 
amniocentesis (Alfirevic et al., 2003).  Although there were several reports of an 
associations between CVS and limb reduction defects (e.g. missing fingers and 
toes) (Firth et al., 1991; Mastroiacovo et al., 1993), the risk for these 
abnormalities may be only increased when CVS is preformed before 9 weeks of 
gestation (Botto et al., 1996) and this risk relates to the specific device used for 
sampling and the size of the sample.  Other complications after CVS include 
vaginal spotting or bleeding, which may occur in up to 32.2% of patients after 
transcervical CVS is performed. The incidence of vaginal bleeding after 
transabdominal CVS is performed is less than that in transcervical CVS (Brambati 
et al., 2004). The incidence of culture failure, amniotic fluid leakage, or infection 
after CVS procedure is less than 0.5% (Brambati et al., 2004).  
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In addition, CVS has very limited use in the detection of neural tube defects 
(Cunniff 2004).  Some cytogenetic laboratories reported that chromosomes from 
CVS were usually too short to identify micro-deletions or subtle chromosomal 
abnormalities (Nicolaides et al., 1996).  Certain metabolic disorders are not 
expressed in villus cells, preventing prenatal diagnosis by CVS (Delisle et al., 
1999). 
 
Fetal blood sampling.  This procedure is associated with a high risk of 
miscarriage (~2%) (Buscaglia et al., 1996).  Thus, it is usually performed for 
those pregnancies in which the information required about the fetus (e.g. fetal 
blood type, fetal anaemia and infection) cannot be obtained accurately, 
completely, and/or in sufficient time to benefit pregnancy management by other 
prenatal diagnostic procedures.  The main causes of fetal loss are rupture of 
membranes, chorioamnionitis, and puncture of the umbilical artery, bleeding from 
the puncture site and prolonged bradycardia (Antsaklis et al., 1998). 
 
The disadvantages of current prenatal tests related to timing, accuracy, low but 
definite risk of fetal loss, fetal and maternal complications worry many women 
who undergo the procedures.  Because of this and testing costs, only at-risk 
pregnant women determined by screening tests (e.g. serum screening, nuchal 
translucency assessment) are currently offered the invasive prenatal diagnostic 
tests, but 1 in 5 women would decline the invasive tests (Cuckle 1996) and this 
rate is at an increasing trend (Kocun et al., 2000).  Maternal serum analyte 
screening and ultrasound are non-invasive methods, and can identify individuals 
at risk of fetal aneuploidy.  However, their roles in the diagnosis of genetic 
disorders are limited due to the relatively low sensitivity and high false positive 
rate.  Thus, the ideal test for aneuploidies and monogenic diseases should be 
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non-invasive, reliable and early prenatal diagnosis, which would be preferred and 
could be offered to all pregnant women. 
 
1.4 Developmental biology relevant to non-invasive prenatal 
diagnosis 
 
1.4.1 Placental development: the fetal-maternal interface 
One week after fertilisation of an egg, it is developing into blastocyst which 
includes three structures:  the trophoblast, which is the layer of cells that 
surrounds the blastocyst; the blastocoele, which is the hollow cavity inside the 
blastocyst; and the inner cell mass, which is a group of cells at one end of the 
blastocoele.  The inner cell mass develops into the fetus while the 
trophoectoderm implants and eventually become part of the placenta (Cross et 
al., 1994).  In the fully developed placenta Figure 1-1), fetal-derived tissue forms 
“finger-like growths” (villi) that enter and intermingle with the surface layer 
(endometrium) of the uterus.  The fetal circulation extends down to the umbilical 
cord and branches into capillaries inside these villi.  The villi are surrounded by a 
network of intervillous spaces, and the mother's endometrial arteries fill these 
spaces with blood.  Endometrial veins remove the blood from these spaces.  As a 
result, maternal blood continuously flows around the villi.  The villi are the sites for 
exchanging materials between the fetal and maternal circulatory systems.  The 
mother’s body supplies the fetus with oxygen, nutrients, and antibodies, removes 
the fetus’s carbon dioxide and other metabolic waste materials, and helps 
regulate fetal growth and physiology by circulating hormones (Gude et al., 2004).  
The fetus produces hormones that help to bring about changes in the mother's 
body to maintain the pregnancy. 
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Figure 1-1 Placenta and chorionic villi 
 
 
                    Picture from http://www.nucleusinc.com 
 
 
1.4.2 Fetal-maternal trafficking 
The fetal and maternal circulations are separated by the placental membranes.  
However, this barrier is incomplete to both nucleic acid and cellular trafficking 
between fetus and its mother. 
 
Nucleic acid trafficking.  The demonstration of DNA trafficking came in 1997 with 
the application of sensitive modern molecular methods (Lo et al., 1997).  In the 
pioneering study, cell-free fetal DNA was found to be present in both maternal 
plasma and serum.  More recently, the presence of stable fetal RNA in maternal 
plasma was demonstrated (Ng et al., 2003a; Poon et al., 2000).  As the fetal 
nucleic acid has relatively high concentration in maternal circulation (Lo et al., 
1998b) and is quickly cleared out after delivery (Lo et al., 1999a), the use of this 
fetal nucleic acid for the development of non-invasive prenatal diagnosis has 
generated much interest (Lo 2005). 
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Shortly after the finding of fetal DNA in maternal circulation, the presence of 
maternal DNA was described in fetal circulation.  Using real-time PCR 
amplification of maternal specific gene, Lo et al. (2000) found that maternal DNA 
were present in 30% of cord plasma samples (n=50), which is higher than 
maternal cellular fraction in cord blood (24%) (n=50).  In another study, Bauer et 
al. (2002) used QF-PCR amplification of nine short tandem repeat markers and 
found that maternal DNA was present in 43 of 57 (75%) umbilical cord plasma.  In 
contrast to fetal DNA in maternal circulation, maternal DNA has much lower 
concentration in fetal circulation, and is not affected by complications of 
pregnancy such as preeclampsia, suggestive of unequally transferred mechanism 
between fetus and mother (Sekizawa et al., 2003). 
 
Cellular trafficking.  Fetal cells were found in maternal circulation in as early as 
1893, when trophoblasts were described in maternal pulmonary vasculature 
(Schmorl 1893).  Since then, various types of fetal cells, such as fetal 
lymphocytes (Herzenberg et al., 1979; Walknowska et al., 1969), fetal 
erythroblastic cells (Bianchi et al., 1990) and their progenitors (Lo et al., 1994; 
Valerio et al., 1996), and fetal mesenchymal stem cells (O'Donoghue et al., 
2003), have been detected and/or isolated from maternal blood.  Not only can 
fetal cells cross into maternal circulation, but also some of them can persist in 
maternal circulation for years after delivery (Bianchi et al., 1996). 
 
The observation of maternal cells trafficking into fetus was reported since 1960s, 
when routine karyotyping of newborn male infants showed the presence of sex 
chromosome mosaicism (el-Alfi et al., 1969; Turner et al., 1966).  The presence 
of circulating maternal lymphocytes is common in peripheral blood of infants with 
severe combined immunodeficiency syndrome (Pollack et al., 1982).  More 
recently, maternal cells were found in umbilical cord blood (Lo et al., 1996; Petit 
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et al., 1995),  third trimester fetal blood (Petit et al., 1997) and even fetal blood at 
13 gestational weeks (Lo et al., 1998a).  Maternal cells can also circulate in fetal 
blood and/or deposit in all kinds of fetal tissues (Srivatsa et al., 2003). 
 
The bi-directional fetal-maternal trafficking of nucleic acids and cells via placenta 
during pregnancy is well established (Hahn et al., 2005).  The focus is now to 
understand the possible biological significance of fetal cells/DNA in maternal 
circulation and maternal cells/DNA in fetal circulation, and to isolate fetal 
cells/DNA from maternal circulation for non-invasive prenatal diagnosis. 
 
1.4.3 Ontological development of erythropoiesis 
During early human fetal development, two waves of erythropoiesis occur: 
primitive and definitive erythropoiesis.  Primitive erythropoiesis begins in the yolk 
sac as early as day 18 of gestational age (Moore et al., 1970), which produces 
large (~25 µm), nucleated primitive erythroblasts expressing embryonic 
haemoglobin (ε, ζ) (Palis et al., 1998) and some primitive macrophages.  These 
large primitive erythroblasts are predominant cell type in the fetal circulation 
during the first trimester pregnancy (Choolani et al., 2003) and likely cross into 
maternal blood.  The primitive erythroblasts are probably able to enucleate during 
the circulation (Kingsley et al., 2004). 
 
Definitive erythropoiesis originates in the aorto-gonado-mesonephros region, and 
migrates to the fetal liver at about 6 gestational weeks, then spleen and bone 
marrow (Galloway et al., 2003).  It generates definitive erythroblasts that are 
smaller, expressing fetal globins (γ), and these cells terminally differentiate into 
anucleate erythrocytes (Peschle et al., 1985).  Fetal globin is widely used as a 
fetal-specific marker for the enrichment and identification of fetal erythroblasts, 
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but it is not nearly specific enough for accurate fetal erythroblast identification 
because of increased maternal fetal globin production in pregnancy (Pembrey et 
al., 1973) and in β-thalassaemia patient (Weatherall 2000).  In contrast, 
embryonic globins are now favoured because of higher specificity. 
 
Besides their difference in sites of their production, timing, globin expression and 
morphology, primitive and definitive haematopoiesis require different 
transcriptional control and growth regulation.  Definitive haematopoiesis requires 
both transcription factors myb and acute myeloid leukemia-1 whereas primitive 
erythropoiesis does not (Muller et al., 1994; Okuda et al., 1996; Wang et al., 
1996).  Similarly, c-kit receptor tyrosine kinase and its ligand are essential for 
progression into the definitive program, but are not required for the establishment 
of primitive erythropoiesis (Nocka et al., 1989).  In addition, erythropoietin (EPO) 
was found to be essential for maturation of definitive erythroid lineage, but not for 
primitive erythropoiesis (Lee et al., 2001).  These distinct features raise the 
possibility that they could have distinct cell surface antigen profiles as well. 
 
1.5 Non-invasive prenatal diagnosis for chromosomal and single 
gene disorders 
In the last decade, considerable efforts were made on development of non-
invasive or minimally invasive techniques for prenatal diagnosis.  These include 
approaches based on the analysis of fetal nucleated cells in maternal blood, the 
analysis of cell-free fetal DNA and RNA present in maternal plasma and serum, 
and the identification and isolation of fetal trophoblastic cellular elements shed 
into the uterine cavity and the endocervical canal. 
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1.5.1 Transcervical samples 
In 1971, Shettles et al. (1971) observed that fetal cells (trophoblastic cellular 
elements) could shed into the uterine cavity and then into the endocervical canal.  
This opened the possibility of performing minimally invasive prenatal diagnostic 
tests by recovering fetal cells from transcervical cell samples.  The collection of 
transcervical cell samples can be started as early as 5 gestational weeks (up to 
15 gestational weeks).  The recovery rate of fetal cells depends on the expertise 
of operators and the methods used for the collection (Rodeck et al., 1995).  High 
rates of success (70-97%) have been reported using aspiration, lavage, or a 
cytobrush (Adinolfi et al., 2001). 
 
Investigations have demonstrated the usefulness of transcervical samples for 
gender determination (Falcinelli et al., 1998), detection of aneuploidy (Sherlock et 
al., 1997) and RhD phenotype (Adinolfi et al., 1995).  However, poor recovery of 
fetal cells (Overton et al., 1996), contamination by foreign genetic material 
(Antsaklis et al., 1998), and considerable variation in the composition and quality 
of recovered material (Miller et al., 1999) limit its applicability for non-invasive 
prenatal diagnosis. 
 
1.5.2 Fetal DNA in maternal blood 
In 1997, Lo et al. (1997) first demonstrated that cell-free fetal DNA was present in 
maternal plasma and serum using quantitative real-time PCR amplification of fetal 
sex-determining region Y (SRY).  Subsequently, they found that fetal DNA has 
relatively high concentration in both maternal plasma and serum in early and late 
pregnancy (Lo et al., 1998b), and that fetal DNA is quickly cleared from maternal 
circulation after delivery (Lo et al., 1999a).  These characteristics allow the 
diagnostic test by analysing cell-free fetal DNA to be more sensitive, and less 
susceptible to false positive results from previous pregnancy. 
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Two common applications of fetal DNA in maternal circulation are determinations 
of fetal gender and fetal RhD genotype.  A 100% sensitivity and specificity could 
be achieved in fetal gender determination by amplification of fetal SRY gene in 
maternal plasma and serum at as early as 5 gestational weeks (Guibert et al., 
2003; Ho et al., 2003; Honda et al., 2002).  This highly accurate, non-invasive 
determination of fetal gender has important clinical implication in at-risk pregnant 
women bearing a fetus with an X-linked disorder.  RhD genotype determination 
during pregnancies has been validated (Zhong et al., 2000a), and a 100% 
accuracy could be achieved with the use of maternal plasma from second 
trimester of pregnancy onwards (Lo et al., 1998c).  Similarly, a 95-100% 
sensitivity and specificity were achieved in detection of RhD and E allele of RhCE 
using fetal DNA in maternal plasma (Legler et al., 2002). 
 
Use of cell-free DNA to detect many other single gene disorders has been 
explored recently.  These include the detection of achondroplasia (Saito et al., 
2000), myotonic dystrophy (Amicucci et al., 2000), cystic fibrosis and  Huntington 
disease (Gonzalez-Gonzalez et al., 2003a; Gonzalez-Gonzalez et al., 2003b), 
congenital adrenal hyperplasia (Chiu et al., 2002a), and β-thalassaemia (Li et al., 
2005b). 
 
The origin of cell-free fetal DNA in maternal circulation remains unclear, but 
accumulating data suggest that placenta is the major source (Bianchi 2004).  An 
elevated level of fetal DNA was observed in complications of pregnancy, such as 
preeclampsia initiated by a placental lesion (Bianchi 2004), or fetal cytogenetic 
abnormalities (Bianchi 2004; Zhong et al., 2000b).  Thus, the concentration of 
fetal DNA alone may serve as a marker for certain fetal chromosomal 
abnormalities, in particular trisomies 21 and 13.  Indeed, a quantitative study has 
shown that a 2-fold increase in fetal DNA levels for pregnancy with trisomy 21 
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compared to normal cases (Lo et al., 1999b).  However, development and 
standardisation of protocols for quantitation and amplification of fetal DNA would 
be required to make the test of fetal DNA in maternal plasma a clinically relevant 
analytical method. 
 
To date, developments have been achieved in the use of fetal DNA in maternal 
plasma to detect some single gene disorders.  However, the inability to 
distinguish maternally inherited fetal DNA from native maternal DNA is clearly a 
diagnostic impediment.  Moreover, the use of fetal DNA in maternal circulation is 
thus far inapplicable to accurately diagnose fetal chromosomal disorders. 
 
1.5.3 Fetal RNA in maternal blood 
Presence of fetal RNA in maternal plasma was described shortly after the 
detection of cell-free fetal DNA in maternal circulation (Poon et al., 2000).  Fetal 
RNA in maternal plasma is likely present in the form of apoptotic bodies, hence 
rendering them more stable as compared to ‘free RNA’.  Both placenta and 
haematopoietic cells probably contribute to the stable RNA pool in the maternal 
plasma as evidenced by the detection of placenta specific genes (Ng et al., 
2003b) and erythroid specific epsilon/gamma gene (Xu et al., 2003) respectively, 
but probably much of them originates from the placenta (Wong et al., 2005).  
Similar to fetal DNA in maternal circulation, fetal RNA is rapidly cleared following 
delivery (Chiu et al., 2006). 
 
Fetal RNA in maternal plasma is detectable from 4 gestational weeks, and 
increases with the advance of gestational age (Chiu et al., 2006).  Concentration 
of fetal RNA is higher in the carriers of the female fetus than in the carriers of the 
male fetus in the first trimester (Ge et al., 2005).  Elevation of fetal RNA was 
shown in maternal plasma with certain pregnancy disorders such as 
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preeclampsia (Ng et al., 2003b).  Collectively, these may allow profiling of fetal 
RNA in maternal plasma for non-invasive prenatal diagnosis.  In addition, 
circulating fetal RNA can be applied to all pregnancies without the limitations of 
fetal gender.  However, there is lack of fetal- and disease-specific plasma RNA 
marker currently and thus more investigation is needed. 
 
1.5.4 Fetal cells in maternal blood 
As early as in 1893, fetal cells were thought to be present in maternal circulation 
(Schmorl 1893).  However, definitive proof of fetal cells in maternal blood did not 
come until 1960s when leukocytes bearing chromosome-Y-specific DNA 
sequences were detected in maternal blood (Walknowska et al., 1969).  
Successful detection and enrichment of fetal leukocytes using FACS was 
reported in the late 1970s (Herzenberg et al., 1979) and early 1980s (Iverson et 
al., 1981).  More convincing evidence of the existence of fetal cells in maternal 
blood came in the 1990s with the application of modern molecular techniques 
such as PCR and FISH to detect unique fetal DNA sequences from cellular 
components of maternal blood (Bianchi et al., 1990; Bianchi et al., 1992; 
Camaschella et al., 1990; Ganshirt-Ahlert et al., 1993). 
 
Fetal erythroblastic cells have been recovered and identified from maternal blood 
by the combined use of FACS cell sorting and PCR or FISH detection technique 
(Bianchi et al., 1990; Holzgreve et al., 1992).  Trophoblasts have also been 
successfully isolated and identified from an abnormal pregnancy (XXY fetus) 
using FACS and FISH (Cacheux et al., 1992).  Similar results were obtained 
when MACS was used for cell sorting of fetal NRBCs (Ganshirt et al., 1994b; 




However, despite considerable progress in detection and isolation of fetal cells 
from maternal blood, the reproducibility and reliability remain poor, probably 
because of the rarity and variability of fetal cells among pregnancies.  Thus, 
several groups attempted to quantify fetal cells in maternal circulation using either 
unsorted (Bianchi et al., 1997; Hamada et al., 1993; Krabchi et al., 2001) or 
sorted samples (Price et al., 1991).  Bianchi et al. (1997) reported an estimated 1 
fetal cell per ml of maternal blood using quantitative PCR to amplify Y 
chromosome-specific sequence of unsorted maternal blood samples.  However, 
the number may be overestimated in their study in that there were possible false 
positive detections as 25.7% of 109 female pregnancy samples appeared to have 
Y-cell equivalents, and that they included all kinds of fetal cells (e.g. progenitors, 
leukocytes  and lymphocytes), some of which tend to persist postpartum and thus 
could be from a previous pregnancy (Bianchi et al., 1996; Ciaranfi et al., 1977; 
Schroder et al., 1974).  Hamada et al. (1993) examined the frequency of fetal 
cells in maternal blood across three trimesters in unsorted samples using FISH 
technique.  They reported an even higher frequency of fetal cells in maternal 
blood and showed that the frequency of fetal nucleated cells was positively 
correlated with gestational age: fetal cells changed from 1 in 100,000 maternal 
nucleated cells (~10 fetal cells per ml maternal blood) in the first trimester to 1 in 
10,000 at term.  However, using similar method, Krabchi et al. (2001) found only 
2-6 fetal nucleated cells per ml of second trimester maternal blood. 
 
Specifically, Price et al. (1991) quantified fetal NRBCs using sorted blood sample. 
They enriched fetal NRBCs from first and second trimester blood samples before 
invasive procedure using Ficoll density gradient centrifugation and FACS with 
anti-CD71 and anti-Glycophorin A (GPA) antibodies.  PCR amplification of Y 
chromosome-specific sequence gave a ratio of 1 fetal NRBC: 108 maternal 
nucleated cells (equivalent to 1 fetal NRBC in 10 ml of maternal blood).  
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However, this study also has limitations.  First, while CD71 was strongly positive 
on 100% of fetal definitive erythroblasts and on 96% of maternal NRBCs, it was 
only expressed on ~68% fetal NRBCs in the first trimester (Choolani et al., 2003).  
As such, first trimester fetal NRBCs could be lost during FACS sorting.  Second, 
the density of fetal NRBCs varies in a wide range and a significant loss was 
reported even with optimised density gradient centrifugation (Choolani et al., 
2003). 
 
Despite the differences in the observed frequencies of fetal cells in maternal 
blood, there is consensus of elevated fetomaternal cellular trafficking in some 
abnormal pregnancies.  The elevated number of fetal NRBCs in the maternal 
circulation in pregnancies affected by preeclampsia and before the onset of 
preeclampsia symptoms were first shown in 1969 (Jones et al., 1969) and 
confirmed by several recent studies (Al-Mufti et al., 2000; Ganshirt et al., 1998; 
Holzgreve et al., 1998; Simchen et al., 2001).  The increase of fetomaternal 
trafficking in pregnancies with abnormal Doppler of the uterine artery without 
symptoms of preeclampsia (Al-Mufti et al., 2000), fetal growth restriction and 
polyhydramnios (Zhong et al., 2000c) was also observed.  Moreover, it was 
shown of a 6-fold elevation of fetal cells in the maternal blood in pregnancies 
bearing trisomy 21 fetus (Bianchi et al., 1997; Parano et al., 2001), and 2-5 times 
higher in other aneuploid pregnancies including trisomy 18, 13, triploidy (69,XXX), 
aneuploidy (47,XXX, 47,XXY, 47,XYY, 47,XY,r(22),+r(22)) (Krabchi et al., 2006). 
 
The usefulness of fetal cells in maternal blood for non-invasive prenatal diagnosis 
has been demonstrated in gender determination (Bianchi et al., 1993; Mavrou et 
al., 1998), diagnosis of fetal chromosomal aneuploidies (Lin et al., 2002; Wang et 
al., 2000a), and single gene disorders such as Mendelian disorders (Camaschella 
et al., 1990; Cheung et al., 1996), human leukocyte antigen (HLA) 
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polymorphisms, and fetal RhD genotype (Toth et al., 1998).  By examining fetal 
cells isolated from maternal blood, the NIFTY clinical trial demonstrated a 74.4% 
detection rate in the determination of common aneuploidies (13, 18, 21, X and Y), 
with a false positive rate as low as 0.6%, which is slightly better than current non-
invasive methods such as serum screening or ultrasound (Bianchi et al., 1999; 
Bianchi et al., 2002). 
 
1.5.5 Candidate of fetal cells for non-invasive prenatal diagnosis 
Trophoblasts.  As the first fetal cell type found to have crossed into maternal 
circulation (Schmorl 1893), trophoblasts appeared as an attractive cell type for 
non-invasive prenatal diagnosis.  They have distinct morphology which permits 
microscopic identification and are commonly deported into maternal circulation 
extensively during the first trimester pregnancy.  The early separation of this cell 
type came in 1980s.  Goodfellow et al. (1982) reported that trophoblasts were 
detected in 6 out of 10 pregnant women by immunofluorescence stain of sorted 
maternal blood sample.  Since then, many studies have demonstrated successful 
isolation of trophoblasts from maternal blood using other antibodies.  Mueller et 
al. (1990) screened 6,800 antibodies and found five that were specific to 
trophoblasts.  When two of them (FDO161G and FDO66Q) were applied to enrich 
trophoblasts from maternal blood for gender determination, they correctly 
determined fetal sex in 11 out of 12 pregnancies but with 1 false positive result.  
Bruch et al. (1991) isolated trophoblasts from peripheral blood of women bearing 
male fetuses using three monoclonal antibodies (GB17, GB21, and GB25) 
against trophoblasts.  They were able to detect PCR amplification of Y-
chromosome specific sequence in two of three samples.  Van Wijk et al. (1996) 
isolated trophoblasts by depletion of maternal white blood cells (WBCs) using 
anti-α-CDw50 from the enriched mononuclear cells by Percoll density gradient 
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centrifugation, and obtained a 91.7% success rate in fetal gender determination 
(n=36). 
 
However, some recent studies reported the inability to identify trophoblasts in 
maternal blood.  Hviid et al. (1999) could not recover trophoblasts from maternal 
blood using anti-LK26, despite the successful use of this antibody for the 
separation of trophoblasts in spiked sample.  Kuhnert et al. (2000) used anti-
EGF-receptor, which was shown to be specific to trophoblasts (Durrant et al., 
1994), to isolate fetal cells from maternal blood and yielded no fetal cells.  
Similarly, Schueler et al. (2001) used both trophoblast-specific antibodies and 
separation strategies that were successfully used by others (Durrant et al., 1996; 
Mueller et al., 1990) to isolate fetal cells from 30 ml maternal blood in the first 
trimester.  No positive identification was possible with either immunoreactive 
proteins or mRNAs for specific expressed genes for trophoblasts. 
 
These conflict data indicate that although trophoblast deportation is a common 
biological phenomenon, trophoblasts may not be consistently detectable for all 
pregnancies.  Indeed, it is known that trophoblasts are often cleared rapidly by 
the pulmonary circulation in a normal pregnancy (Attwood et al., 1961), and that 
there is apparent paucity of highly specific antibodies for their enrichment.  In 
addition, trophoblasts are part of the placenta, which carries a 1% incidence of 
chromosomal mosaicism (Bianchi 1999).  As such, the isolated trophoblasts may 
not be fully representative of fetal genotype.  Moreover, syncytiotrophoblasts are 
multinucleate and not suitable for FISH analysis of aneuploidy.  Thus, 
trophoblasts do not appear to be a viable candidate for fetal screening using 
maternal blood as the source. 
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Leukocytes.  Walknowska et al. (1969) first described a Y chromosome in 
mitogen-stimulated lymphocytes in blood cells from pregnant women bearing 
male fetuses.  This report provided practical and theoretical implications of 
fetomaternal lymphocyte transfer.  Ten years later, fetal leukocytes were 
recovered from maternal blood using FACS with antibodies against paternally-
derived HLA antigens (Herzenberg et al., 1979) and subsequently, fetal gender 
and HLA type were predicted using the isolated lymphocytes (Iverson et al., 
1981).  However, the clinical use of this cell type is considered somewhat 
impractical in that it requires to perform HLA tests of both parents prior to cell 
sorting and that some apparent fetal lymphocytes in the maternal blood could 
persist years after delivery (Schroder et al., 1974).  Moreover, fetal leukocytes 
were not consistently isolated from maternal blood (Adinolfi 1995). 
 
Stem cells and progenitors.  The problem of the rarity of fetal cells in maternal 
blood could be overcome if the enriched fetal cells can be expanded in vitro.  This 
would allow the amplification of the limited number of cells enriched and thus 
more genetic materials for diagnostic tests.  In this regards, fetal stem cells and 
progenitors would be ideal cell types. 
 
Early, investigators demonstrated some success of in vitro expansion of fetal 
erythroid progenitors isolated from maternal blood (Lo et al., 1994; Valerio et al., 
1996).  However, in a similar experiment, Chen et al. (1998) were not able to 
reproduce these data.  Other groups focused on CD34+ fetal cells because of 
their higher proliferative potential.  Little et al. (1997) found a 0-7 fetal CD34+ 
cells in 20 ml maternal blood.  Coata et al. (2001) reported similar number (0-11 
cells) of fetal cells in 20 ml maternal blood after culturing CD34+ cells.  The small 
number and the inability to recover CD34+ fetal cells from all maternal samples 
limit their potential for clinical tests.  In addition, these cells are able to persist in 
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the maternal circulation for as long as 27 years (Bianchi et al., 1996), thereby 
complicating diagnosis in subsequnt pregnancies. 
 
Campagnoli et al. (2001b) recently identified mesenchymal stem cells in fetal 
blood.  These cells are present in fetal blood from first trimester pregnancy 
onwards and account for 0.4% of fetal nucleated cells.  The frequency of these 
cells declines with gestational age.  Their presence in maternal blood was 
demonstrated in 1 out of 20 post-termination maternal blood by the culture of 
CD45-/GPA- cell fraction (O'Donoghue et al., 2003).  Clearly, this low frequency 
and possible persistence after delivery render this cell type inapplicable for non-
invasive prenatal diagnosis in clinical setting. 
 
Fetal erythroblasts.  The ideal cell type for non-invasive prenatal diagnosis should 
be short-lived within the maternal circulation, morphologically distinct from 
maternal cells, and possess cell surface markers to ease enrichment in all 
pregnancies.  These requirements led to the choice of fetal NRBCs as target 
cells.  Moreover, fetal NRBCs are consistently found in maternal blood during 
pregnancy (Parano et al., 2001), bear a fully representative complement of fetal 
genes, are the predominant fetal cell type in the first trimester gestation fetal 
blood (Thomas et al., 1962), and harbour developmentally-specific markers (e.g. 
embryonic globin). 
 
The transfer of this cell type between mother and fetus is an early documented 
phenomenon (Schroder 1975), but considerable effort to isolate them from 
maternal blood came in 1990s.  Bianchi et al. (1990) successfully enriched fetal 
NRBCs using anti-CD71 and FACS in 75% maternal blood samples prior to 
amniocentesis.  Wachtel et al. (1991) enriched fetal NRBCs using multiparameter 
FACS and correctly determined fetal gender in 17 of 18 pregnancies by PCR 
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amplification of Y-chromosome specific sequences.  Subsequently, Bianchi et al. 
(1993) demonstrated that a 100% gender determination could be achieved using 
enriched fetal NRBCs from either anti-GPA alone or in combination with anti-
CD71 or anti-CD36 enrichment. 
 
One of the earliest use of enriched fetal NRBCs for prenatal diagnosis was 
reported in 1991 (Price et al., 1991).  Many chromosomal abnormalities have 
since been detected using fetal NRBCs enriched by either FACS or MACS 
(Bianchi et al., 1992; Ganshirt-Ahlert et al., 1992; Ganshirt-Ahlert et al., 1993).  
These promising results had led to a large scale clinical trial (NIFTY) to use fetal 
NRBCs in maternal blood for the determination of fetal gender and the detection 
of fetal aneuploidies (Bianchi et al., 2002). 
 
1.5.6 Fetal NRBCs for non-invasive prenatal diagnosis: current state of the 
art 
 
1.5.6.1 Current enrichment of fetal NRBCs from maternal blood 
Due to the rarity of fetal cells in maternal blood, a rapid, simple, and consistent 
procedure for their isolation has to be developed before their clinical applications 
for non-invasive prenatal diagnosis.  During the last decade, many approaches 
were developed to recover fetal NRBCs from maternal blood, that include density 
gradient centrifugation, filtration, selective RBC lysis, charge flow separation, 
lectin-affinity separation and antibody-based separation (Bianchi 1999, 2000; 
Wachtel et al., 2001). 
 
Density.  The buoyant densities of RBCs, WBCs and fetal NRBCs in maternal 
blood are different.  Most of fetal NRBCs have a density close to that of 
mononuclear cells and slightly lower than RBCs.  Thus, density gradient 
 25 
centrifugation can be used as an initial enrichment step to deplete the bulk of 
maternal RBCs.  For this purpose, single, double or triple density gradients have 
been developed as a routine first step to isolate fetal NRBCs from maternal blood 
using either Percoll or Ficoll density solutions (Al-Mufti et al., 1999; Prieto et al., 
2001; Samura et al., 2000). 
 
In 1993, Bhat et al. (1993) described a discontinuous triple density gradient and 
obtained a 25-fold enrichment of fetal NRBCs in their spiking experiment.  
Ganshirt-Ahlert et al. (1993) used a triple density gradient (Ficoll 1077, 1110 and 
1119) that enabled them to recover 100 to 1000 NRBCs from 40 ml of maternal 
blood.  Takabayashi et al. (1995) developed a discontinuous Percoll density 
gradient with which they enriched a mean of 4.1 fetal NRBCs from 2 ml of 
maternal blood (n=11).  Other investigators used continuous Ficoll gradients with 
different densities varying from 1077 to 1119 (Lewis et al., 1996; Oosterwijk et al., 
1998b; Troeger et al., 1999).  In 1999, Sekizawa et al. (1999) introduced an 
appropriate density gradients: Percoll density gradient 1.083 and 1.090, with 
which they recovered a mean of 13.3 and 11 fetal NRBCs from 10 ml maternal 
blood respectively. 
 
The denser gradients allow more fetal NRBCs to be recovered from the gradient 
interface and less fetal cells to settle in the cell pellet (Samura et al., 2000; 
Troeger et al., 1999).  Over time, single denser gradients are preferred and most 
investigators prefer Ficoll 1119.  This density gradient has been shown to be 
useful in the separation of fetal NRBCs from maternal blood (Prieto et al., 2001; 
Samura et al., 2000; Troeger et al., 1999).  In 2003, Choolani et al. (2003) 
showed, in the separation of first trimester primitive fetal NRBCs, that although 
Ficoll 1119 gave the most promising recovery (32%) in all Ficoll solutions, Percoll 
1118 yielded much better recovery rate (64.1%) of fetal NRBCs. 
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More recently, Sitar et al. (2005) described a novel method to enrich fetal NRBCs 
by modifying their densities using non-physiological conditions.  In their study, 
whole maternal blood was suspended into a medium of low pH and slightly high 
osmolarity.  Under such conditions, cell volume perturbations occurred either by 
osmolarity and/or pH changes and the composition of extracellular fluids which 
eventually enlarged the density difference between fetal NRBCs and maternal 
cells.  Fetal NRBCs were then separated from maternal cells (RBCs and WBCs) 
using one-step density gradient centrifugation.  In the study, they could detect 
fetal NRBCs and correctly diagnosed fetal aneuploidies by FISH in all 105 
maternal blood samples. 
 
Enrichment of fetal NRBCs by density gradient centrifugation is currently the most 
commonly used method.  However, this method is associated with an inevitably 
high loss of fetal NRBCs, usually between 30% and 70%.  Meanwhile, the 
resulting fetal NRBCs are still dispersed in a large amount of maternal WBCs.  As 
such, further enrichment would be required, usually by an antibody dependent 
procedure such as FACS or MACS. 
 
Filtration.  Fetal NRBCs are larger than adult RBCs (5-8 µm).  Based on this 
property, fetal NRBCs can be enriched using a molecular filter (non-woven cloth) 
in place of commonly used density gradient centrifugation by filtering through of 
the bulk of maternal RBCs.  This strategy enabled Wachi et al. (2004) to recover 
as many as 19.5 (± 12.8) NRBCs from 3.5 ml maternal blood samples (n=12), 
and 63.6% of them were fetal origin.  The recovery rate of fetal NRBCs were 4.2 
(± 5.0) times higher than commonly used Ficoll density separation.  However, this 
approach has not been used by other groups, probably due to the need to make 
in-house optimal molecular filters. 
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Charge flow separation.  Negative charge on most blood cells is conferred by 
sialic acid molecules and the negative surface charge density on RBCs is 
dependent on the sialic acid content (Suzuki et al., 1998).  As most blood cells 
have their surface charge densities characterised, they can be sorted by charge 
flow separation.  It was demonstrated that fetal NRBCs could be separated from 
maternal blood cells under optimal charge conditions (Shulman et al., 1998; 
Wachtel et al., 1996) but the efficiency is lower compared to that of surface 
antigen based separation. 
 
Lectin-binding method.  The sugar moiety resulted from protein glycosylation on 
the surface of fetal NRBCs and RBCs was suggested to be different (Wachi et al., 
2004).  Such a difference could be used for cell separation by differential lectin-
binding selection.  One of the lectins, Soyabean agglutinin (SBA), recognises N-
acetylgalactosamine and galactose and can simultaneously bind to blood cells 
and polymers coated on plates (Reisner et al., 1981).  The usefulness of SBA for 
the enrichment of fetal NRBCs was recently demonstrated by Kitagawa et al. 
(2002).  In this study, one to several hundreds NRBCs were recovered from only 
2.3 ml of maternal blood in 96% of 131 pregnant women between 6 and 27 
gestational weeks.  In a similar study, Shinya et al. (2004) identified fetal gene in 
all seven cases using SBA isolation, micromanipulation and PCR analysis. 
 
Selective RBC lysis.  RBC lysis in isotonic solutions containing ammonium 
chloride (NH4Cl), ammonium bicarbonate (NH4HCO3), and a carbonic anhydrase 
enzyme inhibitor (acetazolamide) is a function of RBC enzyme activity and 
permeability of cells to the inhibitor.  Carbonic anhydrase is at least 5-fold greater 
and acetazolamide permeability about 10-fold lower in RBCs compared to fetal 
NRBCs (Boyer et al., 1976).  As a result, fetal NRBCs are much more resistant to 
NH4Cl lysis than RBCs.  This characteristic could be used for the development of 
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a protocol to enrich fetal NRBCs from maternal blood by selective lysis of RBCs 
(de Graaf et al., 1999).  However, recent data suggested that the lysis procedure 
may affect the fetal NRBCs by modifying the membrane properties, which causes 
significant clumping and poor cell morphology, and hence has a limited role in 
fetal NRBC enrichment (Choolani et al., 2003). 
 
Intracytoplasmic marker.  Fetal globin (e.g. γ-globin) is expressed predominantly 
in fetal NRBCs but rarely in adult RBCs, and thus can be useful marker for 
enrichment and identification of fetal NRBCs.  DeMaria et al. (1996) developed an 
intracellular staining protocol that combined anti-γ-globin monoclonal antibody 
and Hoechst 33342 to enrich fetal NRBCs using FACS.  In their sorting of spiking 
sample with male umbilical cord cells and female adult, non-pregnant peripheral 
blood mononuclear cells,  the yield of NRBCs was 39-100% with a purity of 59-
73%.  Subsequent FISH analysis demonstrated that 83-100% (mean: 98%) of γ-
globin enriched cells were male, whereas 82-100% (mean: 92.5%) of γ-globin 
negative cells were female.  However, targeting intracellular antigens makes the 
purification steps more subject to cell loss, as the fragile erythroid cells need to 
be permeabilised to make globin chain accessible to these antibodies. 
 
Surface antigen.  At present, no surface antigen highly specific to fetal NRBCs 
has yet been found.  A combination of antibodies is commonly used for 
separating fetal NRBCs from maternal blood.  Possible targeting surface antigens 
include CD45, GPA, CD71, CD36, CD35, CD47 and erythropoietin receptor 
(EPO-r).  GPA is present on all erythrocytes while CD45 is absent.  CD71 is a 
transferrin receptor that is expressed on all cells that incorporate iron such as 
activated lymphocytes, trophoblasts and erythroid cells from the burst forming 
units-erythroid (BFU-e) to the reticulocyte stage (Loken et al., 1987) and definitive 
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fetal NRBCs in maternal blood (Cheung et al., 1996).  CD71, CD36 and EPO-r 
expression are lost beyond the reticulocyte stage, while CD35 is only expressed 
on mature erythrocytes (Telen 2000). 
 
Thus, strategies for enrichment of fetal NRBCs could be developed using EPO-r 
(Valerio et al., 1997), CD71 (Price et al., 1991; Zhong et al., 2000c), CD36 or 
their combinations (Bianchi et al., 1993) after density gradient centrifugation.  
Valerio et al. (1997) showed that the enrichments by anti-EPO-r and anti-CD71 
displayed similar detection sensitivity for fetal gender (55% EPO-r, 61% CD71).  
This relatively low sensitivity was mainly due to the lack of EPO-r and CD71 
expression specificity.  A higher sensitivity could be obtained by enhancing the 
purity of fetal NRBCs using dual MACS sorting, in which depletion of WBCs 
(Ganshirt et al., 1998) was followed by positive selection of erythroid cells.  It has 
been demonstrated that fetal NRBCs could be found in about 70-90% 
pregnancies in a combined use of CD45 with CD14 (Busch et al., 1994; Reading 
et al., 1995) or with CD32 (Andrews et al., 1995; Zheng et al., 1993) to deplete 
maternal nucleated cells and CD71 to select fetal NRBCs. 
 
Bianchi et al. (1993) compared the effectiveness of CD71, CD36 and GPA  alone 
or their combinations for the separation of fetal NRBCs from maternal blood by 
flow sorting.  The use of CD71 and CD36 alone gave 57% and 88% gender 
prediction respectively; whereas the use of GPA alone or in combination with 
CD71 or CD36 gave 100% gender prediction.  This suggested that CD71 alone 
might not be efficient for fetal NRBC enrichment.  Indeed, only some of fetal 
NRBCs express CD71 in healthy pregnancies throughout the first trimester and 
the expression on positive cells was weak compared to that of definitive fetal 
NRBCs (Choolani et al., 2003). 
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Thus, instead of using CD71, some investigators used CD45 and/or GPA for 
selection of fetal NRBCs followed by selective lysis of maternal RBCs (de Graaf 
et al., 1999).  However, the use of anti-GPA for selection is also problematic 
because GPA separation often causes agglutination of non-NRBCs, thereby 
changing both light scatter and fluorescence properties of cells by flow cytometry 
(Lewis et al., 1996) and complicating FISH analysis.  Thus far, there is no specific 
surface marker that can efficiently separate fetal NRBCs from maternal RBCs. 
 
Device for cell sorting.  Systems suitable for cell sorting include Dynal system, 
ferrofluid suspensions, micromanipulation, FACS and MACS.  Of these, FACS 
and MACS are the two most commonly used systems for antibody labelled cell 
sorting. 
 
FACS was first used for isolation of fetal cells by Herzenberg et al. (1979).  FACS 
is able to enrich cells with high purity so that slides with sorted cells can be 
readily scanned manually.  Furthermore, it also allows multiparameter sorting: 
simultaneous analysis of several criteria on a single cell and can be adapted for 
use with intracytoplasmic antigens.  Its limitations are the high cost, high 
maintenance and the need for specially trained laboratory staff.  Reported studies 
and clinical trials suggested that MACS was more suitable than FACS for the 
enrichment of fetal cells from maternal blood, as the target cell recovery and fetal 
cell detection were better with MACS than FACS (Bianchi et al., 2002). 
 
The use of MACS for non-invasive prenatal diagnosis was first recommended by 
Ganshirt-Ahlert et al. (1992).  MACS is a fast and economical bench top 
technique that is able to process higher cell numbers.  This technique can be 
performed without the requirement for equipped personnel.  Positive selection or 
depletion by MACS can be carried out by exploiting the antigenic differences 
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between cells.  The disadvantages include that cell separation can only be 
accomplished in order as cell selection is based on one antigen at a go, and that 
purity is poorer as compared with FACS (Wang et al., 2000b). 
 
1.5.6.2 Identification of fetal origin of enriched NRBCs from maternal blood 
The accuracy of prenatal diagnosis using fetal cells enriched from maternal blood 
depends on the specificity of their identification.  Methods to identify fetal origin of 
enriched cells include the use of morphological criteria, immuno-labelling with 
embryonic (ε, ζ) and fetal (γ) globin, and molecular techniques PCR and FISH to 
detect Y-chromosome specific sequence. 
 
Fetal NRBCs include primitive NRBCs and definitive NRBCs.  Definitive fetal 
NRBCs, which generated from fetal liver, spleen and bone marrow, are usually 
isolated from maternal blood of late first trimester and second trimester 
pregnancy.  These cells contain fetal globin (γ).  It was early suggested that fetal 
origin of NRBCs could be confirmed by labelling intracytoplasmic, 
developmentally-specific fetal globin (Zheng et al., 1993).  Since then, most 
investigators used γ-globin for fetal cell identification (de Graaf et al., 1999; 
DeMaria et al., 1996; Parano et al., 2001).  More recently, it has been suggested 
that the γ-globin mRNA specific probes could be used to detect and isolate fetal 
NRBCs from maternal blood (Larsen et al., 2003).  However, the use of γ-globin 
has its limitation as some of maternal NRBCs also express γ-globin (Pembrey et 
al., 1973).  This “leaky” expression of γ-globin in adults led Cheung et al. (1996) 
to suggest the use of the embryonic ζ-globin instead.  They have demonstrated 
this principle in the case of sickle cell anaemia and also in the case of β-
thalassaemia on micromanipulated, ζ-globin positive NRBCs enriched from 
maternal blood between 10-12 gestational weeks.  However, although ζ-globin is 
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less likely to be present in adult blood cells, its expression exists in adults with the 
α-thalassaemia trait (Chung et al., 1984).  Moreover, its expression is not 
completely switched off after the embryonic period and ζ-globin is present in 53% 
of definitive erythrocytes between 15-22 gestational weeks and 34% at term (Luo 
et al., 1999). 
 
Primitive fetal NRBCs generated from yolk sac are large and contain embryonic 
globins and fetal globin.  Thus, it is possible that primitive NRBCs, enriched from 
first trimester pregnancy, can be identified morphologically, but more conclusive 
evidence has been usually achieved by immuno-labelling with embryonic globin.  
The use of ζ-globin for fetal NRBC identification has its limitation as discussed 
above.  The ε-globin was earlier demonstrated to be present in male fetal NRBCs 
from post-CVS maternal blood samples (Mesker et al., 1998).  Subsequently, 
Mavrou et al. (1999) described the use of ε-globin for the identification of fetal 
NRBCs from supernatant fluid during CVS procedure and suggested that it was 
more reliable and specific than ζ-globin for the identification of fetal NRBCs in 
maternal blood, which was confirmed by other studies (Choolani et al., 2003; 
Christensen et al., 2003). 
 
The use of fetal specific protein expression for identification of fetal NRBCs has 
an important role currently.  However, modern molecular techniques FISH and 
PCR for the detection of fetal specific gene (Y-sequence in male pregnancy, or 
paternally inherited fetal HLA-DQa gene sequences (Geifman-Holtzman et al., 




1.5.6.3 Diagnosis of chromosomal and monogenic disorders by analysing fetal 
NRBCs from maternal blood 
The three most important molecular techniques that have allowed genetic 
analysis of enriched fetal cells are PCR, reverse transcription-polymerase chain 
reaction (RT-PCR) and chromosomal FISH. 
 
PCR.  The ability of PCR to amplify minute quantities of DNA over a billion-fold, in 
particular, in combination with micromanipulation to reduce PCR noise, has been 
exploited by several investigators to demonstrate the possibility of prenatal 
diagnosis of monogenic disorders using fetal cells enriched from maternal blood.  
Sekizawa et al. (1996) demonstrated that it was possible to select a single fetal 
NRBC by micromanipulation and to potentially diagnose genetic conditions such 
as Duchenne muscular dystrophy by PCR.  One limitation of that study was that 
NRBCs identified by morphology alone were presumed to be fetal.  Cheung et al. 
(1996) used micromanipulation to pick ζ-globin positive NRBCs and correctly 
diagnosed fetal haemoglobinopathy in two pregnancies between 10-12 
gestational weeks.  The usefulness of micromanipulation prior to PCR has since 
been confirmed by Watanabe et al. (1998) who demonstrated the prenatal 
diagnosis of the X-linked ornithine transcarbamylase deficiency syndrome and by 
Samura et al. (2001) who demonstrated the adjunctive use of PCR and FISH to 
correctly diagnose trisomy 21.  Other investigators have used fluorescent PCR to 
detect single gene defects and/or aneuploidy (Griffin et al., 1999; Osborne et al., 
2005).  The main advantage of single-cell PCR based analysis is the relative high 
efficiency and specificity.  The disadvantage is that the collection of single cells 
needs a lot of experience with regard to micromanipulation and transferring the 




RT-PCR.  In cells expressing a particular gene, there are many more copies of 
the RNA message compared with only one or two alleles within the genome.  
Thus, RT-PCR for the analysis of fetal mRNA could be more sensitive than PCR 
amplification of genomic DNA.  Indeed, a double sensitivity for the non-invasive 
prenatal diagnosis of fetal RhD status using RT-PCR was observed (Al-Mufti et 
al., 1998).  However, a later study showed that PCR detection of fetal DNA in 
maternal plasma was more sensitive than RT-PCR detection of fetal RNA, as 
fetal RNA is more susceptible to enzymatic degradation in maternal blood than 
fetal DNA (Poon et al., 2000).  These conflict data suggested that the value of 
RT-PCR in non-invasive prenatal diagnosis remains controversial. 
 
Chromosomal FISH.  The place of FISH in non-invasive prenatal diagnosis has 
been firmly established.  Price et al. (1991) demonstrated the use of this 
techniques in the prenatal diagnosis of trisomies 18 and 21.  Elias et al. (1992) 
extended these observations by diagnosing fetal trisomy 21 in the maternal blood 
of a 42-year-old woman taken before CVS.  The first series was reported by 
Ganshirt-Ahlert et al. (1993) who confirmed five cases of trisomy 18 and ten 
cases of trisomy 21 using NRBCs enriched from maternal blood.  Subsequently, 
Trisomy 13 was also reported to be non-invasively diagnosed by FISH analysis at 
11 gestational weeks pregnancy (Oosterwijk et al., 1998b).  Ever since, many 
studies have reported to non-invasively detect these commonest trisomies using 
fetal NRBCs from maternal blood by FISH (Hromadnikova et al., 2002; Yang et 
al., 2003). 
 
Meanwhile, non-invasive diagnosis of other chromosomal abnormalities was also 
reported by FISH analysis of enriched fetal cells.  Cacheux et al. (1992) showed 
the reliable detection of sex chromosome aneuploidy and Bischoff et al. (1995) 
could detect sex chromosome mosaicism.  Similarly, Pezzolo et al. (1997) 
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described to correctly diagnose fetal triploidy by FISH on enriched fetal cells.  
Some investigators attempted to increase the number of chromosomes that could 
be analysed by interphase FISH by performing simultaneous, dual-colour (Al-
Mufti et al., 1999) and multicolour FISH (Bischoff et al., 1998) or by sequential 
hybridisation of chromosome pairs (Zhen et al., 1998).  The main advantage of 
FISH is that the counting of fetal cells could be realised automatically in the 
future.  With such automatic analysis it could be possible to examine a large 
number of cells in short time; it could also be more sensitive than manual 
evaluation (Oosterwijk et al., 1998a).  The disadvantage of FISH for fetal cells is 
low efficiency as compared to PCR. 
 
1.6 Challenges to the use of fetal NRBCs in maternal blood for non-
invasive prenatal diagnosis 
The initial promising results using fetal cells in the maternal blood to diagnose or 
screen fetal chromosome abnormalities, either by PCR, RT-PCR or FISH had led 
to a large scale clinical trial (NIFTY) (Bianchi et al., 1999).  However, the 
relatively low accuracy to detect fetal aneuploidies indicates that currently fetal 
cells derived from maternal blood could only be used alone or (more likely) in 
combination with other modalities (e.g. biochemical tests) as a screening method, 
but not yet as a diagnostic tool.  This is mainly due to the difficulty in recovering 
enough fetal NRBCs from maternal blood.  Thus, while some researchers are 
working to improve the efficiency of enrichment techniques, other groups 
attempted to expand fetal erythroblasts in vitro before or after the enrichment. 
 
1.6.1 Inability to expand fetal cells from maternal blood in vitro 
Fetal erythroid cells are more sensitive to EPO than their adult counterparts 
(Weinberg et al., 1992).  Thus it is possible to preferentially expand fetal erythroid 
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cells over adult cells under an EPO-enriched culture medium (Lo et al., 1994).  
Indeed, the formation of colony forming unit (CFU)-erythroid containing fetal cells 
by culturing anti-EPO selected cells was demonstrated (Valerio et al., 1996) but 
these results were not reproduced by independent group (Chen et al., 1998).  
More recently, Han et al. (1999) developed an optimal two-phase liquid culture 
protocol to expand fetal erythroid cells: mononuclear cells from maternal blood 
were firstly cultured for 4-5 days and non-adherent cells were re-cultured with 
EPO for another 3-4 days.  They found that fetal erythroid cells were up to about 
5.7% of the total erythroid cells displayed by fetal globin staining, and that male 
DNA was detectable by PCR in 7 out of 10 cases.  However, 4 out of the 7 SRY 
positive pregnancies and one of SRY negative pregnancy were actually bearing 
male fetuses.  This suggests the low sensitivity and specificity of the culture 
protocol.  Other efforts were made to optimise fetal erythroid cell selection 
methods and/or culture conditions using model experiment where a known 
number of fetal cells were spiked with adult blood (Bohmer et al., 2002; Huber et 
al., 2000).  It was often shown that an optimised culture condition for fetal cell 
preferential growth could be developed, but when similar culture condition was 
applied to maternal blood, no fetal cell could be detected by FISH or PCR 
analysis.  Similar scenario occurred in the attempts to culture fetal progenitor 
cells.  Jansen et al. (2000) showed that fetal cord blood CD34+ cells were 
expanded in a 1500-fold over their maternal counterpart in spiking experiment, 
but no preferential growth of fetal cells was observed in maternal blood samples.  
Similarly, CD34+ fetal haematopoietic progenitors were shown to selectively 
expand in vitro in model mixture (Campagnoli et al., 2002) but not in maternal 
blood samples (Manotaya et al., 2002). 
 
Some attempts were also made to culture the whole mononuclear cells from 
maternal blood.  This idea is attractive due to its simple step and thus minimal cell 
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loss.  With this strategy, Tutschek et al. (2000) reported a successful culture and 
isolation of single clones of fetal progenitor cells.  If this could be reproduced or 
confirmed by other groups, it would ease the recovery of fetal cells from maternal 
blood and non-invasive prenatal diagnosis would be possible in the near future.  
However, the results were questioned by several independent groups 
(Campagnoli et al., 2001a; Zimmermann et al., 2002). 
 
Thus, although many efforts for optimal fetal cell culture conditions that favour the 
proliferation of fetal over adult cells have been made, the culture of fetal 
haematopoietic cells from maternal blood samples has not yet been achieved 
reproducibly.  The inability to expand fetal erythroid progenitors in vitro from 
maternal circulation might be due to the fact that the frequency of expandable 
fetal haematopoietic progenitor cells in maternal blood are very rare or that they 
require some as yet unidentified culture conditions (Elicha Gussin et al., 2002).  
To overcome all the difficulties, our group chose to in vitro expand fetal primitive 
erythroblasts using a novel nuclear reprogramming strategy and achieved 
encouraging results (Choolani and Zhang, unpublished data). 
 
1.6.2 Lack of cell surface markers specific to fetal NRBCs 
As discussed in section 1.5.6.1, majority of studies have used density gradient 
centrifugation followed by anti-CD71 in combination with MACS or FACS to 
enrich fetal NRBCs from maternal blood (Al-Mufti et al., 2003; Bianchi et al., 
1990; Ganshirt et al., 1998; Hennerbichler et al., 2003).  However, the recovery of 
less dense fetal NRBCs during density gradient centrifugation is accompanied by 
a significant cell loss and a high contamination by maternal cells, mainly WBCs, 
which may complicate subsequent purification and identification of fetal NRBCs.  
Moreover, CD71 is not highly specific to fetal NRBC marker (Larrick et al., 1979).  
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These may explain the low efficiency of current protocols for the isolation of fetal 
NRBC from maternal blood. 
 
Several attempts were made to search for a more specific marker for fetal 
NRBCs.  Zheng et al. (1997) found FB3-2 and H3-3 to be more specific to fetal 
cells compared to CD71 and were suitable for fetal cell enrichment.  However, 
there is no further application of these antigens.  Troeger et al. (1999) compared 
the expression of five antigens-CD71, GPA, HAE9, CD36 and i type antigen and 
found that i blood type antigen was most fetal cell specific, but subsequent 
attempts to enrich fetal NRBCs from maternal blood samples using anti-i antibody 
yielded no fetal cell. 
 
With an aim to produce more specific antibodies against fetal NRBCs, Alvarez et 
al. (1999) used hybridoma technology to generate fetal NRBC specific antibodies.  
One of the generated antibodies was shown to be useful in the enrichment of 
fetal NRBCs from maternal blood.  However, subsequent characterisation 
showed that this antibody was targeting a known surface antigen (CD71).  In 
another study, Huie et al. (2001) used a phage library screening approach to 
generate fetal liver NRBCs specific antibodies and yielded a panel of antibodies 
which may also target known antigens: CD71, CD36, I/i etc.  Although some of 
these generated antibodies were suggested to have a higher specificity 
compared to commercial anti-CD71 (Fernandez et al., 2005), data demonstrating 
their successful application for the enrichment of fetal NRBCs from maternal 
blood are very limited.  Moreover, these antibodies might have very limited role in 
the isolation of fetal cells from first trimester pregnancy as liver fetal NRBCs were 
used for antibody production. 
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Many attempts to identify antibodies more specific to fetal NRBCs have been 
made as mentioned above, but all of them are far from satisfactory.  The recent 
advance of mass spectrometry (MS) based “proteomics” is a highly sensitive and 
high throughput method for the protein identification, and thus offers an 
opportunity for a comprehensive analysis of surface antigens.  Proteomic 
approach was explored in my study to investigate the surface antigens expressed 
on the membranes of primitive fetal NRBCs and adult RBCs. 
 
1.7 Proteomics for protein identification and biomarker discovery 
The term “proteomics” was coined in 1995 as global analysis of the proteins 
expressed in a cell and/or tissue (Wasinger et al., 1995).  MS is currently most 
important tool for proteomic study.  In the last decade, the advance of two key 
elements, MS technology and various genome projects, has allowed detection 
and identification of relatively low abundance proteins.  Concurrently, 
considerable effort has been focused on and thus improved sample preparation 
and separation to reduce sample complexity prior to MS analysis, which further 
enhances the yield of low abundance proteins.  The integration of good sample 
preparation, sensitive MS and powerful data analysis has now enabled efficient 
protein identification from a complex sample and become a major tool for 
biomarker discovery. 
 
1.7.1 Sample preparation for proteomic study 
Despite the use of high performance technology for protein separation (e.g. 
HPLC) and identification (e.g. sensitive MS), study of proteome presents 
considerable challenge because of their extraordinary complexity and vast 
dynamic range of proteins in cells, tissues, body fluids and organisms (Banks et 
al., 2000).  In human cells, for example, actin could have a concentration up to 
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108 molecules per cell (Corthals et al., 2000), whereas some cellular receptors 
are present at only 102-103 molecules per cell.  Such a dynamic range (105-106) 
limits the simultaneous identification of both high abundance and low abundance 
proteins.  This situation is even worse in some tissues or body fluids (e.g. serum 
and plasma), where dynamic range is up to 109.  Thus, it is often required to 
prepare partial proteomes of a given sample in order to maximise the coverage of 
the proteome and to increase the chance to identify low abundance proteins.  At 
present, two approaches are commonly used for this purpose, that is, 
conventional sample fractionation based on chemical and physical properties 
(e.g. density, size, solubility) and affinity separation based on biological properties 
of a sample.  More details of these methods are reviewed below. 
 
1.7.1.1 Conventional sample fractionation 
Differential centrifugation.  The process of differential centrifugation is based on 
the fact that organelles have difference in size, shape and density.  As a result, 
the effect of gravity on each is different, which make it possible to isolate them by 
centrifugation.  Often, cells and tissues are first homogenised and then applied to 
differential centrifugation that leads to several distinct fractions: (1) nuclei, heavy 
mitochondria, cytoskeletal networks and plasma membrane, (2) light 
mitochondria, lysosomes and peroxisomes, (3) Golgi, endosomes and 
microsomes, and (4) cytosol fraction (Huber et al., 2003).  Differential 
centrifugation can also be used in combination with density gradients such as 
sucrose, Percoll, or Nycodenz gradients to isolate highly pure organelles.  Bell et 
al. (2001) used sucrose density gradient to purify Golgi and subsequently 
identified a large number of Golgi membrane proteins including a novel Golgi-
associated protein using one-dimensional gel electrophoresis (1-DE) and MS.  
Similar approach has also been applied to the analysis of mitochondria (Hanson 
et al., 2001) and nucleus (Andersen et al., 2002), where a large set of proteins 
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including a number of novel proteins were identified respectively.  Murayama et 
al. (2001) described a novel approach that used Nycodenz solution for 
fractionation of organelles from rat liver homogenate and two-dimensional gel 
electrophoresis (2-DE) for subsequent analysis.  They showed that this protocol 
allowed separating endoplasmic reticuli (ER), lysosomes, mitochondria, and 
peroxisomes in a single step.  The application of selective purification of cellular 
organelles for proteomic study was recently reviewed (Jung et al., 2000) and has 
meanwhile led to numerous efforts concerning organelle proteomics (Huber et al., 
2003; Li et al., 2005a). 
 
In addition to isolation of organelles based on their native densities, several 
groups demonstrated successful fractionation of a specific cell compartment by 
modifying its density.  De Duve group purified lysosomes from rat liver after using 
Triton WR-1333 to modify its density (Leighton et al., 1968).  Gupta and 
Beaumelle group used colloidal gold to coat endocytic organelles and plasma 
membranes for their purifications respectively (Beaumelle et al., 1990; Gupta et 
al., 1989).  The usefulness of this strategy for proteomic study has been recently 
demonstrated.  Rahbar et al. (2004) reported a large number of plasma 
membrane proteins from cancer cell membranes purified by cationic colloidal 
silica coating and differential centrifugation.  Similarly, Derr et al. (2004) isolated 
plasma membranes from luminal endothelial cells (ECs) of rat lungs and from 
cultured rat lung microvascular ECs using a modified silica-coating methodology.  
They selectively coated the luminal EC surface by perfusing lung vasculature via 
pulmonary artery in situ, and coated cultured rat lung microvascular ECs by 
overlaying confluent monolayers of cell culture.  Both silica-coating methods 




The advantage of differential centrifugation is that a high purity target 
compartment can be obtained and thus allowing to recover a more 
comprehensive proteome.  However, this method requires a relatively long 
process time, and the yield is very low and hence a large amount of starting 
material is required (Lehner et al., 2003). 
 
Sequential extraction.  In this method, cells or tissue samples are solubilised in 
different solvents sequentially to extract proteins with differing properties.  It can 
be used alone or in combination with differential centrifugation to reduce protein 
cross-contamination from different organelles.  Detergent Triton X-100, Triton X-
114, Tween-40 and sodium dodecylsulfate (SDS) are often used in this method.  
Nonionic detergent Triton X-100 is very useful for the separation of Triton-soluble 
membrane proteins from cytoskeleton proteins (Patton et al., 1989; Patton et al., 
1990).  Triton X-114 can be used to fractionate cells or tissue sample into 
cytoskeleton, membrane and cytosol fraction (Bordier 1981).  The combined use 
of Triton X-100 with EDTA and Tween-40 allows a more dedicate fractionation 
that can separate cell lysate into four distinct fractions: cytosol, 
membrane/organelle, nuclear and cytoskeletal fractions (Ramsby et al., 1994).  
The steroidal compound digitonin, which enhances the permeability of cell 
membrane, is widely used to extract cytosolic proteins and/or purification of 
membrane proteins for MS analysis (Foucher et al., 2006; Heinemeyer et al., 
2004; Hoffmann et al., 2001; Lehner et al., 2003; Nielsen et al., 2005). 
 
Use of Triton X-114 to extract a specific class of proteins provides a significant 
advantage for the identification of low abundance proteins.  Taylor et al. (2000) 
presented a first relatively comprehensive rat liver Golgi protein map by the 
combined use of Triton X-114, 2-DE and MS.  Bell et al. (2001) applied similar 
approach to analyse hepatic Golgi and identified 81 proteins including a novel 
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Golgi-associated protein of 34 kDa.  Sinha et al (2005) used this method to 
analyse membranes of Mycobacterium tuberculosis and successfully identified 
105 membrane proteins including 9 new proteins. 
 
Triton X-100 is extensively used in the study of lipid raft proteins.  Lipid rafts are 
glycolipid- and cholesterol-enriched membrane microdomains containing many 
proteins that are important for the molecule transporting and cell signalling, and 
they are insoluble or resistant to Triton X-100.  The purification of lipid rafts can 
thus be achieved by separating lipid rafts from Triton X-100 soluble fraction.  
Indeed, this approach has been used by many researchers to mine lipid raft 
proteins.  Blonder et al. (2004b) analysed lipid rafts of Vero cells from Triton X-
100 insoluble fraction using liquid chromatography (LC) coupled with MS/MS, and 
identified 380 proteins including a large number of integral membrane proteins 
(24%).  In a similar approach, Li et al. (2004) identified 71 proteins including 45 
novel proteins from monocyte lipid rafts.  Borner et al. (2005) analysed proteins 
from Triton X-100 insoluble extracts of plant cells (Arabidopsis callus) and 
identified many “lipid raft proteins”, suggesting that lipid domain phenomena was 
also present in plant cell membranes. 
 
Use of organic solvents for protein fractionation, in particular membrane protein 
fractionation, was recently reported.  The propensity of hydrophobic proteins to 
partition in organic chloroform/methanol (CHCl3/MeOH) phase rather than water 
allowed the successful enrichment of membrane proteins from chloroplast cells 
(Ferro et al., 2000) and rat liver cells (Zhang et al., 2006).  In these studies, not 
only a high number of peripheral membrane proteins but also integral membrane 
proteins were identified.  In another phase partition mixture of chloroform/ 
trifluoroethanol (CHCl3/TFE), TFE phase was able to satisfactorily extract 
membrane proteins with a wide range of properties (Deshusses et al., 2003).  
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Similar use of CHCl3/TFE mixture for membrane protein extraction enhanced the 
resolution of spots, and allowed double the number of spots to be visualised in 2-
DE when compared with membrane extraction using 1% SDS buffer (Zuobi-
Hasona et al., 2005).  These observations indicate a higher efficiency for 
membrane protein extraction using the organic solvent TFE compared with strong 
detergents such as SDS. 
 
1.7.1.2 Affinity enrichment 
Affinity separation is one of the most powerful sample preparation techniques.  It 
utilises the interactions between target proteins and ligands (e.g. biotin, lectin, 
antibodies) which are either immobilised with a solid support surface or by 
inclusion in the pores of a porous solid matrix.  The proteins captured by the 
ligands can be released under certain conditions (e.g. high pH, high salt) and 
thus lead to the enrichment of target proteins.  Commonly used affinity separation 
methods include biotin affinity, lectin affinity, metal binding, hydrophobic binding 
(reversed phase) and immunoaffinity. 
 
Biotinylation.  Biotin affinity separation is utilising the interaction between primary 
amino groups of proteins and biotinylation reagent.  Hydrophilic biotinylation 
reagent S-NHS-LC-biotin has been shown to be effectively label almost all 
detectable proteins but unable to access hydrophobic membranes (Bradburne et 
al., 1993), which makes it possible to selectively purify cell surface proteins by the 
biotinylation.  Indeed, Sabarth et al. (2002) used this strategy to enrich surface 
proteins of Helicobacter pylori.  Subsequent analysis of the enriched membrane 
using 2-DE and MS enabled them to identify 18 surface proteins which include 9 
novel proteins.  Shin et al. (2003) applied a similar approach to analyse surface 
membrane proteins of cancer cells, and discovered that many chaperone proteins 
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(e.g. GRP94, GRP78, GRP75, HSP90A/B, HSP70, HSP60, HSP54) were present 
at the surface membrane of cancer cells. 
 
Besides direct biotin affinity purification, proteins can be purified by indirect biotin 
labelling.  For example, many phosphorylated proteins (e.g. phosphoserine), 
which often bind avidin, can be labelled with avidin beads, and separated through 
an immobilised biotin column (avidin-biotin interaction) (Thaler et al., 2003).  
However, this technique does not work for phosphotyrosine and has limited use 
for phosphothreonine due to poor reactivity.  An alternative was to perform site-
specific modification of phosphoseryl/phosphothreonyl residues, based on the 
fact that the phosphate moiety on these residues is labile and can be chemically 
replaced by biotinylated moieties (Oda et al., 2001).  The target proteins can then 
be purified by the affinity handles using immobilised avidin column through the 
interaction with the added biotinylated moiety. 
 
Lectin affinity.  Lectins are proteins that can specifically bind carbohydrate 
components (Rudiger et al., 2001).  This specificity forms the basis for various 
lectin-based affinity separations of glycoproteins and glycopeptides.  Lectin 
affinity separation is fast and targets specific molecular species or classes of 
glycoproteins (Geng et al., 2001), and can be used to analyse membrane 
glycoproteins (Ghosh et al., 2004).  Combined use of different lectins (e.g. Wheat 
Germ Agglutinin, Concanavalin A, Elderberry lectin, Maackia amurensis lectin) 
yields more types of glycoproteins and is useful for global study of glycoproteins 
in cells or body fluid:  Zhao et al. (2006) demonstrated the usefulness of this 
strategy for the identification of serum biomarkers of pancreatic cancer patients.  
In their study, after depletion of the 12 high abundance proteins by an IgY-12 
antibody column, they enriched sialated glycoproteins from normal and cancer 
serum using three different lectin columns.  The comparative proteomic analysis 
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of the enriched samples enabled them to identify a pancreatic cancer marker 
(sialylated plasma protease C1 inhibitor). 
 
Metal binding.  It has been estimated that more than 30% of the proteins in a 
given mammalian cell are phosphorylated (Larsen et al., 2005).  These proteins 
are usually low abundant but play an essential role in many cellular processes 
(e.g. proliferation, differentiation, and apoptosis).  To efficiently study these 
proteins, it is often required to perform some enrichment procedures prior to MS 
analysis.  Immobilised metal affinity chromatography (IMAC) (e.g. Fe3+ or Ga3+ 
columns) allows selectively bind negatively charged phosphate groups from 
mixture (Larsen et al., 2001) and thus is very useful for the enrichment of 
phosphorylated proteins for MS analysis (Schmidt et al., 2007).  The use of  
multiple IMAC columns (Cu2+, Ni2+ and Zn2+) would enhance the overall recovery 
of various phosphoproteins (Sun et al., 2005). 
 
Reversed phase liquid chromatography (RP LC).  RP LC separations are based 
on hydrophobic interactions between the immobilised RP material and target 
proteins.  The captured proteins by RP LC column can be eluted out by 
increasing the proportion of an organic solvent in the mobile phase, thereby 
gradually eluting more hydrophobic proteins.  This approach allows not only 
efficient separation but also concentration of low abundance proteins, which 
helps to visualise and identify low abundance proteins.  Indeed, Van den Berth et 
al. (2003) compared 2-DE patterns of tissue lysates with and without RP LC 
fractionation and found that significant more protein spots were observed in RP 
LC fractionated sample as compared to unfractionated tissue lysate.  Similar 
approach and results have been shown in the analysis of human breast epithelial 
cell lysates (Reid et al., 1998). 
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Immunoaffinity separation.  When an immune protein is used as the ligand to 
target a specific protein, the affinity separation can be termed as immunoaffinity 
separation.  Its application involves enrichment or depletion of a specific protein 
or a class of proteins.  One of its common applications is to deplete abundance 
proteins in serum and plasma using antibody immobilised on a matrix (e.g. 
sepharose).  Brzeski et al. (2003) used this strategy to remove an abundance 
protein (albumin) from plasma and showed an improved spot detection for 
glycoprotein analysis in 2-DE.  Pieper et al. (2003) developed a more efficient 
method by using a multi-component immunoaffinity chromatography column.  Ten 
high abundance proteins (albumin, IgG, IgA, transferrin, α-1-antitrypsin, 
haptoglobin, α-2-macroglobulin, hemopexin, α-1-acid glycoprotein, and α-2-HS 
glycoprotein) were selectively removed in this method and as a result, 350 low 
abundance proteins were identified from the depleted plasma sample. 
 
In summary, various sample preparation or fractionation methods are available to 
reduce sample complexity and to enrich low abundance proteins.  Clearly, there 
is no simple universal strategy that is suitable for all proteomic analyses.  Each 
specialised method has its advantages and disadvantages.  The values of these 
methods must be weighed in relation to the specific samples and specific 
application. 
 
1.7.2 Protein separation techniques 
Prior to analysis by MS, a mixture of proteins or peptides, even after dedicate 
sample fractionation, must be further separated to reduce sample complexity.  In 
this regard, three approaches have been commonly used: (1) protein separation 
using 1-DE, (2) protein separation using 2-DE, and (3) protein and peptide 
separation using LC.  These techniques help for comparative analyses, lower the 
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dynamic range, simplify the identification of the proteins and allow more accurate 
results. 
 
1.7.2.1 One-dimensional gel electrophoresis (1-DE) 
In 1-DE (also referred as SDS-PAGE), the denaturing detergent SDS is included 
in the sample solution and buffer.  This inclusion enhances protein solubilisation 
and adds negative charges to the proteins.  SDS is considered to bind proteins 
fairly specifically in a mass ratio of 1.4: 1.  Thus, the negative charge to mass 
ratio of any protein and detergent complex is approximately constant, and the 
separation is determined solely by the apparent molecular weight of the proteins 
passing through the sieving gel.  One lane in the gel is usually run along with 
proteins of known molecular weights, to which the unknown proteins are 
characterised.  This method can provide rough molecular weight estimations with 
an accuracy of 5-10%.  1-DE is simple to perform and has good reproducibility.  
Moreover, it has good protein solubility that is capable to separate hydrophobic 
proteins and resolve proteins with wide range of molecular masses (10 to 300 
kDa).  The limitation of this approach is that the single dimensional separation 
constrains its capability to resolve complex proteome samples.  Thus, when a 
relatively complex protein mixture (e.g. whole cell lysate) is encountered, 2-DE is 
usually recommended. 
 
1.7.2.2 Two-dimensional gel electrophoresis (2-DE) 
2-DE technique was originally described by O’Farrell (1975), where the proteins 
are separated according to their isoelectric points (pIs) in the first dimension and 
their apparent molecular mass in the second.  This orthogonal approach allows 
the separation of more than 1000 proteins simultaneously in a single gel.  After 
the separation, the protein spots can be visualised with various staining methods 
(e.g. silver stain, Coomassie blue stain and fluorescent dye stain), and excised 
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from the gel for enzymatic digestion followed by MS identification.  The 
appearance or disappearance of protein spots can provide information about 
differential protein expression, while the intensity of those spots provides 
quantitative information about protein expression levels. 
 
These features allow 2-DE to be very useful for the identification of all proteins in 
a sample as well as the comparison of differential expression for two or more 
samples.  Indeed, most of the relatively comprehensive proteomes of subcellular 
organelles were initially obtained by the combined use of 2-DE and MS, for 
example, mitochondria (Hanson et al., 2001), lysosome (Chataway et al., 1998), 
Golgi (Fialka et al., 1997), ER (Vlasuk et al., 1980) and other endovacuolar 
organelles (Scianimanico et al., 1997).  The comparison of differential expression 
using 2-DE allows the identification of biomarkers for normal or diseased states, 
and the assessment of the effects of some exposure (e.g. drugs or stimuli) on 
cells.  Ueno et al. (2000) used 2-DE and MS to analyse plasma proteins in 
patients with Alzheimer’s disease and identified three disease-specific protein 
markers.  In a similar use, Skaar et al. (1998) identified 7 protein markers that 
were associated with estrogen-induced proliferation in MCF-7 breast cancer cells.  
In addition, 2-DE can distinguish protein isomeric forms.  Thus, it can play an 
important role in the study of protein post-translational modification such as 
phosphorylation (Kovarova et al., 2003) and glycosylation (Packer et al., 1998). 
 
The limitations of conventional 2-DE include poor reproducibility, poor sensitivity 
and limited dynamic range, which constrain 2-DE to identify only relatively high 
abundance proteins (Gygi et al., 2000).  The use of narrow-range IPG strips could 
minimise these problems by expanding the resolving power, thereby increasing 2-
DE resolution and enhancing the recovery of low abundance proteins.  The 
introduction of difference gel electrophoresis (DIGE) (Unlu et al., 1997), on the 
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other hand, has dramatically improved the reproducibility and applicability.  In the 
DIGE, control and treated protein samples are covalently bound with structurally 
similar but spectrally distinct fluorophores, e.g. Cy 3 or Cy 5.  The dye-tagged 
proteins are mixed and separated on the same 2-DE.  The same form of a given 
protein from each sample will migrate to the same position on 2-DE.  The 
differential expression could then be identified by scanning the gel using 
excitation and emission wavelengths that are unique to each dye. 
 
These technical advances improved the reproducibility and enhanced the yield of 
low abundance proteins but a number of problems remain.  It is still a labour-
intensive and time-consuming process.  A typical 2-DE experiment can take two 
days, and a maximum two samples can only be analysed per gel.  It is clear that 
the proteins of high molecular weight and extreme acidity or basicity (proteins 
with pIs below pH 3 and above pH 10) are intractable, and that its usefulness is 
limited when hydrophobic proteins (e.g. membrane proteins) are studied 
(Nouwens et al., 2000).  Under-representation of hydrophobic proteins is due to 
the inability of detergents to effectively solubilise these proteins in the aqueous 
solution used for the isoelectric focusing (Molloy 2000), and the use of chaotrope 
mixtures (Rabilloud 1998), novel detergents (Luche et al., 2003) and organic 
solvents (Molloy et al., 1999) demonstrated little improvement over detergent 
based protocols.  Until now, hydrophobic proteins whose grand average of 
hydropathicity (GRAVY) scores are larger than 0.1, 0.15, and 0.3 in 
Saccharomyces cerevisiae, Bacillus subtilis, and E. coli, respectively, have not 
been detected by 2-DE (Kashino 2003). 
 
The limitations of 2-DE lead to the development of an alternative chromatography 
strategy for the effective separation of protein mixtures.  Indeed, the gel-free 
separation technique allows automated, sensitive, reproducible, and quantitative 
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analysis of complex samples through a single chromatography unit or the 
combination of various chromatography methods, which are gaining incremental 
popularity. 
 
1.7.2.3 Liquid chromatography 
Liquid chromatography (LC) is one of the most powerful protein separation 
methods that are based on the specific interaction between an immobilised ligand 
and a target protein or peptide.  Depending on the absorbents used, LC can 
include ion-exchange, size exclusion, reversed phase.  Accordingly, the bounded 
proteins or peptides in the column can be eluted off by changing the properties of 
the buffer (mobile phase).  Different types of LC can be used as a single 
operating unit or as a combination under the two- or multi-dimensional LC to 
achieve higher resolving power. 
 
LC has many applications.  It can be used for protein sample preparation prior to 
gel electrophoresis as discussed in section 1.7.1.2.  It is often used for the 
purification and enrichment of proteins or peptides after gel electrophoresis.  For 
example, lectin affinity LC is widely used to isolate a specific class of 
glycoproteins and followed by trypsin digestion and MS analysis (Madera et al., 
2007).  The commonest application of LC in proteomic study, however, is to 
separate enzymatic peptides into simple components for direct MS analysis.  This 
approach is also referred to shotgun proteomics (Link et al., 1999), where 
proteins are first enzymatically digested in solution and the resulting peptides are 
fractionated using various types of LC, in most cases, strong cation exchange 
(SCX) LC and RP LC.  In SCX LC a peptide sample is passed through a charged 
column.  The peptides are captured in the column based on the interaction 
between charged groups of a peptide and oppositely charged groups on the ion 
exchange support.  Changing the pH of the mobile phase buffer allows the elution 
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of captured peptides.  RP LC is a separation technique which is based on 
hydrophobic interactions between the peptides and the immobilised ligands on a 
support material fixed.  Captured peptides are eluted by gradually increasing the 
proportion of an organic in mobile phase.  The eluted peptides can be analysed 
by an on-line or off-line coupled MS.  This approach, first described by John 
Yates group (Link et al., 1999), has now become a major tool for large scale 
protein identification (Wu et al., 2002), biomarker discovery (McDonald et al., 
2002) and analysis of post translational modification (Cantin et al., 2004). 
 
Similar to 2-DE in DIGE, the LC method allows for quantitative protein analysis by 
selective labelling with isotope-coded affinity tag (ICAT) (Gygi et al., 1999) or 
isobaric tags (iTRAQ) (Ross et al., 2004).  In both approaches, the peptides from 
different samples (e.g. normal and disease) are labelled with distinct affinity mass 
tags, mixed together and then analysed using LC-MS/MS.  The peak intensity in 
MS or MS/MS spectra provides quantitative information of protein expressions 
and is therefore useful for biomarker discovery.  The ICAT is used for quantitative 
analysis of two cell states, whereas iTRAQ reagent strategy contains four 
isotopically distinct tags, enabling quantitative analysis of four cell states 
simultaneously.  Although iTRAQ was introduced only recently (Ross et al., 
2004), it has gained enormous interests for biomarker discovery (Chong et al., 
2007; DeSouza et al., 2005; Liu et al., 2006). 
 
In summary, the LC-based approaches are automated, sensitive and 
reproducible.  It can be on-line or off-line coupled with MS to allow rapid protein 
characterisation and quantitative analysis of complex samples, which are far 
more efficient than gel-based approaches. 
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1.7.3 Mass spectrometry 
Mass spectrometry (MS) continues to play a central and essential role in 
proteomic study.  MS consists of three basic components: an ion source, a mass 
analyser and an ion detector (Figure 1-2).  Protein and peptide must be converted 
into gas phase ions prior to MS analysis.  A mass analyser sorts these ions 
according to their mass-to-charge (m/z) ratios.  The ions motion is then recorded 
based on the number of events or electrical currents created. 
 
Figure 1-2 Simplified diagram of mass spectrometer 
Transfer of ions from liquid or solid phase to gas phase, and separation of ions 




1.7.3.1 Ionisation techniques 
The electrospray ionisation (ESI) (Whitehouse et al., 1985) and matrix-assisted 
laser desorption/ionisation (MALDI) (Karas et al., 1988) are two most commonly 
used ionisation techniques.  They are belonging to “soft” ionisation techniques, 
which can ionise large biomolecules such as proteins and peptides without 
significant change of their integrity. 
 
ESI operates at atmospheric pressure and generates a continuous stream of 
charged droplets when a high electric potential is set between a capillary and the 
inlet to a mass spectrometer.  As the droplets evaporate in a drying gas or heat 
atmosphere, the charged droplets shrink and eventually desolvated ions are 
formed (Fenn et al., 1989).  The introduction of microelectrospray and 
nanoeclectrospray (Emmett et al., 1994; Wilm et al., 1996), coupled with LC 
(McCormack et al., 1997), allows analysis of a very small amount of sample 
Ion source Ion optics Mass analyser Detector 
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mixture.  Additionally, ESI produces multiply charged ions which lowers the m/z 
values for higher molecular weight compounds and thus allows measurement of 
m/z values in MS with limited m/z ranges.  Multiple protonation of peptides and 
proteins could further dissociate under activation.  These features of ESI have led 
to its widespread application in proteomic study. 
 
In MAIDI instead, sample is incorporated into matrix to form co-crystals, ionisation 
occurs with ultraviolet (UV) absorption from laser energy.  The gas phase 
analytes are ionised through proton transfer from the matrix, cation adduct 
formation, electron transfer or electron capture.  Single charged ions resulting 
from proton transfer from sample to matrix are observed in the gas phase.  
Usually, small UV absorbing molecules such as 2, 5-dihydroxybenzoic acid and 
alpha-cyano-4-hydrozycinnamic (CHCA) are used as matrix.  In contrast to ESI, 
MALDI has a relatively good tolerance to salts which reduces complications for 
sample preparation, in particular, integral membrane proteins and hydrophobic 
peptides.  Furthermore, ions generated are in bunches coincident with a pulsed 
laser beam rather than a continuous mist, which allows customised MS/MS 
analysis.  Recently, the coupling of MALDI-TOF/TOF with LC to generate an off-
line MS platform (Zhen et al., 2004) has improved the applicability for analysing 
protein and peptide complexes. 
 
1.7.3.2 Mass analysers 
As ions exit the ion source, they pass into a mass analyser.  The mass analyser 
is responsible for separating ions by their mass-to-charge ratios.  Mass analysers 
use electric and/or magnetic fields to manipulate ions in a mass-dependent 
manner.  There are four basic types of mass analysers used in proteomic 
research: Ion trap, Time-of-flight (TOF), Quadrupole and Fourier transform ion 
cyclotron analysers.  These analysers can be stand alone or, in some cases, put 
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together in tandem to take advantage of the strengths of each.  Currently, 
TOF/TOF and linear Ion trap are the most commonly used tandem mass 
analysers for protein analysis by peptide fingerprinting and peptide sequence 
analyses. 
 
TOF/TOF analysers are usually coupled to MALDI ionisation method, whereas 
linear Ion traps have mostly been coupled to ESI.  In the MALDI-TOF/TOF, ions 
of a particular m/z are selected in a first TOF, fragmented in a collision-induced 
dissociation (CID) cell and the fragment ion masses are detected by a second 
TOF analyser.  The separation of ions is based on the fact that the MALDI 
generated ions contain the same amount of energy but have different masses, 
the lighter ions travel faster and reach the detector ahead of the heavier ions.  
These instruments have high sensitivity, resolution and excellent mass accuracy.  
The resulting fragment ion spectra are often more extensive and informative than 
those generated in Ion trap instruments. 
 
In the ESI linear Ion traps, the ions are first captured or ‘trapped’ for a certain time 
interval and are then subjected to fragmentation in CID.  It has a propensity to 
generate multiply charged analyte ions, thus enabling multiple stages of MS.  
Linear Ion traps are robust, sensitive and relatively inexpensive.  A disadvantage 
of linear Ion traps is their relatively low mass accuracy.  The comparison of linear 
Ion trap and TOF/TOF-MS is shown in Table 1-1. 
 
Table 1-1 Comparison of performance characteristics for two common 
tandem MS 
 
Instrument Resolution Mass accuracy MS scan rate MS/MS scan rate 
Linear Ion traps 2–15,000 100–300 ppm Moderate to fast Moderate to fast 
TOF/TOF 20-25,000 10-20 ppm Fast  Slow 
(ppm: parts per million) 
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1.7.4 Database searching and bioinformatic analysis 
Database searching through appropriate algorithms is used for protein 
identification by correlating MS or MS/MS spectrum with theoretical spectrum.  It 
can include de novo peptide sequence, uninterpreted MS/MS database 
searching, peptide mass fingerprinting (PMF) and peptide sequence.  PMF and 
peptide sequence are two most commonly used methods for protein 
identification.  Bioinformatic tools, on the other hand, are integral tools providing 
functional information and correlating this information to some specific biological 
pathways.  For example, gene ontology tool Gofigure can help to functionally 
annotate identified proteins. 
 
Peptide mass fingerprinting (PMF) database searching.  In this method, the mass 
spectrum of an enzymatic peptide of an unknown protein is compared to 
spectrum in database of known proteins.  The high number of peptide matches 
and better matches allow for protein identification with higher confidence.  PMF is 
simple, which does not require sophisticated MS/MS machine.  The disadvantage 
is the ambiguity in protein identification.  This is because many different peptides 
may have same mass, which causes a single MS spectrum matched with more 
than one theoretical spectrum in a database.  In practice, it is often required a 
large number of peptide matches for a confident protein identification. Also, 
higher confidence of protein identification can be achieved by correlating 
identified protein with apparent molecular weight obtained from 1-DE or 2-DE 
separation.  Other disadvantages include that the use of PMF is limited to 
completely sequenced and well annotated genome, and that PMF does not work 
well with protein mixtures (Cottrell 1994). 
 
Peptide sequence database searching.  This method is the most specific for 
protein identification and is often used in MS/MS analysis.  The ionised peptides 
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selected by mass in the first MS are subjected to the subsequent fragmentation 
during collision with a gas (in CID).  The resultant smaller fragments are used for 
determination of amino acid sequence, which is done by comparing experimental 
fragmentation with a theoretical fragmentation of the peptide in database.  Once 
the amino acid sequence of a peptide is determined, it can be used to search 
databases to find the protein from which it is derived.  Peptide sequence has 
higher mass accuracy as compared with PMF and is suitable for analysing 
protein mixtures. 
 
Searching programmes or algorithms.  A number of novel algorithms for database 
searching are available through the internet and listed in Table 1-2.  Algorithms 
are developed to determine peptides and/or their amino acid sequences de novo 
from MS or MS/MS data.  The simplest algorithm for protein search in database 
matches experimentally obtained and theoretical mass spectra and ranks 
database proteins according to number of matching peptides.  Such algorithm 
often overestimates large proteins, for which a greater number of calculated 
peptides is possible.  This is the case for the algorithm used for PMF.  More 
effective algorithms (e.g. MASCOT, SEQUEST) use additional information such 
as protein pI, Mw, and amino acid composition.  These tools allow for the 
identification of proteins with higher sensitivity and specificity than algorithms 
used for PMF. 
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Table 1-2 Various tools for MS-based protein identification 
   
SPONSOR URL 
Eidgenossische Technische Hochschule http://cbrg.inf.ethz.ch 
European Molecular Biology Laboratory (EMBL) http://www.mann.emblheidelberg.de 
Swiss Institute of Bioinformatics (ExPASy) http://www.expasy.ch/tools 
Matrix Science (Mascot) http://www.matrixscience.com 
Rockefeller University (PepFrag, ProFound) http://prowl.rockefeller.edu 
Human Genome Research Centre (MOWSE) http://www.seqnet.dl.ac.uk 
University of California (MS-Tag, MS-Fit, MS-Seq) http://prospector.ucsf.edu 
Institute for Systems Biology (COMET) http://www.systemsbiology.org 
University of Washington (SEQUEST) http://thompson.mbt.washington.edu/sequest 
 
 
Bioinformatic tools.  In proteomic study, bioinformatic tools may include all 
methods that are involved in data analysis, storage, management, search and 
retrieval.  More specifically, they can be categorised into two groups.  One group 
is referred to tools for mass spectra analysis for protein identification and 
characterisation as reviewed by Palagi et al. (2006).  The raw output of a MS 
study consists most of a list of peaks from MS spectra.  Bioinformatic tools (e.g. 
MASCOT) that correlate the peak information with database (e.g. Swiss-Prot, IPI) 
are required to identify proteins.  The other is referred to tools related to “post-
identification” annotations which often elucidate biological significance of the 
identified proteins  (Lisacek et al., 2006).  In this context, the annotations may 
describe functional properties of identified proteins and refer to pathway data, and 
protein-protein interactions.  Such information is commonly integrated and stored 
in on-line public databases, such as an integral protein sequence database with 
high-quality annotation (Swiss-Prot: http://au.expasy.org/sprot/), protein family 
databases defined on sequence similarity (e.g., Pfam: 
http://www.sanger.ac.uk/Software/Pfam/; InterPro: http://www.ebi.ac.uk/interpro/), 
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structural databases defined on structure similarity (e.g., SCOP; http://scop.mrc-
lmb.cam.ac.uk/scop/).  In each database, there may be different criteria for 
grouping proteins together.  Various GO tools based on gene ontology (e.g. 
Gofigure: http://udgenome.ags.udel.edu/gofigure/) can usually be meaningful 
links between independent classifications of proteins described in a collection of 
databases.  Moreover, these GO tools allow inferring biological process, 
molecular function and cellular component for unknown or uncharacterised 
proteins.  In addition, there are some tools to calculate protein physical and 
chemical parameters.  For example, the programme ProtParam 
(http://au.expasy.org/tools/protparam.html) can be used to computer protein 
molecular weight, theoretical pI and grand average value of hydropathicity 
(GRAVY); TMHMM (http://www.cbs.dtu.dk/services/TMHMM-2.0/) can be used to 
predict transmembrane domain(s) of proteins.  These bioinformatic tools are 
integral components of proteomic analysis and essential in the discovery of 
sensitive and specific biomarkers. 
 
The availability of complete sequence databases, optimised sample preparation 
and separation protocols, the advance of MS, and the powerful bioinformatic 
tools, together, converged into a mature, robust, sensitive, and rapid technology 
that allows a large scale of protein identification and biomarker discovery. 
 
1.7.5 Proteomic strategies for membrane protein analysis 
Cell membranes are essential for cells to maintain the integrity of their structure, 
and segregate processes within intracellular compartments.  Study of membrane 
proteome is important not only for understanding of the biology of diseases and 
for biomarker discovery, but also to enhance the drug discovery process as more 
than two-thirds of the known protein targets for drugs are membrane proteins 
(Hopkins et al., 2002).  Commonly used proteomic strategies for membrane 
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protein analysis include: (1) gel-based approach where proteins are separated by 
2-DE or 1-DE and identified by MS, and (2) shotgun approach where proteins are 
digested in solution, separated by LC and identified by MS.  The features of these 
methods were discussed in more detail in the following paragraphs. 
 
1.7.5.1 Gel-based approach 
2-DE coupled with MS.  As the first technique enabling large scale, high 
resolution of protein separation, 2-DE coupled with MS has a key role in early 
proteomic analysis of membrane proteins.  Shortly after the introduction of 2-DE 
(O'Farrell 1975), this method was used to separate membrane proteins (Ames et 
al., 1976).  Proteins were fairly separated and many spots were visualised.  
However, protein identification was difficult due to lack of resources then, and 
thus the spots in 2-DE may not represent true membrane proteins.  Indeed, a 
later paper found that an abundance integral membrane protein Band 3 did not 
enter 2-DE gel when using nonionic detergent mixtures for membrane protein 
analysis  (Rubin et al., 1978), which was confirmed by Klein et al. (2004). 
 
As conventional 2-DE using nonionic detergents is not effective to separate 
membrane proteins (Santoni et al., 2000), other  detergents were used to improve 
2-DE separation of membrane proteins.  The zwitterionic detergent (3 [(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate) (CHAPS) has superior 
membrane protein solubilising capability as compared to nonionic detergents.  Its 
use enabled effective separation of crude microsomal proteins (Perdew et al., 
1983).  Another detergent aminosulphobetaine 14 (ASB-14) was shown to be 
more effective than CHAPS in solubilising membrane proteins and its use allowed 
the separation of a number of integral membrane proteins that were not 
previously detected using 2-DE (Nouwens et al., 2000; Taylor et al., 2003a).  
Several studies suggested that the surfactant C80 was an even more potent 
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solvent for integral membrane proteins over ASB14 and CHAPS (Babu et al., 
2004; Henningsen et al., 2002). 
 
The use of various chaotrope mixtures and novel detergents improves 2-DE 
separation of membrane proteins, and enables recovery of some, or a small class 
of membrane proteins.  However, the usefulness of 2-DE for global membrane 
protein analysis remains very limited as the diversity, low abundance, and high 
hydrophobicity of membrane proteins.  Galeva et al. (2002) compared 2-DE and 
1-DE for the analysis of rat ER membrane proteins, and found that while twenty-
two ER membrane proteins were identified from 1-DE separated proteins, only 
three were from 2-DE separation.  Vanrobaeys et al. (2005) identified 38 proteins 
from myelin membrane using 2-DE method, whereas the number was doubled 
(93)  in shotgun approach.  These studies suggested that 2-DE should not be a 
first choice for membrane proteins analysis. 
 
1-DE coupled with MS.  In contrast to 2-DE, the protein solubility in 1-DE is 
seldom a problem as the strong detergent SDS is included in the sample buffer.  
This advantage has allowed 1-DE coupled with MS to become one of most 
effective strategies in various membrane protein analyses.  Galeva et al. (2002) 
used this strategy to analyse rat ER membrane proteins, and identified 22 out of 
34 known ER membrane proteins in a single experiment.  In a similar approach, 
Bell et al. (2001) identified all known Golgi membrane proteins and a novel 
membrane protein GPP34.  The successful application of this approach was also 
reported in the analyses of membrane proteins from chloroplasts (Ferro et al., 
2002), mycobacterium tuberculosis (Sinha et al., 2005), human macrophage 
(Slomianny et al., 2006) and rat liver (Zhang et al., 2006). 
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The limitation of this approach is the relatively poor resolving power of 1-DE.  It is 
often noted that more than one proteins are present in a fine band when studying 
complex protein mixture, thereby limiting the identification of low abundance 
proteins.  This problem can be overcome by the use of LC to resolve the eluted 
peptides from each band prior to MS analysis (Simpson et al., 2000).  Indeed, this 
strategy has been demonstrated as a powerful tool to study membrane proteins.  
Brugiere et al. (2004) used this approach to analyse mitochondrial membrane 
and reported a total of 114 proteins including ~40% novel proteins.  In a similar 
approach, Bagshaw et al. (2005) analysed lysosome membranes and identified 
215 proteins including 20 novel proteins; Rahbar et al. (2004) analysed plasma 
membranes and presented 366 proteins including 43% of plasma membrane 
proteins. 
 
Despite the effectiveness, however, this approach is inherently not quantitative 
(Han et al., 2001) and that peptides may not efficiently recovered with tedious in-
gel digestion procedure (Zhang et al., 2004).  In addition, difficulty is encountered 
with low molecular weight proteins due to the low number of peptides available, 
and this situation is worse if only a small amount starting sample is available.  
Finally, this approach requires multiple LC separations prior to MS analysis, 
which is very time-consuming. 
 
1.7.5.2 Shotgun approach 
Compared to gel-based strategy, shotgun approach was introduced more 
recently (Link et al., 1999).  In this approach, proteins are firstly digested in 
solution, and then resolved by one-dimensional LC or multidimensional LC prior 
to MS analysis.  It circumvents some challenges that 2-DE faces, for example, 
the digestion of intact proteins into peptides creates more soluble analytes, which 
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eases subsequent separation.  It is faster, high throughput and more efficient in 
peptide recovery as compared with 1-DE based method. 
 
In shotgun approach, the major challenge is the protein solubility.  A buffer, which 
is effectively solubilising membrane proteins and compatible with enzymatic 
digestion, is necessary to increase peptide recovery.  For this purpose, three 
solubilisation buffers for extraction and analysis of membrane protein with 
shotgun approach have been used and demonstrated to be effective, that are, 
detergent, organic acid and organic solvent. 
 
Detergent buffered solution.  Strong detergent SDS has excellent solubilisation 
characteristics and is widely used to extract and solubilise membrane proteins.  
The commonly used concentrate SDS solution for membrane protein 
solubilisation, however, hurdles trypsin activity.  In 2001, Han et al. (2001) 
described the use of a relatively low concentration of SDS solution (0.5%) for 
both pre-digestion procedures (protein extraction, reduction, and alkylation) and 
protein digestion prior to LC-MS analysis.  More recently, a slightly modified 
protocol was developed (Zhang et al., 2004), where pre-digestion procedures 
were carried out in a concentrate SDS solution (1%), and the protein digestion 
was performed in a diluted solution (0.1%).  This protocol is not only efficient for 
membrane protein solubilisation but also more compatible with trypsin digestion, 
and has been widely used to analyse various hydrophobic proteins such as 
membrane proteins (Zhang et al., 2004), lipid raft proteins (Li et al., 2004) and 
proteins in myelin sheath (Vanrobaeys et al., 2005). 
 
Other detergents (e.g. urea) have also been used for shotgun analysis of 
membrane proteins.  Urea-based protocol, similar to SDS-based protocol, often 
consists of two steps: use of concentrate urea solution for pre-digestion 
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procedures and use of a diluted urea solution for the protein digestion.  Durr et al. 
(2004) used 8 M urea solution for pre-digestion procedures, and 1.6 M urea 
solution for the protein digestion.  In their study, a total of 450 proteins were 
identified from luminal endothelial cell plasma membrane.  In a similar use, Pasini 
et al. (2006) could present a relatively comprehensive RBC membrane proteome.  
Nielsen et al. (2005) used 4 M urea and 1 M urea in the two steps, which enabled 
them to identify a large number of membrane proteins (>500) from mouse brain 
cortex in a single experiment. 
 
The detergent solution for membrane protein solubilisation and digestion in 
shotgun approach generally allows efficient recovery of membrane proteins, and 
has significant advantages over gel-based approach (Wu et al., 2006).  However, 
the detergents can interfere with LC separations, suppress analyte ionisation, and 
additional manipulations to remove them could lead to the loss of significant low 
abundance proteins (Puchades et al., 1999), rendering its inapplicability of this 
approach for analysis of a small amount sample. 
 
Organic acid solution.  The usefulness of organic acid for shotgun analysis of 
membrane proteins has also been demonstrated.  In a pioneering study 
(Washburn et al., 2001), yeast membranes were solubilised in 90% formic acid 
and proteins were chemically cleaved by cyanogen bromide into relatively large 
fragments.  These fragments, more soluble than intact proteins, were then 
enzymatically digested in neutral medium (pH 7-8) and analysed by LC-MS/MS.  
This approach enabled them to identify 131 yeast integral membrane proteins 
with ≥3 TMDs.  In a similar use, Xiang et al. (2004) analysed membrane proteins 
from two breast cancer cell lines BT474 and MCF7, and presented a total of 604 
proteins from BT474 membrane and 313 proteins from MCF7 membrane. 
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Despite its high efficiency, this approach was less commonly used in current 
proteomic study, mainly because of three possible reasons: (1) cyanogen 
bromide is a highly combustible, toxic chemical and very difficult to handle; (2) it 
is a time-consuming and tedious digestion process as multiple-step digestions 
and pH adjustment are needed; and (3) it involves potential sample losses 
caused by protein precipitation (Blonder et al., 2004a). 
 
Aqueous organic solvents.  Organic solvent for shotgun proteomics was first 
described by Blonder et al. (2002).  In their study, the membranes from 
Deinococcus radiodurans were solubilised into aqueous methanol (60%) with 
intermitting sonication.  Protein mixture was denatured and digested by addition 
of trypsin with a 1:20 (w/w) trypsin-to-protein ratio.  The subsequent analysis 
using LC-MS/MS enabled them to identify a total of 503 proteins that include 135 
hydrophobic proteins and 53 integral membrane proteins.  This organic solvent-
based approach is more compatible with LC-MS/MS analysis, as sample clean-
up could be avoided leading to lower sample loss and better recovery of low 
abundance, highly hydrophobic transmembrane peptides. 
 
More recently, organic solvent 2,2,2-trifluoroethanol (TFE) was described for the 
analysis of whole cell lysate in a shotgun approach (Wang et al., 2005).  In their 
study, mouse brain tissue or MCF7 cells were lysed in aqueous TFE (50%) and 
pre-digestion procedures (protein extraction, reduction and alkylation) were 
carried out in this solution.  The protein digestion was performed in a dilute TFE 
solution (5%).  This TFE-based approach had a comparable or slightly better 
efficiency than SDS-based approach in the analysis of large amount of sample, 
and provided much higher efficiency when analysing a small amount sample (<1 
µg protein), as sample clean-up could be avoided.  However, it is not yet to know 
if this approach is suitable for the analysis of membrane proteins. 
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In summary, various methods, as reviewed above, are available for membrane 
protein analysis and biomarker discovery.  Each method has its own advantages 
and disadvantages and the method chosen is largely dependant on the specific 
sample type to be analysed.  It is advisable to identify a suitable method or 
combination of methods using similar sample prior to the analysis of a rare 
sample type, e.g. fetal NRBCs. 
 
1.8 Adult RBC membrane proteins 
Human adult RBCs represent evolutionary genius.  Enucleation of terminally 
differentiated mammalian erythrocytes is thought to be a recent evolutionary 
adaptation, as birds, reptiles, amphibians and fish have nucleated red blood cells 
(Kingsley et al., 2004).  Despite not having a nucleus, internal organelles or a 
transcriptome, human adult RBCs are able to carry out their oxygen transport 
function, survive in the circulation for 120 days, and undergo programmed cell 
death (Bratosin et al., 2001).  The size, shape and function are tightly regulated 
throughout their lifespan, and much of this is due to its membrane proteins and 
the interaction of the latter with molecular signals in the blood (Walsh et al., 
2002). 
 
Over the last 40 years, adult RBC membrane has been studied extensively via 
biochemical method, thus the identity, topology and function of many RBC 
membrane proteins have been determined.  The three major groups of RBC 
membrane proteins include: (a) integral membrane proteins, (b) peripheral 




Integral membrane proteins.  Integral proteins comprise up to 80% of all RBC 
membrane proteins, and are embedded in the membrane matrix spanning the 
entire bilayer. These proteins are characterised by at least two hydrophilic 
domains composed mainly of polar amino acids, and by at least one hydrophobic 
domain composed mostly of apolar amino acids.  The hydrophilic sections of the 
proteins are in contact with the surrounding water phases-the extracellular 
domain is usually glycosylated (Steck et al., 1974), whereas the cytoplasmic 
domain is usually phosphorylated.  The important integral membrane proteins, 
tightly bound to the cytoskeleton architecture, include band 3, and the 
glycophorins.  Band 3 acts as the anion transport and gas exchange channel 
(Bruce 2006), which consists of N-terminal cytoplasmic domain and C-terminal 
membrane domain.  Structural models predict that the membrane domain 
consists of 12 to 14 transmembrane helices, and the longest, fourth loop is N-
glycosylated and its single lactosamine-rich glycan chain carries over half of the 
red cell ABO blood group epitopes (Jarolim et al., 1998).  Glycophorins are 
associated with the MNS blood group system (Poole 2000).  About 60% of the 
glycophorin molecule is made up of carbohydrate chains, which provide a 
negative charge to the surface of RBCs (Marchesi et al., 1976).  Other major 
integral proteins consist of glucose transporter (band 4.5), Rh polypeptides, Rh 
glycoproteins, and band 7 (stomatin) (Wang et al., 2000c).  
 
Peripheral proteins.  Peripheral proteins are located on the cytoplasmic surface of 
the membrane.  They are bound loosely to the membrane, and can be readily 
removed in low ionic strength medium, in the presence of chelating agents, or 
under alkaline conditions.  This group is represented by the proteins of bands 1, 
2, 2.1, 2.2, 2.3, 4.1, 4.2, 4.9, 5, and 6. 
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Spectrin (band 1 and band 2) is the major constituent of the membrane skeleton; 
it accounts for 25% of the total RBC membrane proteins.  The spectrin fraction 
consists of two fibrous proteins that can be resolved on SDS-PAGE into two 
closely adjacent bands, band 1 (α-chain) and band 2 (β-chain). Two α-β helices 
are linked end-to-end to form a single tetramer, which has binding sites for 
several other proteins including other spectrin molecules (Bennett et al., 1993; 
Branton et al., 1981; Marchesi 1985).  Ankyrin (band 2.1) is a peripheral 
membrane protein with a molecular mass of 210 kDa.  Band 2.2 and band 2.3 
proteins are probably ankyrin analogues.  Band 4.1 is a globular protein with a 
molecular mass in the range of 78 to 82 kDa.  Band 4.2 (palladin) is found in RBC 
membrane as a homo-tetramer closely associated with band 3 protein (Jarolim et 
al., 1992).  Band 4.9 (Dematin) is an actin-bundling protein, which contains at 
least two actin-binding sites, one in the headpiece domain, and another in the 
amino-terminal portion (Azim et al., 1995).  Actin (band 5) oligomers of 10-15 
units are essential components of the membrane skeleton and the molecular 
mass of this protein is approximately 43 kDa.  Band-6 protein is a 
glyceraldehyde-3-phosphate dehydrogenase (G3PD) with a pivotal function in 
erythrocyte metabolism.  Immunostaining demonstrated that G3PD is 
preferentially associated with the RBC plasma membrane, and approximately 
10% of G3PD exists in their cytoplasmic fraction (Rogalski et al., 1989). 
 
GPI-anchored proteins.  GPI-anchored membrane proteins are a class of 
membrane proteins that attach to the outer surface of the cell membrane through 
a glycosyl-phosphatidylinositol unit.  This glycolipid anchor is composed of 
phosphatidylinositol, phosphatidylethanolamine, one non-acetylated glucosamine 
and three mannose residues; the anchor unit is connected to the C-terminal 
amino acid of the protein via an amide bond.  This complex molecule is attached 
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to the cell membrane by the fatty acid residues of the phosphatidylinositol moiety 
embedded in the outer leaflet of the bilayer (Kinoshita et al., 1995). 
 
GPI-anchored RBC membrane proteins include complement control proteins 
(decay accelerating factor (CD59), and C8 binding protein), immune control 
proteins (LFA-3 and CD16), and various enzymes (acetylcholinesterase, alkaline 
phosphatase, and 5’-nucleotidase) (Rosse 1990).  Furthermore, it has been 
shown that antigens of several different blood group systems, Cromer, 
Dombrock, Cartwright, and John Milton Hagen (JMH), are located on GPI-linked 
membrane proteins (Telen et al., 1990; Telen 2000). 
 
Proteomic studies of RBC membrane proteins.  The proteomic study of RBCs has 
closely followed the technical advance in the last decade.  An early study of RBC 
membrane proteome was carried out using gel-based proteomic approach and a 
total of 102 proteins were identified (Low et al., 2002).  Of the 102 proteins, all 
major RBC band proteins (bands 1-7) were identified but a few of them (<10) 
were transmembrane proteins.  Two years later, Kakhniashvili (Kakhniashvili et 
al., 2004) utilised a shotgun proteomic approach to analyse RBC membrane 
proteome.  In the study, a total of 91 proteins were identified from RBC 
membrane preparation and about 25% of them were transmembrane proteins.  
More recently, Pasini et al., (2006) used two advanced mass spectrometers 
(Quadropole TOF Q-STAR and linear ion trap Fourier transform LTQ-FT MS) for 
the analysis of RBC membrane proteins and reported a substantive increase in 
the number of RBC membrane proteins (341 proteins).  In all these studies, many 
proteins (e.g. proteasomal proteins), which were thought to be absent in mature 
RBCs, were also identified.  Some of them have been recently validated using 
confocal immuno-fluorescence and western blot analysis (Neelam et al., 2006).  
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Therefore, proteomics has now become an efficient and high-throughput tool for 
the analysis of RBC membrane proteins. 
 
1.9 Experimental aims and hypotheses 
The enrichment of primitive fetal NRBCs from maternal circulation would allow an 
early non-invasive prenatal diagnosis.  Many efforts have been made to enrich 
this most desirable cell type from maternal blood but all of them are far from 
satisfactory.  As discussed, the enrichment is being difficult for two reasons: small 
number of fetal NRBCs in maternal circulation and the lack of appropriate surface 
biomarker that can be used to differentiate fetal NRBCs from adult RBCs.  
Attempts on in vitro amplification of fetal cells and generation of antibodies 
against fetal NRBC surface antigens for enrichment protocol were also not 
successful.  Thus an alternative would be to explore more on the surface 
protein/antigen profiles of fetal NRBC and adult RBC membranes, so that the 
enrichment procedure could be strengthened by obtaining or generating new 
antibodies. 
 
Two possible means to gather surface protein information are: (1) profiling the 
membrane proteomes of fetal NRBCs and adult RBCs using MS-based proteomic 
approaches, and (2) an immunocytochemical screening of fetal NRBCs and adult 
RBCs using commercially available surface antibodies.  My study is centred on 
the identification of differences between fetal NRBC and adult RBC membrane 
proteins.  First trimester primitive fetal NRBCs obtained from placental tissue at 
the time of termination of pregnancy (TOP) will be used.  Adult RBCs from 
laboratory volunteer will also be studied in parallel with an ultimate objective to 




1 To profile both primitive fetal NRBC and adult RBC membrane proteomes. 
2 To identify surface membrane protein(s) unique to primitive fetal NRBCs by 
comparing the two membrane proteomes. 
3 To identify surface antigen(s) differentially expressed between primitive fetal 
NRBCs and adult RBCs by immunocytochemical screening. 
 
1.9.2 Hypotheses  
1 The most comprehensive membrane protein profiles of fetal NRBCs and adult 
RBCs can be obtained by developing an efficient proteomic platform for 
membrane protein analysis. 
2 It is possible to identify unique surface protein(s) on fetal NRBCs or adult 
RBCs by comparing the membrane profiling data obtained by proteomic 
approaches. 
3 Differential expression of surface antigen(s) is (are) present in primitive fetal 
NRBCs or in adult RBCs, and could be identified by immunocytochemical 
screening using commercially available antibodies. 
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2.1.1 Human tissue and blood samples 
 
2.1.1.1 Ethical approval for use of human tissues and blood samples 
Placental tissue and adult blood collection for this research were approved by the 
NHG Domain Specific Review Board in compliance with national guidelines 
regarding the use of human sample for research purposes.  All research 
participants gave written informed consent for the collection and use of human 
tissues. 
 
2.1.1.2 First trimester placental tissues 
First trimester placental tissues (7+0 to 11+4 gestational weeks) were collected 
immediately after surgical termination of pregnancy.  The tissues were washed 
carefully to eliminate maternal blood contamination and kept in phosphate-
buffered saline (PBS) in 50 ml polypropylene tube. 
 
2.1.1.3 Peripheral blood from healthy male and female volunteers 
Peripheral blood samples (2-10 ml) were collected via venepuncture from healthy 
male and female volunteers. 
 
2.1.2 Antibodies, reagents, solutions and kits 
All antibodies, reagents, solutions and kits used in the experiments are listed 




Primary antibodies against following human antigens (all host in mouse unless 
otherwise stated): CD34, CD46, CD55, CD100, CD117 (host in rabbit), CD175s, 
HLA-DR (Neomarkers, LAB VISION, CA); CD29, CD31, CD35, CD36, CD44, 
CD45, CD45RB, CD47, CD59, CD81, CD99, CD108, CD147, CD147-FITC 
(fluorescein isothiocyanate), CD164, CD222, E-cadherin (BD Pharmingen, San 
Diego, CA); CD14, CD90, CD105, CD133, monocarboxylate transporter 1 
(MCT1) and neutral amino acid transporter ASCT2 (host in rabbit) (Chemicon, 
Temecula, CA); CD71, HLA-ABC (DAKO, Carpinteria, CA); CD233 (Sigma-
Aldrich, St Louis, MO); CLC-6 (host in rabbit) (Alpha Diagnostics, San Antonio, 
TX); azurocidin/CAP37 (R&D Systems, Minneapolis, MN). 
 
Secondary antibodies: biotinylated goat anti-mouse IgG, biotinylated rabbit anti-
mouse IgG (Vector Laboratories, Burlingame, CA); goat anti-mouse IgG 
conjugated to horseradish peroxidase (HRP) (Pierce, Rockford, IL); goat anti-
mouse IgG conjugated Dynabeads M-450 (Dynal, Oslo, Norway); rat anti-mouse 




Oligo dT (18 T nucleotide) and all other primers listed in Table 2-1 were 
purchased from Sigma-Proligo, Singapore. 
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Table 2-1 Primer pairs used for the amplification for individual gene 
 
Selected protein identifications Gene 
name 
Forward Reverse Amplified bp 
Hemoglobin epsilon chain HBE1 5’-TTTTACTGCTGAGGAGAAGGCTGC C-3’ 
5’-CTTGCCAAAGTGAGTAGCCAGAATAA-
3’ 355 
Hemoglobin gamma-2 chain HBG2 5’-ACGCCATGGGTCATTTCACAGA-3’  5’-GAGCTCAGTGGTATCTGGAGGA-3’ 455 
Band 3 anion transport protein SLC4A1 5’-ACACAGCTCTTCTGTGAGCA-3’ 5’-TCCGACACTCCCATCTGGTT-3’ 727 
BCG induced integral membrane protein 
BIGM103 SLC39A8 5’-GTCTGAGATGCCTGGTATATAG-3’ 5’-TCTTTGGCTCCTTAAAGACTTGG -3’ 314 
Chloride channel protein 6 CLCN6 5’-GGGACCTTGTGCTGAGGGA-3’ 5’-AGCTGCGACTGCGGCAAT-3’ 246 
Azurocidin precursor AZU1 5’-GTGCTGGGTGCCTATGACCTGAGG-3’ 5’-AAGAGCGCCACTCGG GTGAAGAA-3’ 467 
Vitamin K epoxide reductase complex subunit 
1-like protein 1 VKORC1L1 5’-AGACACCTCAGGCAGCACTT-3’ 5’-TATTTCACCTTTTCTGGGCG -3’ 134 
Protein GPR107 precursor GPR107 5’-TCAGAACATGGTTGTTCTCCC-3’ 5’-GCTTGCTCTTCCTCCACATC-3’ 164 
Neutral amino acid transporter B SLC1A5 5’-TGGCTGCTGGAGTACATGTG’-3’ 5’-CCCAGTGGGGGCTAGAATTC-3’ 196 
Glyceraldehyde-3-phosphate dehydrogenase GAPDH 5'-AAGGACTCATGACCACAGTCCATG-3' 5'-TTGATGGTACATGACAAGGTGCGG-3' 673 
Solute carrier family 3 (activators of dibasic 
and neutral amino acid transport), member 2, 
isoform A 
SLC3A2 5’- ATGGACCCACTACCCTTCTC -3’ 5’- CATGCAGGGGTGACTTTTAT -3’ 150 
Solute carrier family 22 member 11, isoform 2 SLC22A11 5’- CTGGGTTCCAATCTCACCC -3’ 5’- TTTTTCTGGCAGCTCTCTCA -3’ 150 
Antibacterial protein FALL-39 precursor CAMP 5’- GATAACAAGAGATTTGCCCTGC -3’ 5’- GGGTAGGGCACACACTAGGA -3’ 146 
Vesicle-associated membrane protein 2 VAMP2 5’- AGTCCCTTAACCTGCCACG -3’ 5’- CTGGGATAATATGGGGGGTC -3’ 165 
Transferrin receptor protein 1 TFRC 5’- TAGGCAGCAGCTTTTAATACAGG -3’ 5’- AAAGTAAGCGAACCACTTACAACC -3’ 238 
Cleft lip and palate transmembrane protein 1 CLPTM1 5’-AGGTTCCCACAGCAGCAG-3’ 5’-CCTCTGCTGGCTTTGGAG-3’ 155 
CAAX prenyl protease 1 homolog ZMPSTE24 5’-CCTAAG GCTAAAGAGGAGCAG-3’ 5’-GCGTTGGCAATGTTTAATGT-3’ 146 
Steroid dehydrogenase homolog HSD17B12 5’-TGAAATATGCAGCAAGAAGATTGG-3’ 5’-AATGATGCTGATAGCAGATGGCT-3’ 193 
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Table 2-1.  Continued     
Olfactory receptor 11H4 OR11H4 5’-AACAACTGAATGTCTCTTTCT-3’ 5’-GGAGTCGTTACTGAATATACC-3’ 483 
Vacuolar proton translocating ATPase 116 
kDa subunit a isoform 1 ATP6V0A1 5’-ACCTGACCCGACCTTGTG-3’ 5’-CTGAACTCTGCTTCAAACCCC-3’ 96 
CDNA PSEC0252 fis, clone NT2RP3003258, 
highly similar to Likely ortholog of mouse 
embryo 
SLC43A3 5’-ATGTCCTAGAAGGTTTTAGG-3’ 5’-CAAAGATAGTCTGTCAGAAA -3’ 104 
Synaptophysin-like protein SYPL1 5’-TGCATCATAAAGGAACCTAAGTG-3’ 5’-TGTAAGAATAAGAAACCTGAATCC C-3’ 144 




Chemical reagents: methanol (MeOH) and ethanol (Fisher Scientific, Fairlawn, 
NJ); acetic acid, and acetone (Merck, Darmstadt, Germany); urea, tris-base, SDS 
and glacial acetic acid (BDH Merck, Whitehouse Station, NJ); ammonium 
persulphate, dithiothreitol (DTT), mineral oil, 30% bis/acrylamide, overlay 
agarose, rehydration buffer, protein assay dye reagent concentrate and 
N,N,N',N'-Tetramethylethylenediamine (TEMED) (Bio-Rad Laboratories, 
Hercules, CA); Tween-20 (DAKO Corporation, Carpinteria, CA); Percoll (GE 
Healthcare, Uppsala, Sweden); Hanks' Balanced Salt Solution (HBSS), 
ethylenediaminetetraacetic acid (EDTA) and (2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 1 M (Invitrogen, Carlsbad, CA); Nonidet 
P-40 (NP-40) (Roche diagnostics, Mannheim, Germany); bromophenol blue, 
thiourea, glycerol, N-decyl-N, N-dimethyl-3-ammonio-1-propane sulfonate (SB3-
10), n-octylglucoside, tris-carboxyethyl phosphine hydrochloride (TCEP), Trition 
X-100, potassium ferricyanide, sodium thiosulphate, sucrose, ammonium 
bicarbonate (NH4HCO3), iodoacetamide (IAA), formic acid, trifluoroacetic acid 
(TFA), HPLC grade acetonitrile (ACN) and Ficoll (Histopaque) 1077 (Sigma-
Aldrich, St. Louis, MO); 2, 2, 2-trifluoroethanol (TFE) (Fluka, Buchs, Switzerland); 
DPX mountant (RA Lamb, East Sussex, UK). 
 
Biological reagents: bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis, MO); 
complete mini® protease inhibitor cocktail (Roche diagnostics, Mannheim, 
Germany); fetal calf serum (Pierce, Rockford, IL); RNase-Free DNase (QIAGEN 
GmbH, Hilden, Germany); RNase Inhibitor (New England Biolabs, Beverly, MA); 
modified sequencing grade trypsin (Promega, Southampton, UK); PCR buffer, 
MgCl2, dNTPs (PE Biosystems, Warrington, England); AmpliTaq Gold 
polymerase (Roche, Mannheim, Germany); precision plus protein all blue 
standards (Bio-Rad Laboratories, Hercules, CA). 
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2.1.2.4 Water and solutions 
Millipure water (Mili-Q systems, 18 MΩ/cm at 25°C) (Millipore, Bedford, MA); 
DEPC-treated water (0.1% Diethylpyrocarbonate (DEPC) in pure water); 5× SDS-
PAGE sample buffer (0.313 M tris-base, pH 6.8 at 25°C, 10% SDS, 0.05% 
bromophenol blue, 50% glycerol, and 0.5 M DTT); tris solution for stack gel (0.5 
M tris-base, pH 6.8, 0.4% SDS); tris solution for resolving gel (1.6 M tris-base, pH 
8.8, 0.4% SDS); 1× SDS/glycine electrophoresis buffer (0.25 M tris, pH 8.6, 1.9 M 
glycine and 1% SDS); 2-DE sample buffer (7 M urea, 2 M thiourea, 100 mM DTT, 
4% CHAPS, 0.5% carrier ampholytes pH 4–7, 0.01% Bromophenol blue and 
40mM Tris); equilibration buffer I (6 M urea, 2% SDS, 0.375 M Tris-HCl (pH 8.8), 
30% glycerol, and 2% (w/v) DTT); equilibration buffer II (6 M urea, 2% SDS, 
0.375 M Tris-HCl (pH 8.8), 30% glycerol and 2.5% IAA); silver stain fixative 
solution (40% MeOH, 10% acetic acid (v/v) in pure water); silver stain stop 
solution (0.5% acetic acid); trophoblast digestion buffer (0.1% trypsin and 25 mM 
HEPES in HBBS); protein digestion solution (12.5 ng/µl trypsin in 50 mM 
NH4HCO3 solution); HES buffer (20 mM HEPES, pH 7.4, 1 mM EDTA and 250 
mM sucrose); PBST (1× PBS/0.5% Tween-20); MACS, FACS and Dynal cell 




Alkaline phosphatase Vector blue substrate labelling kit (Vector Laboratories, 
Burlingame, CA); chemiluminescence HRP substrate WEST PICO (Pierce, 
Rockford, IL); RC DC protein assay kit (Bio-Rad Laboratories, Hercules, CA); 
Sensiscript RT kit and RNeasy Mini kit with QIAshredder spin column (QIAGEN 
GmbH, Hilden, Germany). 
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2.1.3 IPG Strip, gels, membrane and film 
IPG ReadyStrip/pH 3-10/7cm, RGel/4-20%Tris-HCl/IPG and CrtGel/4-20%Tris-
HCl/1.0mm (Bio-Rad Laboratories, Hercules, CA); HYBOND-C EXTRA 
nitrocellulose membrane (GE Healthcare, Uppsala, Sweden); CL-XPOSURE film 




All specialised hardware used in the experiments is listed below together with 
their source. 
 
2.1.4.1 Pipettes, centrifuge tubes, freezing box and filters 
Positive-pressure pipettes (Gilson, Villiers-le-Bel, France); Pipette-Aid motorised 
(BD Diagnostics, Franklin Lakes, NJ); 1.5 ml conical-bottom polypropylene tubes, 
0.2 µm filters and 70 µm cell strainers (BD Biosciences, Bedford, MA). 
 
2.1.4.2 Blood collection tubes, needles, slides, coverslips, haemocytometer and 
coplin jars 
Vacutainer tubes and needles (BD Vacutainer systems, Franklin Lakes, NJ); 
uncoated microscope slides, coverslips, coplin jars and Neubauer 
haemocytometer (BDH Merck, Whitehouse Station, NJ).  
 
2.1.4.3 Immuno-cell sorting equipment 
MACS multistand, miniMACS separation units and MS columns (Miltenyi Biotech, 
Bergisch-Gladbach, Germany); Dynal Magnetic Particle Concentrator (MPC) 
(Dynal, Oslo, Norway); FACStarPLUS (Becton Dickinson, San Jose, CA). 
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2.1.4.4 Centrifuges for polypropylene tubes, cytocentrifuge and speedvac 
L-80 ultracentrifuge, bench top centrifuge for 15 ml and 50 ml polypropylene 
tubes (Beckman coulter, Fullerton, CA); bench top microcentrifuge for 0.5 ml and 
1.5 ml polypropylene tubes (Sanyo Gallenkamp PLC, Loughborough, UK); 
cytocentrifuge (Shandon, Cheshire, England); Savant speedvac (Model SC110, 
Global Medical Instrumentation, Minnesota). 
 
2.1.4.5 Water bath, thermo bath, thermo cycler and freeze dryer 
Standard water bath (GFL, INNOV Solutions, Milan, Italy); ALB64 thermo bath 
(ESEL TechTra Inc, Korea); freeze dryer (ThermoSavant, Holbrook, NY); PTC-
200 Peltier Thermal Cycler (MJ Research, Watertown, MA). 
 
2.1.4.6 Sonicator, electrophoresis system and supplements 
Misonix sonicator (ultrasonic processor)-XL2020 (Misonix Inc., Farmingdale, NY); 
Electrode wicks, forceps, PowerPac BasicTM, Mini-PROTEAN 3 cell, UltraRocker 
Rocking Platform, Tran-Blot® Semi-Dry Transfer cell, PowerPacTM 3000 power 
supply and GS-800 calibrated densitometer (Bio-Rad Laboratories, Hercules, 
CA); M-35 X-OMAT processor (Kodak, Rochester, NY). 
 
2.1.4.7 Peptides desalting tip and columns 
ZipTip C18 tip (Millipore, Chicago, IL); Sep-Pak-plus C-18 cartridge (Waters, 
Milford, MA). 
 
2.1.4.8 2-D LC, SELDI-TOF-MS and MALDI-TOF/TOF-MS 
LC SCX column, LC trap column, LC RP column, Probot Micro Fraction collector; 
Ultimate Dual HPLC system (LC Packings/Dionex, Sunnyvale, CA); Ciphergen 
ProteinChip SELDI-TOF-MS system and H50 chips (Ciphergen Biosystems, 
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Fremont, CA); Mixing tee (Upchurch Scientific, Oak Harbor, WA); MALDI target 
plate and ABI 4700 Proteomics Analyser (Applied Biosystems, Framigham, MA). 
 
2.1.4.9 Microscope and spectrophotometer 
Microscope (Olympus America, Melville, NY); Beckman DU 650 
spectrophotometer (Beckman Coulter, Fullerton, CA). 
 
2.1.4.10   Computer and software 
IBM R40 (IBM, Armonk, NY); Adobe Photoshop graphics software (Adobe 
Systems Inc., Mountain View, CA); Ciphergen software (v3.0, Ciphergen 
Biosystems, Fremont, CA); GPS Explorer® software (Applied Biosystems, 
Framigham, MA); SPSS Software (SPSS Inc., Chicago, IL); Summit software 





2.2.1 Preparation of Percoll gradient 
Commercially available Percoll has a density of 1.130 g/ml.  Required Percoll 
gradients were prepared from this stock by mixing with 1.5 M NaCl (ρ=1.058 
g/ml) (Percoll Methodology and Applicants 2nd Edition, Amersham Pharmacia 
Biotech, Buckinghamshire, UK).  Percoll has a very low osmolality (<25 mOs/kg 
H2O) and can therefore form density gradients with iso-osmotic solutions (0.15 M 
NaCl or 0.25 M sucrose) without significantly affecting the physiological 
conditions.  This is important for obtaining preparations of cells with intact 
morphology. 
 
To prepare 50 ml of Percoll at a specified density, the following were mixed 
together: 5 ml 1.5 M NaCl; and Percoll (1.130 g/ml), the volume of which was 










ρρVV , where 
V0   = volume of Percoll (1.130 g/ml) in ml 
V    = volume of the final working solution in ml (50 ml) 
ρ    = desired density of the final working solution in g/ml 
ρ0   = density of Percoll stock in g/ml (1.130 g/ml) 
ρ’   = density of 1.5 M NaCl (1.058 g/ml) in g/ml 
Distilled water to make up to 50 ml. 
 
2.2.2 Nucleated and red blood cell count 
Up to 10 µl of a nucleated cell sample was diluted 1 in 2 with 3% glacial acetic 
acid and 10 µl were loaded onto Neubauer haemocytometer.  Nucleated cells 
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were counted under the inverted microscope.  At least 200 cells or four separate 
area were examined and the average number of cells, N, per mm2 (0.1 µl volume) 
determined and the concentration of nucleated cells in the original sample 
calculated (N × dilution × 104 per ml).  To count RBC concentrations manually, 
dilutions were of the order of 1 in 200-400 in 0.4% formalin/0.1M tri-base. 
 
2.2.3 Cytospin preparation 
Up to 5 × 104 nucleated cells were resuspended in 300 µl 0.5% BSA/PBS (w/v), 
loaded into a cytospin chamber and cytospun onto a slide at 500 rpm for 5 min 
inside the cytocentrifuge.  Slides were air dried and processed immediately or 
stored in aluminium foil and parafilm at -20°C. 
 
2.2.4 Wright’s staining 
Cells cytospun onto glass slides were Wright’s stained by sequentially immersing 
in 100% MeOH containing additive for 1.5 min, methylene blue stain solution for 1 
min, eosin Y stain solution for 1 min, rinsed in water.  Processed slides were air 
dried and mounted with coverslips over DPX mountant. 
 
2.2.5 Separation of adult RBCs from whole blood 
Blood from male and female adult volunteers was diluted 1:1 in PBS and carefully 
layered over an equal volume of Ficoll 1077 in 15 ml propylene tubes.  The 
samples were centrifuged at 450 × g at room temperature for 30 min.  The 
supernatant containing mononuclear cell layers was discarded.  The red pellet 
was washed with 5-10 ml PBS four times and each time, the upper 1-2 mm layer 
of packed cells was aspirated along with liquid phase to completely remove 
WBCs.  The resultant RBC pellet was used for slide preparation or membrane 
preparation for protein analysis. 
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2.2.6 Recovery of fetal NRBCs from placental tissues obtained from 
termination of pregnancy 
The placental tissues were carefully dissected off adjacent deciduas and washed 
twice in PBS to remove maternal blood contamination.  The cleaned specimen 
was incubated in 45 ml of trophoblast digestion buffer at 37°C for 30 min under 
vigour shaking.  The trypsin activity was stopped with addition of 5 ml fetal calf 
serum.  The cell suspension was then strained through a 70 µm cell strainer to 
obtain single cell suspension and centrifuged at 2000 × g at room temperature for 
10 min.  The cell pellet was resuspended in 5 ml of PBS, which was layered over 
Percoll 1083 and then centrifuged at 2000 × g for 20 min.  The red pellet 
containing fetal NRBCs was washed once using PBS and resuspended into PBS 
buffer.  Up to 10 µl of the suspension was taken for cell count.  The rest of 
sample was used for slide preparation, mRNA analysis or membrane protein 
analysis.  For protein analysis, the sample was washed twice with HES buffer and 
then stored in 300 µl HES buffer with protease inhibitor cocktail at -80°C. 
 
2.2.7 Adult RBC Membrane preparation 
Adult RBCs were separated as in section 2.2.5.  The RBC pellets were washed 
using PBS and pelleted down by centrifugation for 10 min.  Before membrane 
preparation, purity of RBCs prepared was assessed by examining WBCs in 
cytospin slides: only 7 WBCs (average) per slide containing 5 × 104 RBCs were 
observed (purity >99.9%).  RBC ghosts were prepared as described by Hanahan 
et al. (1974).  Briefly, RBC pellets were resuspended in 30 mM (310 imosM) 
isotonic Tris-HCl buffer (pH 7.6, 4°C) to a hematocrit of 50%.  Cell suspensions 
were diluted 7-fold with 20 imosM Tris-HCl, and incubated at 4°C for 5 min to 
allow hypotonic lysis.  RBC ghosts were pelleted by centrifugation at 20 000 × g 
at 4°C for 45 min in an L-80 ultracentrifuge.  Pellets were washed five times using 
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20 imosM Tris-HCl by centrifugation at 20 000 × g for 45 min until the membrane 
preparation became colourless.  White pellet (ghost cells) was resuspended in 
0.1 M Na2CO3 (pH 11), sonicated and shaken for 20 min at 4°C.  Membrane 
fractions were pelleted down by centrifugation at 100 000 × g at 4°C for 45 min, 
and washed twice with Millipure water.  Membrane pellets were lyophilised and 
stored at -80°C. 
 
2.2.8 Fetal NRBC membrane preparation 
Membranes from pooled fetal NRBCs (5 × 107 cells) were prepared as described 
by Simpson et al. (2000) with some modifications.  Briefly, fetal NRBCs stored in 
HES buffer were lysed by thawing and sonication.  Membranes were then 
pelleted down by centrifugation at 100 000 × g at 4°C for 1 hour, and washed 
once with high pH solution (0.1 M Na2CO3, pH 11) and twice with Millipure water.  
Membrane pellets were lyophilised and stored at -80°C. 
 
2.2.9 Protein estimation 
2.2.9.1 Bradford assay 
The protein contents of samples were determined using Bio-Rad protein assay 
dye reagent concentrate and BSA standards (0.2, 0.6, 1 and 1.4 µg/µl).  10 µl of 
samples or standards were mixed with 390 µl of pure water.  100 µl of Bradford 
dye was added to each mixture and incubated for 5 min.  Absorbance was read 
at 595 nm using a spectrophotometer and protein concentrations were calculated 
based on BSA standard curve. 
 
2.2.9.2 RC DC protein assay 
The protein contents of samples were determined using Bio-Rad RC® DC protein 
assay kit following the manufacturer’s instructions with slight modifications.  25 µl 
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of BSA standards (0.2, 0.6, 1 and 1.4 µg/µl) or samples were mixed with RC® DC 
reagent I and II, and then centrifuged at 15 000 × g for 10 min.  Supernatants 
were discarded and pellets were dissolved in 127 µl of working reagent A (20 µl 
of reagent S per ml reagent A).  Subsequently, 1 ml of reagent B was added into 
the solution and incubated for 15 min.  Absorbance was read at 750 nm using a 
spectrophotometer and protein concentrations were calculated based on BSA 
standard curve. 
 
2.2.10 One-dimensional gel electrophoresis 
Protein samples in SDS-PAGE sample buffer were denatured at 37°C for 30 min 
and centrifuged at 15 000 × g for 1 min.  The samples were loaded into 10% self-
cast polyacrylamide gels or pre-cast Criterion gel (Bio-Rad).  Precision plus 
protein all blue standards were used as molecular weight reference.  
Electrophoresis on the gel was carried out at 120 V for about 90 min in PowerPac 
BasicTM Electrophoresis system. 
 
2.2.11 Two-dimensional gel electrophoresis 
About 100 µg protein was mixed with 2-DE sample buffer to a final volume of 200 
µl and vortexed 4 times for 20 sec at 1 min intervals.  This mixture was applied to 
ReadyStrips (7 cm, pH 4-7) and passively rehydrated at room temperature for 16 
hours.  Proteins were then subjected to isoelectric focusing at 50 V for 2 hours; 
250 V for 1 hour; 500 V for 1 hour; 1000 V for 1 hour and rapidly ramped up to 
8000 V for 3 hours and then maintained at 8000 V for a total of 40 000 V × hours.  
ReadyStrips from the first-dimension were equilibrated with equilibration buffer I 
and II, and then applied to the top of a 4-20% Tris-HCl pre-cast Criterion gel for 
the second dimension separation.  Electrophoresis on the gel was carried out at 
120 V for about 90 min in PowerPac BasicTM Electrophoresis system. 
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2.2.12 Protein bands and spots visualisation  
After electrophoresis, gels were transferred into plastic containers.  The gels were 
incubated in fixative solution for 30 min with gentle shaking and then washed 
twice in 25 ml of deionised water for 10 min each.  Subsequent incubation was 
with 25 ml of silver staining solution.  When the desired staining intensity was 
reached, the gels were placed in 5% acetic acid to stop the reaction and washed 
in deionised water for 5 min.  The images of the stained gels were captured using 
a GS-800 calibrated densitometer. 
 
2.2.13 Western blotting 
The proteins were separated by 1-DE as described in section 2.2.10.  The 
proteins in the gel were transferred onto nitrocellulose membrane using Tran-
Blot® Semi-Dry Transfer cell at a voltage of 15 V for 60 min.  The membrane was 
incubated with 5% non fat dry milk powder in PBST for 60 min and then 
incubated with primary antibody at 4°C, overnight.  The membrane was washed 
thrice in PBST for 10 min each and subsequently incubated with secondary 
antibody conjugated to HRP for 60 min.  The membrane was washed thrice in 
PBST for 10 min each.  The Pierce chemiluminescence HRP substrate was 
added onto the membrane to develop the blotting.  The membranes were 
exposed in the dark room onto X-ray film for appropriate time period for 
visualisation of the chemiluminescence signal.  The X-ray film was developed 
with M-35 X-OMAT processor.  Images of the X-ray films were captured using a 
GS-800 calibrated densitometer. 
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2.2.14 In-gel digestion of proteins for MS analysis 
2.2.14.1   In-gel digestion of proteins from stained gel 
Visible gel bands by silver stain were finely cut into pieces, and transferred into 
600 µl PCR tubes.  A small clean spatula was used to coarsely grind up the gel 
pieces. Destaining was performed by adding 1:1 ratio of 30 mM potassium 
ferricyanide and 100 mM sodium thiosulphate solution, and vortexing.  The 
mixture was washed and dehydrated sequentially in 100 mM NH4HCO3, ACN/50 
mM NH4HCO3 (50:50, v/v).  The sample was dried in a speedvac centrifuge.  
Dried sample was reduced by incubation with a fresh solution of 10 mM DTT in 
100 mM NH4HCO3 at 57°C for 60 min, and alkylated by incubation with 55 mM 
iodoacetamide solution in 100 mM NH4HCO3 at room temperature for 60 min.  
Further procedures included gel washing in 100 mM NH4HCO3 (thrice), 
dehydration in 100% ACN (twice), re-swelling in 100 mM NH4HCO3 (once), 
dehydration in 100% ACN (twice), and drying in a vacuum centrifuge (once).  
Dried sample was re-swelled by adding digestion solution (12.5 ng/µl trypsin in 50 
mM NH4HCO3), and incubated at 4°C for 30 min.  Excess digestion solution was 
removed, and 50 mM NH4HCO3 was added to the sample before incubation at 
37°C, overnight.  After incubation, the solution was centrifuged at 6000 rpm for 10 
min.  The pellet was incubated with 20 mM NH4HCO3 for 5 min and centrifuged at 
6000 rpm for 10 min.  The resultant pellet was finally incubated with 5% formic 
acid in 50% ACN in water for 5 min and centrifuged at 6000 rpm for 10 min.  All 
three supernatants were pooled and dried in a speedvac centrifuge. 
 
2.2.14.2   In-gel digestion of proteins from unstained gel 
After 1-DE separation, a whole protein gel without staining was equally cut into 35 
slices and transferred into 600 µl PCR tubes.  A small clean spatula was used to 
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coarsely grind up the gel pieces.  The destaining procedure was omitted and all 
the other procedures are the same as above. 
 
2.2.15 Peptide sample clean-up 
The protein digests prepared as in section 2.2.14 were dissolved in 0.1% TFA.  
The peptides were extracted using Zip-Tip C18 Cartridge column.  Briefly, Zip-Tip 
column was washed with 100 µl ACN and then with pure water (1 ml) to remove 
ACN.  10-20 µl sample was now pipetted in the column and the sample in the 
column was washed (desalted) with 0.5% formic acid (500 µl).  The desalted 
sample was first extracted using 0.5% formic acid in H2O/ACN (1:1, v/v) mixture 
for 20 sec and the extract collected in a clean PCR tube.  A second extraction 
using 100 µl of ACN for 10 sec was carried out for maximal recovery of peptides 
from the column.  Both extracts were pooled and concentrated for MS analysis. 
 
2.2.16 Adult RBC membrane protein extraction and in solution digestion 
Fresh or lyophilised membranes were resuspended in 50 mM NH4HCO3 (pH 8.0) 
by sonication, and protein concentration was determined using the Bradford 
assay.  Membrane fractions (containing 200 µg protein) were used for the 
following three extraction and digestion methods. 
  
2.2.16.1   Protein extraction using aqueous MeOH and trypsin digestion 
Membrane proteins were extracted using the protocol described by Blonder et al. 
(2002) with some modifications.  Membrane protein extraction was carried out 
using MeOH/50 mM NH4HCO3 (60:40, v/v) mixture with intermittent sonication, 
and the final concentration of solubilised protein was adjusted to 2 mg/ml in 
MeOH/50 mM NH4HCO3 (60:40, v/v).  Pre-digestion procedures included 
reduction of proteins using 2 mM DTT at 37°C for 30 min followed by alkylation at 
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room temperature using 8 mM iodo-acetamide for 1 hour in the dark.  Alkylation 
was stopped by the addition of 2 mM DTT.  Tryptic digestion was carried out 
using sequencing grade modified trypsin 1:20 trypsin-to-protein ratio (w/w) at 
37°C, overnight.  The tryptic digests were lyophilised and stored at -80°C. 
 
2.2.16.2   Protein extraction using aqueous TFE and trypsin digestion 
Membrane proteins were extracted as per the protocol described above, except 
that TFE was used as the solvent in place of methanol and a mixture of TFE/50 
mM NH4HCO3 (50:50, v/v) was used.  The protein concentration was adjusted to 
2 mg/ml in TFE/50 mM NH4HCO3 (50:50, v/v).  Protein reduction and alkylation 
procedures were as described above.  Protein mixtures were then diluted 10 
times with 50 mM NH4HCO3.  Tryptic digestion was carried out as above.  Digests 
were lyophilised and stored at -80°C. 
 
2.2.16.3   Protein extraction using urea solution and trypsin digestion 
Membrane proteins were extracted using 6 M urea in 50 mM NH4HCO3 and the 
protein concentration was adjusted to 2 mg/ml with solid urea and 50 mM 
NH4HCO3.  Protein reduction and alkylation procedures were as described above.  
Protein mixtures were diluted to a final concentration of 1 M urea using 50 mM 
NH4HCO3.  Tryptic digestion was carried out as above.  Digests were desalted 
with Sep-Pak-plus C-18 cartridge, lyophilised and stored at -80°C. 
 
2.2.17 Fetal NRBC membrane protein extraction and trypsin digestion 
Fetal NRBC membranes were prepared as in section 2.2.8.  MeOH and TFE 
were used in this membrane protein extraction and digestion procedure 
sequentially to maximally recover peptides for MS analysis.  Proteins were 
extracted from the purified fetal NRBC membranes using MeOH/50 mM 
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NH4HCO3 (60:40, v/v) and protein reduction, alkylation and digestion were carried 
out as in section 2.2.16.  After centrifugation, the pellet was washed in MeOH 
solution (60% MeOH in 50 mM NH4HCO3) twice.  All supernatants, including 
those from wash steps, were pooled as “MeOH-derived digests”.  The resultant 
pellet was then resuspended and the protein extracted using TFE/50 mM 
NH4HCO3 (50:50, v/v).  Protein mixtures were diluted 10 times with 50 mM 
NH4HCO3 for a second trypsin digestion.  Supernatants recovered from this step 
were defined as “TFE-derived digests”.  The two digests from fetal NRBC 
membranes were lyophilised and stored at -80°C. 
 
2.2.18 SELDI-TOF analysis of proteins and tryptic peptides 
SELDI-TOF profiles for hydrophobic proteins or tryptic peptides were obtained 
using reversed phase protein chips H50.  Protein chips were activated using 5 µl 
of 80% ACN with 0.1% TFA for 5 min.  Five µl of proteins or their tryptic digests 
were spotted onto protein chips, and incubated for 3 hours in a humidity chamber.  
After two washes with PBS, the arrays were semi-air dried. These were then 
treated with saturated sinapinic acid containing 0.5% TFA and 50% ACN, and 
analysed using the Ciphergen protein chip® reader. 
 
Protein mass spectra were generated using (on average) 80 laser shots per 
sample spot.  Data acquisition of low molecular weight peptides was performed in 
the size range set between 0-5 kDa.  Detector intensity was set at 10, and the 
laser intensity was set at 170 V.  Mass-to-charge ratios (m/z) of each of the 
proteins captured on the array surface were determined according to externally 
calibrated standards.  Mass spectra obtained from the spectrometer were 
processed using the Ciphergen protein chip software v3.0 for baseline correction 
and peak detection using standard machine settings. 
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2.2.19 2-D LC separation of tryptic digests 
Tryptic digests were resuspended in 20 µl of solvent (98% H2O, 2% ACN and 
0.05% TFA), and suspensions were separated into insoluble fractions and 
supernatants by centrifugation at 13 000 × g for 5 min.  Supernatants were 
separated using an Ultimate Dual HPLC system coupled with a Famos micro 
autosampler with UV detector and Switchos column switching device.  Six µl of 
sample (approximately 60 µg protein equivalents) was loaded and separated first 
on a SCX LC column (300 µm id × 15 cm) packed with 10 µm of POROS 10S.  
The mobile phases A and B were 5 mM KH2PO4 buffer (pH 3 adjusted with 
H3PO4) + 2% ACN and 5 mM KH2PO4 buffer (pH 3, adjusted with H3PO4) + 2% 
ACN + 500 mM KCl, respectively.  The column flow rate for SCX was 6 µl/min. 
Nine fractions were separated by a step gradient of mobile phase B (unbound, 0-
5, 5-10, 10-15, 15-20, 20-25, 25-30, 30-50, 50-100%).  Eluted fractions were 
captured on the PepMap trap column (300 µm id × 1 mm, packed with 5 µm C18 
100 Å), and eluted by gradient elution to a RP LC column (Monolithic Capillary 
Column, 200 µm id × 5 cm).  The mobile phases A and B used were 98% H2O + 
2% ACN + 0.05% TFA and 20% H2O + 80% ACN + 0.04% TFA, respectively.  
The elution gradient was 0-60% mobile phase B in 10 min (or 60 min for fetal 
NRBC sample) with a flow rate of 2.7 µl/min. 
 
The LC fractions were mixed with MALDI matrix (7 mg/ml α-cyano-4-
hydroxycinnamic acid and 130 µg/ml ammonium citrate in 75 % ACN) at a flow 
rate of 5.4 µl/min through a 25 nl mixing tee before being spotted onto 192-well 
stainless steel MALDI target plates at a rate of one well per 5 sec using a Probot 
Micro Fraction collector. 
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2.2.20 MALDI-TOF/TOF analysis of tryptic peptides 
Samples on the MALDI target plates were analysed using an ABI 4700 
Proteomics Analyser mass spectrometer with a MALDI source and TOF/TOF™ 
optics.  For MS analysis, typically 1000 shots were accumulated for each sample 
well.  MS/MS analysis was performed using nitrogen, at collision energy of 1 kV 
and a collision gas pressure of ~3.0 × 10-7 Torr.  A stop condition was used so 
that 3000 to 6000 shots were combined for each spectrum depending on the 
quality of the data. 
 
2.2.21 Database searching and bioinformatics analysis 
MASCOT search engine (v1.9; Matrix Science) was used to search tandem mass 
spectra.  GPS ExplorerTM software was used to create and search files with the 
MASCOT search engine for peptide and protein identifications.  The International 
Protein Index (IPI) human protein database v2.28 from the European 
Bioinformatics Institute (EBI) was used for the search of tryptic peptides.  MS/MS 
spectra from the LC runs were combined for the search.  Cysteine 
carbamidomethylation, N-terminal acetylation and pyroglutamination, and 
methionine oxidation were selected as variable modifications.  Two missing 
cleavages were allowed.  Precursor error tolerance was set to <100 ppm and 
MS/MS fragment error tolerance was <0.3 Da.  All the proteins identified had at 
least one MS/MS match with an expected value <0.05, and it must be the best 
match.  In addition, peptides with Mascot score more than 30 were counted in the 
reported peptide numbers.  All the MS/MS spectra were further validated 
manually. 
 
Subcellular and functional categories of all identified proteins were obtained on 
the basis of the annotations of Gene Ontology using GoFigure 
(http://udgenome.ags.udel.edu/gofigure/index.html).  The grand average of 
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hydropathicity (GRAVY), a measure of hydrophobicity of proteins and peptides, 
was analysed by ProtParam program (http://tw.expasy.org/tools/protparam.html).  
The number of trans-membrane domains of all identified proteins was predicted 




2.2.22.1   RNA extraction and quantification 
RNA was isolated using an RNeasy Mini Kit according to manufacturer’s 
instructions.  Briefly, fetal NRBCs (about 3 × 106 cells) were washed with PBS 
and then resuspended into 350 µl lysis buffer (RLT*).  The suspension was 
further homogenised by pipetting the lysate directly onto a QIAshredder spin 
column and centrifuged at 15 000 × g for 2 min.  The homogenised lysate was 
mixed with 350 µl of 70% ethanol and pipetted onto an RNeasy mini column, and 
centrifuged at 15 000 × g for 15 sec.  The RNA trapped in the column was 
washed with 350 µl buffer RW1 and incubated with 10 µl of DNase in 70 µl RDD 
buffer at room temperature for 15 min.  The RNA was washed twice with 350 µl of 
buffer RW1 and once with 500 µl buffer RPE# (Qiagen).  The RNA was then 
recovered by addition of 50 µl RNase-free water onto the column and 
centrifugation at 15 000 × g for 1 min. 
 
10 µl RNA was diluted in pure water (v/v, 1:9) and read with spectrophotometer 
using wavelength scan from 220 nm to 350 nm.  The absorbance at 280 nm and 
260 nm were read for the estimation of concentration and purity of RNA.  The 
RNA with an A280/A260 ratio within 1.9-2.1 was used for further experiments. 
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2.2.22.2   RT-PCR 
The cDNA template was synthesised using Sensiscript RT Kit.  Briefly, five µl of 
RNA was mixed with appropriate amount of oligo-dT, RNase inhibitor, dNTP mix 
and RNase-free water, and incubated at 70°C for 5 min and chilled on ice.  RT 
buffer and RT enzyme (in control experiment, RT enzyme was replaced with 
water) were added to the mixture and incubated at 25°C for 15 min, 42°C for 60 
min and 72°C for 15 min.  After the incubation, the mixture was cooled on ice, 
and used for PCR experiments. 
 
Five µl cDNA product was mixed with MgCl2, dNTP, PCR buffer, Taq 
Polymerase, primers and water to give final concentrations of 1× PCR buffer, 1 
mM dNTP, 8 mM MgCl2, 2.5 U Taq Polymerase, and 0.6 µM primers (Table 2-1).  
PCR was performed with a PTC-200 Peltier Thermal Cycler.  Optimal annealing 
temperature was obtained for each primer pairs.  The mixture was denatured at 
94°C for 2 min and followed with a 45 cycle of amplification.  A typical cycle was 
94°C for 15 sec, ~60°C (depends on primer pairs) for 15 sec, 72°C for 1 min.  A 
final extension at 72°C for 4 min was performed for each gene.  The negative 
controls included RT control (no enzyme in RT step) and PCR control (Water 
blanks).  After amplification, the PCR products were separated by electrophoresis 
in a 2% agarose gel, stained with ethidium bromide (0.5 g/ml) and visualised 
under UV light.  The images were captured using a digital imager (Alpha Innotech 
Corp., San Leandro, CA). 
 
2.2.23 Immunocytochemistry 
The cells on glass slides were fixed in methanol/acetone (v/v, 1:1) at room 
temperature for 2 min.  The slides were rinsed in PBS for 30 sec; air dried and 
framed of cell area with hydrophobic pen.  The slides were rehydrated in PBST 
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for 1 min.  They were incubated with goat serum in PBS (1:10) for 2 hours and 
then incubated with primary antibody for 1 hour, and were washed twice in PBST 
for 5 min after each incubation.  Subsequent incubations were with biotinylated 
goat-anti-mouse antibody or goat-anti-rabbit antibody and with streptavidin 
alkaline phosphatase for 30 min each.  The slides were washed twice in PBST for 
after each incubation.  Vector blue substrate was added onto the glass slides and 
incubated in the dark for 10 min.  The slides were rinsed in distilled water for 30 
sec and then dehydrated in 100% ethanol for 30 sec and air dried.  The slides 
were mounted with Vector shield mounting medium and observed under light 
microscope. 
 
2.2.24 Measuring intensity of colour using Adobe Photoshop 
The amount of antigen (e.g. CD147) expressed on the cell surface were 
compared using the luminosity histogram function on graphics software (Adobe 
Photoshop).  Photographs of immuno-stained cells were digitised by reflective 
scanning at 300 dots per inch.  Mean pixel intensity from up to five small 
cytoplasmic areas of cells was determined and luminosity (brightness) 
determined on 256 grey scale (arbitrary units, AU). 
 
2.2.25 Immunomagnetic cell separation 
 
2.2.25.1   Dynal system 
Positive and negative selection using the Dynal system was performed with only 
minor modifications to the manufacturer’s instructions.  Cells to be enriched were 
suspended in sorting buffer (50 µl for up to 107 total cells) in a 1.5 ml Eppendorf 
tube and incubated with appropriate anti-human murine monoclonal antibody at 
4°C for 30 min.  After washing twice with buffer, the cell pellet was resuspended 
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in 500 µl sorting buffer and incubated with 5 µl pre-washed goat anti-mouse IgG 
conjugated Dynabeads M-450 at 4°C for 30 min with slow end-over-end rotation.  
The cells bound to the beads were collected by placing the tube in the MPC.  The 
supernatant was transferred into a new tube as negative fraction.  The cells 
bound with beads were washed twice and lastly incubated with releasing buffer 
(DNase I in sorting buffer) at room temperature for 15 min.  500 µl sorting buffer 
was added and the suspension was mixed by pipetting.  The tube was placed in 
the MPC for 2 min and the supernatant was transferred into a new tube as 
positive fraction.  The cells in positive and negative fraction were pelleted down 
and resuspended into suitable volume for cell count. 
 
2.2.25.2   MACS sorting 
Positive selection using the MACS immunomagnetic separation system was 
performed with only minor modifications to the manufacturer’s instructions.  Cells 
to be enriched suspended in sorting buffer (100 µl for up to 107 total cells) and 
incubated with appropriate anti-human murine monoclonal antibody at 4°C for 30 
min.  After washing twice with buffer, the pellet was resuspended in 80 µl of 
sorting buffer and incubated with 20 µl rat anti-mouse IgG conjugated to Miltenyi-
MACS microbeads at 4°C for 30 min with gentle mixing every 6 min.  The cell 
mixture was washed, and the pellet was resuspended in sorting buffer and 
passed through the MS columns attached to the MACS multi-stand via the 
miniMACS separation units.  Unlabelled cells that passed through the columns 
were collected as the negative fraction.  Cells of the positive fraction, retained 
within the columns, were collected by positive fraction.  The cells in positive and 
negative fraction were pelleted down and resuspended into appropriate volume 
for cell count. 
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2.2.26 Fluorescence-activated cell sorting 
Cells to be enriched suspended in sorting buffer (100 µl for 106 total cells) and 
incubated with appropriate anti-human monoclonal antibody conjugated with 
FITC at 4°C for 30 min.  The cells were washed twice, and the pellet was 
resuspended in 1 ml sorting buffer and sorted by flow cytometry by using 
FACStarPLUS machine.  Positive and negative cells were sorted into different 
tubes coated with 5% BSA.  The cells were pelleted down and resuspended into 
appropriate volume for cell count. 
 
2.2.27 Statistical Analysis 
Distributions were determined by plotting the data as histograms.  Statistics used 
include mean, sample size, standard error (SE), 95% confidence interval (CI; 
1.96SE), and one way analysis of variance (ANOVA). 
 98 
Chapter 3 Proteomic Analysis of RBC Membrane 




This thesis focuses on the identification of unique membrane protein(s) that could 
be used to differentiate primitive fetal NRBCs from adult anucleate RBCs.  In this 
chapter, I aimed to analyse adult RBC membrane proteins using various 
proteomic strategies (including gel-based approach and shotgun method), in 
order to: (1) obtain a more comprehensive RBC membrane proteome for future 
comparison with fetal NRBC membrane proteome; and (2) determine an efficient 
proteomic strategy for fetal NRBC membrane protein analysis. 
 
Adult RBCs, due to the ease in accessibility and lack of internal organelles, have 
been studied extensively, and thus the identity, function, and topology of many 
RBC membrane proteins have been determined (Kakhniashvili et al., 2004; Low 
et al., 2002; Steck 1974).  With advance of modern MS and its associated 
proteomic technologies, however, a more comprehensive RBC membrane 
proteome can be obtained, as it was shown in the result and also in the recent 
report by Pasini et al. (2006). 
 
Moreover, study of adult RBCs is necessary before the analysis of fetal NRBCs 
because it would help us to determine an optimal proteomic strategy for 
membrane protein analysis.  In our study, fetal NRBCs were harvested from the 
trophoblastic villi of placental tissues collected at termination of pregnancy (TOP) 
and the cell numbers were often small (~1×106 cells/TOP).  Thus, it was highly 
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desirable to determine an efficient method for membrane proteome analysis 
using adult RBCs, which could be then applied to the analysis of a limited amount 
of fetal NRBC sample. 
 
3.2 Optimisation of RBC membrane preparation 
Aim.  Fractionation of complex protein sample into a relatively simple components 
helps to increase the chance of identifying low abundance proteins and maximise 
the coverage of the proteome.  It has been shown that high pH washing of 
membranes helped to enrich membrane proteins (Fujiki et al., 1982) and its use 
increased the identification of membrane proteins (Zhao et al., 2004).  Here, I 
aimed to study the effect of high pH washing on our RBC membrane preparation. 
 
Investigation.  RBCs were separated from 2 ml of adult blood (~6×109 RBCs) 
using Ficoll 1077 density gradient (section 2.2.5).  RBC ghosts were prepared as 
described by Hanahan et al. (1974) (crude membrane preparation).  Half of the 
RBC ghosts were further washed in a high pH solution (0.1 M Na2CO3, pH 11) 
(section 2.2.7) (purified membrane preparation).  The protein yields of the two 
preparations were estimated as described in section 2.2.9.  The qualities of the 
two membrane preparations were assessed using western blotting by detecting 
two target proteins, integral membrane protein Band 3 and cytoplasmic protein 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (section 2.2.13). 
 
Results.  The protein yield was 1.42 µg per 106 RBCs in crude membrane 
preparation; whereas it was 0.55 µg per 106 RBCs in purified membrane 
preparation.  The high pH washing step resulted in a lower yield of proteins but a 
significant enrichment of membrane proteins: there was a 3.5-fold increase in 
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Band 3, and a reciprocal disappearance of GAPDH to undetectable levels on 
western blotting (Figure 3-1). 
 
Figure 3-1 Western blotting analysis of RBC membrane preparation with 
Band 3 and GAPDH monoclonal antibodies 
Lane 1, RBC cell lysate; lane 2, RBC membrane preparation without high pH 
washing; lane 3, RBC membrane preparation with high pH washing.  Protein (2 
µg) was loaded in each lane. Western blotting indicates a 3.5-fold increase in 
Band 3 (membrane protein), and a reciprocal disappearance of GAPDH 




Interpretation.  With the commonly used RBC ghost preparation protocol, the 
majority of cytosolic proteins (e.g. haemoglobin) could be efficiently depleted, but 
some of membrane-associated cytosolic proteins (e.g. GAPDH) were instead 
enriched together with integral membrane proteins (Figure 3-1).  The use of a 
high pH washing helped to release membrane-associated cytosolic proteins from 
RBC membrane (Fujiki et al., 1982) and thus resulted in an enrichment of the 
membrane proteins. 
 
The enriched membranes were then used for proteome analysis by either gel-
based method (2-DE/1-DE followed by MS) (section 3.3 and 3.4) or shotgun-
based approach (LC-MS/MS) (section 3.5). 
 
3.3 2-DE separation of RBC membrane proteins 
Aim.  2-DE has been used for separation of the proteins in RBC ghost 
preparation (Low et al., 2002), in which 102 proteins, but including only 2 integral 
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membrane proteins, were identified.  If similar resolution (e.g. >100 spots) could 
be visualised in the 2-DE separation of our purified RBC membrane preparation 
which contained enriched membrane proteins, 2-DE and MS would be very useful 
for subsequent membrane protein identification.  Thus, I aimed to test the 
suitability of 2-DE for the separation of proteins in our purified RBC membrane. 
 
Investigation.  RBC ghost preparation (crude membrane) and RBC ghost 
preparation followed by high pH washing (purified membrane) were carried out as 
described in section 2.2.7.  Both crude and purified membranes were solubilised 
into 2-DE sample buffer for protein extraction and then separated by 2-DE in 
triplicate.  The protein gels were silver-stained, and spot detection was performed 
with the PDQuest software package (v. 7.2) (section 2.2.11). 
 
Results.  2-DE separations of proteins from crude RBC membrane and purified 
RBC membrane preparations were shown in Figure 3-2.  While good separation 
of proteins from crude RBC membrane preparation was observed, only a few 
spots were detected from purified RBC membrane sample, suggesting that 2-DE 
was not suitable for separation of the proteins in our purified RBC membrane. 
 
Interpretation.  In the crude membrane preparation, many membrane-associated 
proteins were enriched as discussed in section 3.2.  These proteins are generally 
relatively hydrophilic, and could be separated well using 2-DE as demonstrated 
by Low et al. (2002) and this study (Figure 3-2): many protein spots were 
observed.  In contrast, hydrophilic proteins were nearly depleted in the purified 
membrane sample, and accordingly the protein spots were not detected.  As a 
result, very few spots were observed in the 2-DE separation, suggesting that 2-
DE was not very suitable for the separation of proteins from our purified RBC 
membrane preparation.  Thus 2-DE was not used for further study. 
 102 
Figure 3-2 2-DE separation of RBC crude membrane and purified membrane 
preparations 
Representative silver-stained 2-DE protein profiles of crude membrane 
preparation and purified membrane preparation.  Protein (100 µg) was extracted 
and focused.  The first dimension is pH 3–10 linear gradients and the second 
dimension is a 4–20% gradient gel.  Molecular weight markers are indicated on 
the right and approximate isoelectric point (pI) is indicated across the top of the 
gels.  The circle area corresponded to abundance protein Band 3 (with possible 
degradation). 
 
          (A) 2-DE of RBC crude membrane 
 
 
          (B) 2-DE of RBC purified membrane 
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3.4 1-DE separation of RBC membrane proteins and MS analysis 
Aim.  Currently, there are two common 1-DE based proteomic strategies for the 
analysis of membrane proteome: (1) proteins are separated using SDS-PAGE 
and then silver-stained.  The visible bands are then cut for peptide elution and 
MS analysis; (2) proteins are separated by SDS-PAGE, and the whole protein gel 
without silver stain is equally cut into certain number of slices for peptide elution 
and MS analysis.  Here I tested both methods for RBC membrane protein 
separation and identification. 
 
3.4.1 Protein identification from silver stained 1-DE gel 
 
Investigation.  The purified RBC membrane was dissolved into SDS-PAGE 
sample buffer.  Proteins were separated by SDS-PAGE as described in section 
2.2.10.  Protein bands were visualised using Bio-Rad silver stain plus kit.  The 
bands were cut separately (similar bands from all 6 lanes were pooled) for in-gel 
digestion (section 2.2.14), and the eluted peptides were desalted (section 2.2.15) 
and analysed using MALDI-TOF/TOF-MS. 
 
Results.  SDS-PAGE separation of RBC membrane proteins with 10 µg proteins 
loaded per well in an 8% polyacrylamide gel was shown in Figure 3-3.  All visible 
bands (31) (as shown) were cut for in-gel digestion and MS analysis.  With this 
approach, a total of 14 proteins (2 integral membrane proteins and 8 peripheral 






Figure 3-3 SDS-PAGE separation and silver stain of RBC membrane proteins 
Protein (10 µg) was loaded in each lane in an 8% polyacrylamide gel.  A total of 
31 distinct bands were cut separately (bands from all 6 lanes were pooled), and 




Interpretation.  Membrane proteins are usually large and have high molecular 
weight.  Thus, low percentage of polyacrylamide gel (8%) was used, as it has 
large-size pore and better resolution of high molecular weight proteins.  In 
addition, similar bands from 6 lanes were pooled for in-gel digestion to elute more 
peptides for MS analysis.  With these procedures, I was able to identify many 
major RBC membrane proteins (e.g. from Band 1 to 7), but unable to recover 
other less abundance well-known proteins, such as GPA, GPC and rhesus blood 
group, indicating the low efficiency of this method for RBC membrane protein 
analysis.  Two possible reasons are: (1) the use of uniformly 8% polyacrylamide 
gel for protein separation does not provide good solution of all RBC membrane 
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proteins; and (2) silver stain of proteins interferes with their subsequent 
identifications as shown in a later study (Richert et al., 2004). 
 
Table 3-1 Proteins identified from silver stained 1-DE gel 
 





1 Spectrin alpha chain, erythrocyte 1174412 4 38 
2 Spectrin, beta, erythrocytic 27413156 1 32 
3 Solute carrier family 4, anion exchanger, 
member 1 4507021 4 47 
4 Ankyrin 1, erythrocyte splice form 3 1360744 5 38 
5 Erythrocyte membrane protein band 4.1 42716291 1 42 
6 Erythrocyte membrane protein band 4.2 112798 2 41 
7 Erythrocyte membrane protein p55 4505237 1 24 
8 Flotillin 2 4758394 2 35 
9 Flotillin 1 5031699 6 30 
10 Actin, beta 14250401 3 47 
11 Tropomodulin 1 4507553 3 37 
12 Aldolase A 4557305 1 28 
13 Glyceraldehyde-3-phosphate dehydrogenase 31645 1 35 
14 Band 7.2b stomatin 1103842 3 35 
Best ion score: a MASCOT score of best match peptide 
 
3.4.2 Protein identification from unstained 1-DE gel 
 
Investigation.  In previous section, I have shown that uniformly 8% gel for RBC 
membrane protein separation followed by silver stain prior to peptide elution and 
MS analysis yielded unsatisfactory results.  In this section, the purified RBC 
membranes were dissolved in SDS-PAGE sample buffer.  Proteins were 
separated using a gradient gel (Crtgel 4-20%, 1 mm, Bio-Rad).  The separation of 
each sample was carried out in duplicate and optimal protein loading was 15 µg 
protein per lane for this type of gel.  One gel was silver-stained as a reference for 
band cutting.  The other without staining was equally cut into 35 slices.  Each 
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slice was in-gel digested, and the eluted peptides were desalted and 
subsequently analysed using MALDI-TOF/TOF-MS. 
 
Results.  SDS-PAGE separation of RBC membrane proteins using Crtgel gel was 
shown in Figure 3-4.  The proteins were well-separated and the bands were very 
fine.  The unstained gel was equally cut for in-gel digestion and MS analysis as 
illustrated in Figure 3-4.  With this approach, a total of 30 proteins (8 integral 
membrane proteins and 9 peripheral membrane proteins) were identified (Table 
3-2). 
 
Figure 3-4 SDS-PAGE separation of RBC membrane proteins using Crtgel 
gel 
Protein (15 µg) was loaded in each lane.  The figure shows a silver stained gel, 
and its duplicate gel without staining were equally cut into 35 slices for in-gel 
digestion (slices from all 4 lanes were pooled), and subjected to in-gel digestion 




Interpretation.  With the gradient gel, despite more proteins loaded into each lane, 
the separation was better as shown that each band was very fine and clearly 
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separated (Figure 3-4) as compared with uniformly 8% polyacrylamide gel.  The 
better separation reduced the possibility of less abundance proteins being 
masked by abundance proteins (e.g. Band 3), thereby increased the chance of 
identifying low abundance proteins.  In addition, protein gel without silver stain 
was cut for in-gel digestion, which simplified in-gel digestion procedures and 
excluded the interference of silver with MS analysis.  As a result, the number of 
total and integral membrane proteins identified was significantly increased as 
compared to that in section 3.4.1. 
 
Using this approach, not only could major RBC membrane proteins be identified, 
but also many less abundant integral membrane proteins such as aquaporin-1, 
glycophorin C, and CD59 were identified.  However, the gel-based method 
yielded a relatively small number of proteins when compared to a more recent 
shotgun proteomic analysis of RBC membrane proteins (Kakhniashvili et al., 
2004), where a total of 99 proteins (including 21 integral membrane proteins) 
were identified from RBC membrane.  Moreover, the facilities for shotgun 
analysis were newly available in our university.  Thus, I also attempted to use 












Table 3-2 Proteins identified from unstained 1-DE gel 
No.   Protein Name Accession Number 
Peptide  
Count 
Best Ion  
Score 
1   Band 3 anion transport protein IPI00022361 16 156 
2   Erythrocyte band 7 integral membrane protein IPI00219682 9 132 
3   Hemoglobin beta chain IPI00218816 6 112 
4   Solute carrier family 2 (facilitated  
  glucose transporter) member 1 IPI00220194 5 92 
5   Alpha 2 globin variant IPI00410714 2 138 
6   Aquaporin-1 IPI00024689 2 137 
7   Glycophorin C IPI00218128 1 159 
8   Spectrin, alpha, erythrocytic 1  IPI00220741 4 68 
9   Ankyrin 1 isoform 1 IPI00216697 3 74 
10   Ras-related protein RAP-2b IPI00550907 2 63 
11   Rhesus blood group, CcEe antigens IPI00465155 2 55 
12   Chromosome 9 open reading frame 19 IPI00479010 1 96 
13   Erythrocyte membrane protein band 4.2 IPI00028614 2 56 
14   CD59 glycoprotein precursor IPI00011302 1 81 
15   Spectrin beta isoform a IPI00216704 2 37 
16   11 kDa protein IPI00514389 1 69 
17   Similar to flotillin 2 IPI00386741 2 38 
18   Stomatin-like protein 3 IPI00152125 1 62 
19   Band 4.1-like protein 1 IPI00024062 1 53 
20   Membrane protein C21orf4 IPI00010146 1 50 
21   Actin, aortic smooth muscle IPI00008603 1 49 
22   Similar to mouse 1500009M05Rik protein IPI00166865 1 50 
23   Proteolipid protein 2 IPI00030362 1 46 
24   Probable helicase senataxin IPI00142538 1 44 
25   Predicted: hypothetical protein XP_291007 IPI00216817 1 42 
26   Titin protein IPI00455173 1 41 
27   Hypothetical protein FLJ42537 IPI00446235 1 41 
28   Protease serine 2 isoform B IPI00011695 1 41 
29   Oxysterol binding protein-related protein 10 IPI00032971 1 41 





3.5 Shotgun proteomic analysis of RBC membrane proteins 
SDS-PAGE coupled with MS analysis is very useful for membrane protein study, 
as the protein solubility is seldom a problem (section 1.7.5.1) and in-gel digestion 
of the denatured proteins is efficient (Lu et al., 2005).  However, several 
limitations are associated with the gel-based method: (1) there is a significant 
loss of peptides during the tedious in-gel digestion procedures (Zhang et al., 
2004); and (2) the limited resolving power of SDS-PAGE often results in poor 
separation of complex protein samples (e.g. several proteins in one small band), 
in which low abundance proteins are masked.  This situation is even worse in the 
study of RBC membrane due to vast dynamic range: the most abundant 
membrane protein (Band 3) accounts for about 30% of the total RBC membrane 
proteins (1.2 × 106 molecules per RBC), whereas some receptors are only about 
500 molecules per RBC (e.g. CR1).  Moreover, Band 3 is easily degraded even 
with careful membrane preparation (Jennings et al., 1986).  Thus when SDS-
PAGE is used to separate RBC membrane proteins, it is often found that Band 3 
is distributed in many bands as observed by us and Low et al. (2002), which 
could cause the failure of the identification of less abundance proteins due to 
being masked. 
 
This problem could be partially overcome by using LC to separate the peptides 
eluted from each band prior to MS analysis, but it means that a large number of 
LC separations are required as there are many protein bands.  Alternatively, a 
gel-free approach (shotgun proteomics) could be used for the RBC membrane 
protein analysis, where proteins are extracted and digested in solution and then 
analysed using LC-MS/MS.  This approach is sensitive, reproducible, rapid 
(required only one injection for LC separation) and high throughput. 
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In shotgun approach, a solution, that can effectively extract membrane proteins 
and compatible with enzymatic digestion, is crucial for efficient peptide recovery 
for MS analysis.  In this section, I tested three solvents (urea, MeOH and TFE) for 
shotgun proteomic analysis of RBC membrane proteins, and based on the 
results, I would determine a most efficient strategy using a solvent or their 
combination for the subsequent analysis of fetal NRBC membrane proteins. 
 
3.5.1 Membrane protein extraction and digestion 
 
Aim.  Urea solution is widely used to extract membrane proteins for 2-DE 
separation (Ueno et al., 2000) and shotgun proteomics (Wu et al., 2003); MeOH 
solution has been newly developed for membrane protein analysis in a shotgun 
approach (Blonder et al., 2002); and TFE is traditionally used together with CHCl3 
for miscible extraction of membrane proteins for 2-DE separation (Zuobi-Hasona 
et al., 2005) and has recently used for shotgun proteomic analysis of cell lysate 
(Wang et al., 2005).  Here, I tested these three solvents for the extraction and 
digestion of proteins from RBC membrane, and the effectiveness of protein 
extraction and digestion processes in three solvents were assessed. 
 
Investigation.  Equal amount of purified RBC membranes (containing 200 µg 
proteins) was used for following three extraction and digestion procedures: (1) 
membrane proteins were extracted in 60% MeOH and followed by tryptic 
digestion in same solution; (2) membrane proteins were extracted using 50% TFE 
and followed by tryptic digestion in diluted solution (5% TFE); and (3) membrane 
proteins were extracted using 6 M urea and followed by tryptic digestion in 1 M 
urea (section 2.2.16).  The efficiencies of protein extraction and digestion 
processes in three solvents were assessed and compared using SDS-PAGE and 
SELDI-TOF as described in section 2.2.18. 
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Results.  SDS-PAGE comparison of the three tryptic digests, with undigested 
RBC membrane protein preparations as a control, revealed that extractions and 
digestions in MeOH, TFE and urea were effective (Figure 3-5).  Only two bands, 
those of trypsin and its self-cleavage product (25 kDa and 17 kDa, respectively), 
were observed in the membrane protein digest lanes when compared with the 
undigested RBC membrane sample lane.  These data suggested efficient 
extraction and adequate digestion of membrane proteins in MeOH, TFE and urea 
solutions. 
 
Figure 3-5 SDS-PAGE analysis of RBC membrane proteins and their tryptic 
digests show the effective digestion 
Lane 1, RBC membrane protein (undigested); lane 2-4, RBC membrane protein 
digests using MeOH, TFE and urea methods respectively; 15 µg of protein or 
their digests was loaded in each lane.  Arrows indicate bands corresponding to 





SELDI-TOF analyses of the digests using reversed phase protein chip H50, that 
bind mainly but not exclusively hydrophobic analytes, also confirmed efficient 
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digestion of the membrane proteins with trypsin (Figure 3-6).  Most peaks were 
detected in the mass range of less than 5 kDa, and some peaks ranged between 
5-10 kDa.  The peaks with masses of 25 kDa and 17 kDa were similar to those 
observed in the SDS-PAGE separation of the digests. 
 
Figure 3-6 SELDI-TOF analysis of RBC membrane proteins and their tryptic 
digests the effective digestion. 
Digests analysed (0-40 kDa) is shown in Figure 3-6a.  Only trypsin and self-
cleaved product detected (17 kDa and 25 kDa) in high Mw range indicates the 
efficient digestion.  Peptide peaks (<5 kDa) are shown in Figure 3-6b. 
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Interpretation.  MeOH and urea have been previously used for membrane 
extraction and digestion process (Blonder et al., 2002; Wu et al., 2003).  TFE is 
commonly used at high concentrations to solubilise, and study protein and 
peptide structure as it is able to stabilise protein secondary structures (especially 
alpha-helices) while destabilising tertiary and quaternary structure (Buck 1998).  
In a phase partition system with chloroform, TFE was able to satisfactorily extract 
membrane proteins with a wide range of properties (Deshusses et al., 2003).  It is 
















identification, but the use of TFE for isoelectric focusing has been shown to 
significantly increase the number and intensity of spots from membrane fractions 
(Deshusses et al., 2003).  That these were intrinsic membrane proteins was 
confirmed by MS/MS.  Similar use of CHCl3/TFE mixtures for membrane protein 
extraction enhanced the resolution of spots, and allowed double the number of 
spots to be visualised when compared with membrane extraction using 1% SDS 
buffer (Zuobi-Hasona et al., 2005).  These observations indicate a higher 
efficiency for membrane extraction using the organic solvent TFE compared with 
strong detergents such as SDS. 
 
In summary, the analysis of the three digests by both SDS-PAGE and SELDI-
TOF suggested efficient extraction, and adequate digestion of membrane 
proteins in aqueous MeOH, TFE and urea solutions.  Thus all three solvents were 
suitable for studying membrane proteins in a shotgun approach. 
 
3.5.2 Mass spectrometric analysis of membrane protein digests 
 
Aim.  In section 3.5.1, it was shown that the three procedures were efficient for 
RBC membrane protein extraction and digestion.  Thus, I used these methods to 
prepare peptides for the subsequent 2-D LC MALDI-TOF/TOF-MS analysis in 
order to identify proteins from RBC membrane. 
 
Investigation.  The digests from three extraction and digestion procedures were 
separated using 2-D LC as described in section 2.2.19.  The LC fractions were 
mixed with MALDI matrix and then directly spotted onto 192-well MALDI target 
plates using a Probot Micro Fraction collector.  The samples on the plates were 
analysed using MALDI-TOF/TOF-MS.  Database searching and bioinformatic 
analysis were carried out following the protocol described in section 2.2.21. 
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Results.  Both common and unique proteins were identified from the three 
extraction methods.  The 106 proteins identified were presented in Table 3-3.  
Information for each identified protein includes the protein name, protein 
accession number, protein molecular mass pI, number of identified peptides, 
score of best peptide match and number of transmembrane domain (TMD).  
Nineteen proteins were identical in all three methods, and 30, 14 and 24 unique 
proteins were identified using MeOH, TFE and urea, respectively (Figure 3-7).  
Among the 106 proteins, 47 were integral membrane proteins and contained at 
least 1 TMD (Figure 3-8): MeOH, 25; TFE, 22; and urea, 23, respectively.  


















Figure 3-7 Schematic graphs showing the number of total proteins identified 
using 2-D LC-MALDI-TOF/TOF-MS from MeOH, TFE and urea recovered 
peptides 
A total of 106 proteins were identified in this study (MeOH: 61, TFE: 46 and urea: 





Figure 3-8 Schematic graphs showing the number of integral membrane 
proteins identified using 2-D LC-MALDI-TOF/TOF-MS from MeOH, TFE and urea 
recovered peptides 







Table 3-3 The proteins identified from urea, MeOH and TFE extracted samples 
 
UREA MeOH TFE 






















1 Ankyrin 1 isoform 4 IPI00374973 203278.55 5.72 0 56 212 78 207 42 167 
2 Spectrin, alpha, erythrocytic 1 (elliptocytosis 2) IPI00220741 280883.88 4.98 0 35 177 39 211 33 117 
3 
Splice Isoform 2 of Spectrin beta chain, 
erythrocyte IPI00216704 267589.56 5.24 0 36 161 35 153 34 127 
4 Band 3 anion transport protein IPI00022361 101727.41 5.08 11 19 212 26 178 16 201 
5 Splice Isoform 1 of Protein 4.1 IPI00003921 96957.32 5.45 0 19 154 23 183 11 110 
6 Erythrocyte membrane protein band 4.2 IPI00028614 76793.61 8.27 0 17 149 15 142 13 130 
7 55 kDa erythrocyte membrane protein IPI00215610 52263.65 6.91 0 6 133 5 225 9 91 
8 Erythrocyte band 7 integral membrane protein IPI00219682 31579.70 7.9 1 11 178 6 88 7 150 
9 
Solute carrier family 2,facilitated glucose 
transporter member 1 IPI00220194 54082.52 8.93 12 10 194 12 140 7 144 
10 Hemoglobin alpha-1 globin chain IPI00410714 15247.93 8.72 0 5 184 8 171 6 103 
11 Flotillin 1 IPI00027438 47325.62 7.08 0 3 114 5 134 9 116 
12 Flotillin 2 IPI00029625 41659.24 5.23 0 5 74 8 130 6 112 
13 Hemoglobin delta subunit IPI00473011 15914.25 7.97 0 4 82 6 138 5 115 
14 
Beta-globin gene from a thalassemia patient, 
complete cds IPI00382950 18918.59 6.28 0 4 136 2 57 4 121 
15 Actin, cytoplasmic 2 IPI00021440 41765.79 5.31 0 5 162 2 159 4 104 
16 
Splice Isoform 6 of Plasma membrane calcium-
transporting ATPase 4 IPI00217169 133845.70 6.04 8 1 124 6 99 3 105 
17 Splice Isoform 2 of Glycophorin C IPI00218128 11491.61 4.76 1 1 148 3 133 1 128 
18 Splice Isoform Long of Dematin IPI00292290 45486.22 8.94 0 1 76 1 73 1 61 
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Table 3-3.  Continued 
          
19 CD44 antigen precursor IPI00305064 81503.40 5.13 1 1 60 1 47 1 52 
20 Multidrug resistance-associated protein 4 IPI00006675 149445.70 8.48 11 2 94 1 44   
21 Ras-related protein Rab-10 IPI00016513 22526.59 8.59 0 1 44 2 44   
22 Calnexin precursor IPI00020984 67525.85 4.47 1 3 107 1 94   
23 Aquaporin-1 IPI00024689 28377.02 7.15 6 2 195 2 59   
24 PREDICTED: similar to Zgc:66168 protein IPI00296120 17639.35 9.3 0 2 53 3 98   
25 
Splice Isoform 1of Intercellular adhesion 
molecule 4 precursor IPI00396335 25914.66 10.19 0 1 47 2 52   
26 Actin, alpha cardiac IPI00023006 41991.88 5.23 0 4 82   3 83 
27 Rhesus blood group-associated glycoprotein IPI00024094 44169.66 6.19 12 2 151   2 113 
28 Kell blood group glycoprotein IPI00220459 82770.92 8.09 1 8 114   5 96 
29 Rhesus blood group CE protein IPI00465155 45421.20 9.4 12 3 66   4 60 
30 ATP-binding cassette half-transporter IPI00465442 99649.17 9.26 9 5 126   4 49 
31 Calreticulin precursor IPI00020599 48111.82 4.29 0 1 63   1 56 
32 PREDICTED: unc-13 homolog A IPI00164441 187567.52 5.51 0 1 40   1 42 
33 Cathepsin G precursor IPI00028064 28819.07 11.19 0   1 52 1 58 
34 Erythroid membrane-associated protein IPI00044556 52571.60 8.75 1   3 68 2 96 
35 Glyceraldehyde 3-phosphate dehydrogenase IPI00219018 43990.02 9.73 0   1 46 3 78 
36 Urea transporter, erythrocyte IPI00298337 42499.76 6.79 8   2 67 1 100 
37 Stomatin IPI00377081 13466.03 7.82 1   4 72 4 113 
38 Glycophorin Erik I-IV precursor IPI00384414 9326.04 5.16 1   2 115 2 85 
39 27 kDa protein IPI00641837 27263.67 9.23 3 6 152     
40 Rhesus blood group D antigen IPI00478119 53180.05 9.19 10 3 131     
41 
Splice Isoform A of Ras-related C3 botulinum 
toxin substrate 1 IPI00010271 21436.24 8.77 0 2 70     
42 Semaphorin-7A precursor IPI00025257 74776.17 7.57 0 2 49     
43 S100 calcium-binding protein A7 IPI00219806 11318.51 6.26 0 2 35     
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44 Probable endonuclease KIAA0830 precursor IPI00001952 54981.26 5.55 3 1 71     
45 UPF0198 protein CGI-141 IPI00007061 15415.41 10.36 3 1 78     
46 
Golgi-associated plant pathogenesis-related 
protein 1 IPI00007067 17076.48 9.44 0 1 99     
47 Ras-related protein Rab-21 IPI00007755 24201.21 8.16 0 1 42     
48 CD59 glycoprotein precursor IPI00011302 14167.79 6.02 0 1 90     
49 Ras-related protein Rab-5B IPI00017344 23691.90 8.29 0 1 67     
50 Splice Isoform 1 of Beta-adducin IPI00019904 80803.43 5.67 0 1 76     
51 Suppressor of actin 1 IPI00022275 66908.01 6.66 2 1 43     
52 PREDICTED: similar to Reticulon protein 3 IPI00177423 25506.59 8.67 1 1 49     
53 
Splice Isoform 2 of Sodium channel protein type I 
alpha subunit IPI00216029 227641.81 5.65 19 1 41     
54 Similar to expressed sequence AA536743 IPI00216890 29321.88 8.57 2 1 60     
55 Triadin IPI00220272 81374.51 9.42 1 1 54     
56 Splice Isoform 1 of Vacuolar protein sorting 13A IPI00255301 360047.44 5.94 0 1 53     
57 Ras-related protein Rab-35 IPI00300096 23010.77 8.52 0 1 72     
58 NADH-cytochrome b5 reductase IPI00328415 34081.68 7.31 0 1 102     
59 Multidrug resistance-associated protein 5 IPI00385383 160856.16 8.87 11 1 48     
60 22 kDa protein IPI00478755 22062.88 5.92 0 1 41     
61 Protein C9orf32 IPI00549389 25239.80 5.31 0 1 48     
62 
Splice Isoform 1 of Acid sphingomyelinase-like 
phosphodiesterase 3b precursor IPI00550115 51682.49 5.5 0 1 48     
63 Hemoglobin beta chain IPI00218816 15988.29 6.75 0   6 206   
64 Similar to Calpain-like protease IPI00550259 81699.97 8.56 0   3 84   
65 
Splice Isoform 2 of Guanine nucleotide-binding 
protein G IPI00219835 44238.32 5.92 0   2 51   
66 Splice Isoform 2 of Transforming protein p21 IPI00423570 21410.90 8.24 0   2 52   
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67 
Splice Isoform 1 of Fanconi anemia group A 
protein IPI00006170 162701.38 6.13 0   1 37   
68 
Low affinity immunoglobulin gamma Fc region 
receptor III-B precursor IPI00023858 26199.20 6.22 1   2 64   
69 Syntaxin-4 IPI00029730 34158.85 5.92 1   1 39   
70 
Intermediate conductance calcium-activated 
potassium channel protein 4 IPI00032466 47664.55 9.87 5   1 61   
71 Flavin reductase IPI00219910 22579.64 7.12 0   2 61   
72 Lactotransferrin precursor IPI00298860 79802.73 8.45 0   1 42   
73 RTN3-A1 IPI00398795 112541.42 4.85 3   1 40   
74 Complement receptor 1 IPI00412546 272673.31 6.6 1   1 39   
75 Rhesus blood group, CcEe antigens IPI00444375 43902.44 9.85 10   2 70   
76 Chromosome 9 open reading frame 19 IPI00479010 14204.11 9.55 0   1 71   
77 Splice Isoform 2 of Myeloperoxidase precursor IPI00236554 73806.61 9.3 0   1 59   
78 Mesenchymal stem cell protein DSCD75 IPI00550002 23849.87 9.71 1   1 51   
79 Splice Isoform 3 of Alpha adducin IPI00220158 84250.40 5.67 0   1 41   
80 Equilibrative nucleoside transporter 1 IPI00550382 60905.51 8.58 11   1 63   
81 Splice Isoform 3 of Beta adducin IPI00220241 72674.54 6.11 0   1 43   
82 Zinc transporter 1 IPI00002483 55292.08 6.02 6   1 75   
83 Solute carrier family 40, member 1 IPI00005547 62501.35 6.08 10   1 50   
84 
Splice Isoform 2 of Cell division control protein 42 
homolog IPI00016786 21245.02 6.15 0   1 57   
85 Stromal cell-derived receptor-1 beta IPI00018311 44359.50 8.11 1   1 62   
86 cAMP-dependent protein kinase IPI00021831 42954.97 5.27 0   1 54   
87 Ras-related protein Rap-1A IPI00019345 20973.71 6.38 0   1 73   
88 Band 4.1-like protein 4A IPI00030794 69332.01 9.33 0   1 52   
89 Hypothetical protein FLJ10903 IPI00102165 16600.10 10.21 0   1 79   
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90 PREDICTED: similar to KIAA0454 protein IPI00457293 42396.36 8.87 0   1 39   
91 Galectin-3 IPI00465431 27371.69 8.89 0   1 73   
92 Novel protein IPI00513701 21456.62 8.08 3   1 100   
93 16 kDa protein IPI00334432 15532.11 8.76 0     3 138 
94 
Solute carrier family 29 (nucleoside transporters), 
member 1 IPI00412547 50186.36 8.61 11     2 79 
95 Eosinophil cationic protein precursor IPI00025427 18428.40 10.31 0     1 68 
96 Ubiquitin and ribosomal protein L40 precursor IPI00456429 14718.96 9.87 0     1 63 
97 64 kDa protein IPI00479914 64379.15 9.15 0     1 54 
98 
Membrane associated progesterone receptor 
component 2 IPI00005202 23803.73 4.76 2     1 49 
99 
Cop-coated vesicle membrane protein p24 
precursor IPI00016608 22746.38 5.08 2     1 59 
100 Ras-related protein Rap-2b IPI00018364 20491.21 4.73 0     1 45 
101 Monocarboxylate transporter  IPI00024650 53922.86 8.91 11     1 78 
102 28 kDa protein IPI00069985 28213.33 8.52 1     1 52 
103 Splice Isoform 2 of Reticulon 4 IPI00298289 40292.95 4.71 1     1 82 
104 Lutheran blood group IPI00328869 67362.59 5.53 1     1 53 
105 
Epidermal growth factor receptor pathway 
substrate 15 IPI00385325 83602.76 4.56 0     1 49 





Interpretation.  Each of the three methods enabled to identify a large set of 
proteins as compared with gel-based method, elucidating the higher efficiency of 
shotgun approach for RBC membrane protein identification. 
 
Our approach identified a large set of proteins (106) and in particular integral 
membrane proteins (47) from the RBC membrane fraction using three runs of 2-D 
LC-MS/MS.  Earlier, Low et al. (2002) identified 102 proteins including 5 integral 
membrane proteins using 1-D/2-DE and MALDI-TOF-MS, while a report using the 
Ion trap MS method reported the identification of 91 unique proteins including 21 
integral membrane proteins from the erythrocyte membrane fraction 
(Kakhniashvili et al., 2004).  Compared with these studies on RBC membrane 
(Kakhniashvili et al., 2004; Low et al., 2002), not only could we identify the major 
RBC membrane proteins such as Band 3, stomatin, rhesus blood protein, 
glycophorin C, Kell blood group glycoprotein (Reid et al., 2004), but we also 
identified relatively lower abundant membrane proteins such as urea transporter 
(Lucien et al., 2002) and complement receptor (CD35) (Rowe et al., 1997).  
Moreover, 39 of 47 integral membrane proteins were verified in a recent study 
(Pasini et al., 2006), confirming the effectiveness of our approach. 
 
3.5.3 Differential recovery of hydrophobic and hydrophilic peptides 
 
Aim.  In previous section, I have shown that both unique and common proteins 
were identified from the three extraction methods.  However, whether there is 
difference in the peptide recovery remains to be determined. If there is a 
difference, it could be very useful to sequentially use different solvents in order to 
maximally recover peptides from one particular sample for MS analysis and thus 
increase total protein identification.  Thus in this section, I aimed to compare the 
hydropathicity of peptides identified from MeOH-, TFE- and urea-based methods. 
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Investigation.  GRAVY values of identified peptides were obtained using the 
ProtParam program, and statistical significance was evaluated using the ANOVA 
analysis for comparison of the means of the GRAVY values of peptides 
recovered from MeOH-, TFE- and urea-based methods using SPSS 13.0. 
 
Results.  A GRAVY value indicates the hydrophobicity of proteins and peptides.  
All identified peptides with their GRAVY values were provided as supporting 
information in our published paper (Zhang et al., 2007).  Mean GRAVY value of 
the peptides recovered were -0.465 (95% CI, (-0.540)-(-0.390)) in MeOH, -0.219 
(95% CI, (-0.304)-(-0.135)) in urea and -0.107 (95% CI, (-0.194)-(-0.020)) in TFE.  
GRAVY values were significantly higher (p<0.001) in the peptide group recovered 
with urea and TFE as compared with MeOH.  This suggested that more 
hydrophobic peptides were recovered using TFE and urea compared with MeOH 
in the membrane extraction and digestion process. 
 
Interpretation. The difference between MeOH and TFE in the recovery of 
hydrophobic peptides could be due to differing conformations in aqueous MeOH 
and TFE.  In MeOH, proteins tended to be denatured (Blonder et al., 2002) and 
thus more accessible for trypsin digestion.  However the hydrophobic peptides 
which prefer beta-sheet formations in MeOH (Wigley et al., 1998) may be lost due 
to the structural changes such as intermolecular antiparallel β-sheet aggregates 
(Dong et al., 1998).  In TFE, proteins and peptides are likely to be stabilised, 
possibly due to the formation of alpha-helical secondary structure (Buck 1998).  
Thus, this differential ability to recover hydrophilic and hydrophobic peptides from 
MeOH and TFE respectively indicates that these two organic solvents could be 
complementary for membrane protein extraction and digestion process, increase 
overall membrane protein identification. 
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3.5.4 Analysis of protein digests with longer LC elution gradient 
 
Aim.  In section 3.5.2, I have shown that the use of LC-MS/MS to identify proteins 
from the three digests (from urea, MeOH and TFE), where the LC elution 
gradients was 10 min.  Recently, it has been shown that longer LC elution 
gradients (e.g. 60 min) has significantly higher resolution, and could greatly 
increase protein identification from complex digests (Vollmer et al., 2004).  In this 
section, therefore, I attempted to find out the effects of length of LC elution 
gradients on identification of RBC membrane proteins. 
 
Investigation.  Membrane protein digests were prepared using MeOH as a 
solvent (section 2.2.16.1).  The digests were separated using 2-D LC as 
described in section 2.2.19 except that the LC elution gradient was extended from 
10 min to 60 min, and followed by MALDI-TOF/TOF-MS analysis (section 2.2.20). 
 
Results. A total of 141 proteins (including 71 proteins with ≥1 TMD(s)) were 
identified (Appendix table 1) from the 60 min LC elution gradient.  In contrast, 
only 61 proteins (including 25 proteins with ≥1 TMD(s)) were identified from 10 
min elution gradient (section 3.5.2).  This indicated that the extension of LC 
elution gradient helped to increase total identifications of proteins and membrane 
proteins. 
 
Interpretation.  LC plays an important role in shotgun proteomic analysis by 
separation of complex digests into relatively simple components prior to MS 
analysis.  The higher LC resolution results in simpler analyte, thereby increasing 
overall protein identifications.  The resolution of LC columns can be enhanced by 
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extending LC elution gradient (Vollmer et al., 2004), leading to an increasing 
number of protein identifications. 
 
3.6 Comprehensive list of RBC membrane proteins 
Adult RBCs have been extensively studied by both conventional methods (e.g. 
immunochemical study) and proteomic analyses.  To obtain a comprehensive list 
of RBC membrane proteins, an in-depth literature review was made against the 
PubMed, and all RBC membrane proteins were retrieved and summarised.  The 
list was further consolidated with my own proteomic dataset.  In the final list, only 
proteins annotated as membrane protein by GoFigure were included; and 
redundant entries were removed regardless of proteins with different name by 
retrieving and comparing the sequences of all membrane proteins. 
 
In addition, RBC membrane proteins with potential surface domain (e.g. integral 
membrane proteins, membrane-associated extracellular proteins) were grouped, 
which was used for future comparison with the counterpart of fetal NRBCs to 
identify unique surface membrane proteins (Chapter 5). 
 
With these criteria, a total of 299 non-redundant membrane proteins were 
identified from adult RBCs (Appendix table 2).  Of these, 202 proteins contain 
potential surface domain (Appendix table 3).  In my study, nearly half of proteins 
in both groups were able to be identified from only four LC-MS/MS procedures 
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With the proteomic studies including gel-based and shotgun proteomics, I have 
identified a large set of RBC proteins, which includes 145 RBC membrane 
proteins and 103 proteins with potential extracellular domain.  In addition, by 
doing in-depth literature review against PubMed, a most comprehensive RBC 
membrane proteome to date have been obtained (Appendix table 2), which 
includes 299 membrane proteins and 202 proteins with potential extracellular 
domain. 
 
Meanwhile, data presented in this chapter have also helped us to determine a 
potentially efficient proteomic strategy for subsequent fetal NRBC membrane 
proteins analysis.  Gel-based proteomic analysis has a very limited role in 
studying RBC membrane proteome because of the poor solubility of membrane 
proteins in 2-DE separation and the limited resolving power in 1-DE separation.  
Shotgun approach is an efficient method as demonstrated by Kakhniashvili et al. 
(2004) in which they could identify 21 integral membrane proteins from RBC 
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membrane.  More recently, Pasini et al. (2006) used a combination of 1-DE 
followed by multiple LC separations of eluted peptides prior to MS, and shotgun 
approach consisting of ≥20 LC-MS/MS experiments to in-depth analyse RBC 
membrane proteins, and identified 314 proteins.  These studies could identify a 
large set of proteins from RBC membrane by using optimised sample 
fractionation and/or more LC-MS/MS experiments, but clearly the methods are 
inefficient and inapplicable in a situation when the starting sample is limited, e.g. 
fetal NRBCs. 
 
In our shotgun proteomic analysis of RBC membrane proteins, firstly, I showed 
that two organic solvents (MeOH and TFE) had comparable efficiency in the 
shotgun analysis of membrane proteins as traditionally used detergent urea when 
a large amount of sample was used (e.g. 200 µg).  In a study by Wang et al. 
(2005), organic solvents were shown to be much more efficient than traditionally 
used detergent in the analysis of limited cell lysate because they are readily 
evaporate, sample clean-up can be avoided and the entire process completed 
within a test tube, with minimal loss of sample.  Together, these indicated that 
organic solvents (MeOH and TFE) could be more efficient in the analysis of 
membrane proteins of limited fetal NRBCs.  Secondly, organic solvents MeOH 
and TFE were shown to be complementary for the recovery of both hydrophilic 
and hydrophobic peptides from RBC membrane proteins, indicating that they can 
be sequentially used for maximal recovery of peptide for MS analysis.  Thirdly, 
the use of longer (e.g. 60 min) LC elution gradient significantly increased the 
number of membrane proteins identified from RBC membrane.  Taken together, 
the sequential use of organic solvents MeOH and TFE for membrane proteins 
extraction and digestion procedures followed by long LC elution gradient (e.g. 60 
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min) separation prior to MS analysis would significantly increase the number and 
type of membrane proteins identified from a limited amount of fetal NRBCs. 
 
Thus, through this chapter, I have obtained a most comprehensive RBC 
membrane proteome, which could allow subsequent comparison with that of fetal 
NRBCs in order to identify unique surface membrane proteins; I have also 
determined a potentially efficient proteomic strategy for fetal NRBC membrane 
analysis. 
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Chapter 4 Proteomic Analysis of Fetal NRBC 
Membrane Proteins Using Shotgun Approach 
 
4.1 Introduction 
Primitive fetal NRBCs are abundant in the circulation of embryo and fetus in the 
first trimester pregnancy, and can cross into maternal blood (Choolani et al. 
2001).  In recent years, extensive attempts have been made to isolate these cells 
from maternal blood for potentially early non-invasive prenatal diagnosis (section 
1.5.6).  However, little success was obtained due to their rarity in maternal blood 
and the lack of antibody highly specific to fetal NRBCs (section 1.6.2).  The 
attempts to search for or to generate antibody specific to fetal NRBCs were 
hampered as proteins of these cells are poorly understood.  To our knowledge, 
they were only known to contain a few proteins such as cytoskeleton protein 4.2 
(Zhu et al., 1998) and spectrin (Boulanger et al., 2002), surface proteins GPA, 
CD47 and CD71 (Choolani et al., 2003) and cytosolic embryonic globins.  Study 
of fetal NRBC membrane proteome is therefore essential to identify potential 
biomarkers that could be used to separate fetal NRBCs from adult RBCs. 
 
This chapter is dedicated solely to the proteomic analysis of fetal NRBC 
membrane proteins which included isolation of these cells from placental tissues, 
extraction of their membrane proteins, profiling and annotation of identified 
proteins. 
 
Proteomics is very sensitive and high throughput for the analysis of membrane 
proteins (Wu et al. 2003).  In chapter 3, the efficiencies of various proteomic 
approaches were compared for the analysis of RBC membrane proteome.  A 
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shotgun approach, that consists of protein extraction using two organic solvents 
(MeOH and TFE) and protein identification by 2-D LC-MALDI-TOF/TOF-MS, was 
suggested to be efficient and suitable for the analysis of membrane proteins from 
a limited amount of sample (section 3.7).  This chapter describes the use of this 
shotgun approach for the analysis of fetal NRBC membrane proteome. 
 
4.2 Recovery of fetal NRBCs from placental tissues 
Aim.  To isolate fetal NRBCs from placental tissues for the membrane proteome 
profiling. 
 
Investigation.  Placental tissues collected from volunteers undergoing elective 
termination of pregnancy were used to obtain fetal NRBCs following the protocol 
described in section 2.2.6.  Up to 20 µl of the sample containing 5×104 fetal 
NRBCs were cytospun and Wright’s stained (sections 2.2.2 to 2.2.4), and the rest 
was stored at -80°C for proteome analysis. 
 
Results.  Total numbers of fetal NRBCs isolated from one placental tissue sample 
varied from 1×104 to 7×106 depending on the gestational age and the expertise of 
the surgeon.  Purity of the preparation varied between 1% and 98%.  Samples 
containing at least 95% of fetal NRBCs were considered satisfactorily pure, and 
used for membrane protein analysis.  Wright stain of a pure fetal NRBC sample is 






Figure 4-1 Wright stain of fetal NRBC sample from placental tissues of 
termination of pregnancy 





Interpretation.  As the placental tissues were collected after surgical termination 
of pregnancy (TOP), the quantity and quality of the tissues were highly depended 
on the expertise of the surgeons who performed the TOP procedure.  Some 
surgeons could provide a large quantity of placental tissues with little maternal 
blood contamination, while others provided a small amount of tissues with heavy 
contamination of maternal blood from one TOP case.   As a result, the number 
and purity of fetal NRBC isolated from those tissues were varied. 
 
The number and purity of target cells are crucial for an effective membrane 
proteome analysis which requires about 30-200 µg proteins.  In our study, the 
protein yield was 0.55 µg per 106 RBCs from a highly pure membrane preparation 
(section 3.2).  Due to sample limitation, protein quantitaion in fetal NRBC 
membrane preparation was not performed.  Assuming that similar protein yield is 
to be obtained from fetal NRBCs, it is clear that fetal NRBC sample from a single 
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termination of pregnancy sample (usually containing ~106 fetal NRBCs) is 
technically not feasible for the study of fetal NRBC membrane proteome.  
Therefore, I have pooled samples with a purity >95% to make up to ~5×107 fetal 
NRBCs (estimated protein yield ~30 µg) for subsequent protein analysis. 
 
4.3 Preparation of membrane protein digests for MS analysis 
Aim.  To prepare fetal NRBC membrane protein digests for 2-D LC-MALDI 
TOF/TOF-MS analysis. 
 
Investigation.  Stages of membrane protein digest preparation were summarised 
in Figure 4-2.  Fetal NRBC membrane was prepared as described in section 
2.2.8.  MeOH and TFE were used in the membrane protein extraction and 
digestion procedures in a sequential manner to maximally recover peptides for 
MS analysis (section 2.2.17). 
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Figure 4-2 Flow chart showing fetal NRBC membrane protein preparation, 
extraction and digestion 
 
             
 
Results.  Two peptide-rich supernatants (digests) from a single fetal NRBC 
sample were obtained for subsequent 2-D LC-MALDI-TOF/TOF-MS analysis. 
 
Interpretation.  As only a limited amount of fetal NRBCs was available, the crucial 
step was to efficiently extract and recover membrane protein digests from fetal 
NRBCs for subsequent MS analysis.  Organic solvents MeOH and TFE 
demonstrated an advantage for proteomic analyses: as these organic solvents 
readily evaporate, sample clean-up could be avoided and the entire process 
completed within one test tube, with minimal loss of sample during the recovery 
phase.  In addition, these two organic solvents were shown to be complementary 
for the recovery of both hydrophilic and hydrophobic peptides (section 3.5.3).  As 
such, it was anticipated that the sequential use of the two organic solvents in the 
Fetal NRBC peptide recovery: 
Protein reduction, alkylation, digestion in 60% MeOH in 
NH4HCO3 
Fetal NRBC peptide recovery: 
Protein reduction, alkylation in 50% TFE and digestion in 10 time 
diluted TFE/NH4HCO3 




Peptide-rich supernatant  
(TFE-derived digests) 
Fetal NRBC crude membrane preparation: 
thawing, sonication and high pH washing 
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protein extraction and digestion procedures would maximise peptide recovery 
from the small amount of fetal NRBCs, and eventually increase total protein 
identifications. 
 
4.4 Mass spectrometric and bioinformatic analyses 
 
4.4.1 Mass spectrometric analysis of fetal NRBC protein digests 
 
Aim.  To identify proteins from fetal NRBC membrane protein digests. 
 
Investigation.  Each of the two peptide-rich supernatants (MeOH- and TFE-
derived digests) from section 4.3 was lyophilised, re-solubilised into a solution 
(98% H2O, 2% ACN and 0.05% TFA) and subsequently analysed using 2-D LC-
MALDI-TOF/TOF-MS as described in section 2.2.19-2.2.20.  MS data processing 
and bioinformatic analysis were performed as in section 2.2.21. 
 
Results.  A total of 315 proteins were identified (Appendix table 4).  The number 
of proteins identified from MeOH-derived digests and TFE-derived digests were 
171 and 226 respectively.  Among these, 82 proteins were common for both 
digests.  Ninety-one out of 315 proteins were considered as integral membrane 
proteins and contained ≥1 TMDs.  Most of them contained either one or two 
TMDs, but as many as 38 proteins with ≥3 TMDs were also identified (Figure 
4-3).  In addition, 43% of identified proteins (141) were membrane proteins based 
on Gofigure annotation.  Of these, 54 proteins were identified with potential 
surface domain(s) (Appendix table 5). 
 
 135 
In addition to membrane proteins, a large number of membrane-associated 
proteins were also recovered.  These findings could provide additional 
information to understand biology and/or physiology of human primitive fetal 
NRBCs.  For example, histone H1o has been reported to be expressed 
predominantly in terminally differentiated cells (Doenecke et al., 1997) such as 
mouse embryonic erythroblasts (Gjerset et al., 1982), but not in peripheral 
lymphocytes, granulocytes and mouse definitive erythroblasts from bone borrow 
(Zlatanova et al., 1994).  If similar erythropoiesis occurs in human as in mouse, 
protein H1o could serve as an important new marker for differentiating human 
primitive NRBCs from its definitive counterparts (e.g. maternal bone marrow 
NRBCs), which would be useful for the identification of primitive fetal NRBCs 
enriched from first trimester maternal blood. 
 























Interpretation.  This was the first study to present a relatively comprehensive fetal 
NRBC membrane proteome.  The sequential use of two organic solvents enabled 
us to identify a large set of membrane proteins including a weakly expressed fetal 
NRBC surface antigen (CD71) from a small amount of fetal NRBCs (5×107), 
which clearly demonstrated the strength of our approach for maximal 
identification of proteins from a small amount of sample as discussed in section 
3.7. 
 
4.4.2 Subcellular and functional groups of identified proteins 
Aim.  To obtain global information of identified proteins in term of subcellular 
locations and function groups. 
 
Investigation.  Subcellular and functional group of all identified proteins were 
obtained by GoFigure (http://udgenome.ags.udel.edu/gofigure/index.html).  
Proteins, which were classified as plasma membrane proteins and had 
transmembrane domain(s), were identified as integral to the surface of NRBC 
membrane. 
 
Results.  The detailed subcellular location of all identified proteins was shown in 
Figure 4-4a.  Forty-one proteins (13%) were classified as plasma membrane 
proteins, which included integral plasma membrane protein, extracellular 
membrane associated proteins and peripheral membrane proteins.  A large 
number of proteins were assigned to ribosome (49), nucleus (64) and 
mitochondria (72), which accounted for 58% of total identifications.  This was 
because that in our preparation, total membranes were recovered by sonication, 
high pH washing and ultracentrifugation, in which some of the organelles are not 
disrupted or resealed during the process and therefore the highly abundant 
proteins within the organelles, e.g. 40S, various histones, were not efficiently 
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depleted.  The rest identified proteins included microsomal proteins (45), cytosolic 
proteins (21) and unclassified proteins (23). 
 
The functional categories of identified proteins were shown inFigure 4-4b.  The 
largest group consisted of proteins with binding function (27%).  Many of them 
are involved in RNA and DNA binding, corresponding to abundant nuclear and 
mitochondrial proteins recovered.  Other proteins have catalytic activity (23%), 
structural molecular activity (19%) and transporter activity (19%).  These 
abundant proteins in fetal NRBCs, undoubtedly, play a vital role in the 
maintenance of their normal structure and function, as the erythroid cells required 
an active metabolism such as glycolysis, structurally extreme deformability and 
high transport activity for gases, water, ions and amino acids. 
 
Interpretation.  As total membranes from fetal NRBCs were prepared and 
analysed, the identified protein dataset represents a global recovery of 
membrane proteins and reveals their relative functional preponderance in the 
fetal NRBC membrane proteome. 
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Figure 4-4 Subcellular classifications (a) and functional categories (b) of fetal 









































4.4.3 Hydropathy analysis of identified peptides and proteins 
 
Aim.  Fetal NRBC membrane protein digests were prepared using a sequential 
extraction and digestion method by two solvents (MeOH and TFE) (section 4.3) 
and thus two digests were obtained.  Subsequent MS analyses of the two digests 
revealed a large number of proteins unique to MeOH- and TFE-derived digest 
respectively (section 4.4.1).  In this section, the hydrophobicity of peptides and 
proteins identified from the digests were compared in order to assess the 
differential recovery of proteins and peptides from the two organic solvents. 
 
Investigation.  GRAVY values of identified peptides and proteins were obtained 
using the ProtParam program, and statistical significance was evaluated using 
the ANOVA analysis for comparison of the means of the GRAVY values of 
peptides and proteins recovered from MeOH- and TFE-based methods using 
SPSS 13.0. 
 
Results.  Analysis of GRAVY values of identified peptides and proteins derived 
from MeOH and TFE extractions of fetal NRBC membranes showed that mean 
GRAVY values of both, the recovered peptide groups (MeOH, mean -0.230 and 
95% CI, -0.301-(-0.152); TFE, mean 0.114 and 95% CI, 0.043-0.185) and the 
recovered protein groups (MeOH, mean -0.467 and 95% CI, -0.532-(-0.402); 
TFE, mean -0.284 and 95% CI, -0.340-0.228) were significantly different 





Figure 4-5 Hydropathy comparison of the identified proteins from MeOH and 
TFE sequential extraction and digestion of fetal NRBC membrane 
Mean of GRAVY values of identified proteins were significant lower in MeOH-





Interpretation.  The significant difference (p<0.001) of mean GRAVY values in 
both recovered peptide and protein groups from MeOH- and TFE-based methods 
respectively confirmed our earlier observations: the differential recovery of 
hydrophobic and hydrophilic peptides of organic solvents MeOH and TFE 
(section 3.5.3), and as a result, the sequential use of the two solvents maximised 
the protein identification from a limited amount of fetal NRBCs. 
 
4.5 Conclusion 
Use of the proteomic strategy enabled us to present the first relatively 
comprehensive fetal NRBC membrane proteome (315 proteins), which included 
141 membrane proteins, 91 integral membrane proteins, and 54 proteins with 
potential extracellular domain.  In addition, this study also presented a large 
number of membrane-associated proteins, and some of which were found in 
erythroid cells for the first time, e.g. azurocidin.  These findings would not only 
provide us a first relatively comprehensive fetal NRBC membrane protein list for 
the identification of potential biomarkers by comparing with adult RBC membrane 
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proteome, but also provide values to understand the biology and/or physiology of 




Chapter 5 Identification of Unique Surface 
Protein(s) of Primitive Fetal NRBCs by Comparing 
Fetal NRBC and Adult RBC Membrane Proteomes 
 
5.1 Introduction 
The primary aim of this thesis was to identify membrane proteins unique to either 
fetal NRBCs or adult RBCs, which could be potentially used for the 
immunoseparation of fetal NRBCs from adult RBCs, for non-invasive prenatal 
diagnosis.  Earlier efforts to investigate known antigenic differences between 
these two cells types did not yield any differences that could be exploited 
(Choolani et al., 2003).  In this thesis, I used a proteomic strategy to profile 
membrane proteomes of adult RBCs (Chapter 3) and fetal NRBCs (Chapter 4) 
and obtained the two most comprehensive membrane proteomes to date.  I also 
investigated their subcellular locations.  It would therefore be logical to compare 
the membrane proteins, specifically those with potential surface domain, in order 
to identify unique surface membrane proteins.  Subsequently, the identified 
unique proteins in fetal NRBCs were validated using RT-PCR and 
immunocytochemistry, and functionally annotated. 
 
5.2 Identification of unique membrane proteins 
 




Investigation.  Membrane proteins with potential surface domain from fetal 
NRBCs (Appendix table 3) and adult RBCs (Appendix table 5) were compared to 
identify unique surface membrane proteins. 
 
Results.  The comparison of these two groups of proteins revealed that these two 
cell types were highly similar in their plasma membrane proteins.  The major RBC 
membrane proteins, which could be identified in the earler studies using MS 
technology with relatively low accuracy and low resolution (Kakhniashvili et al., 
2004; Low et al., 2002), were also found in fetal NRBCs.  These include Band 3, 
stomatin (Band 7), glycophorin C, rhesus blood protein, Kell blood group 
glycoprotein, aquaporin, calcium-transporting ATPase, sodium/potassium-
transporting ATPase, solute carrier family 2, equilibrative nucleoside transporter 
and ATP-binding cassette half-transporter. 
 
Moreover, the comparison resulted in the identification of 23 unique fetal NRBC 
membrane proteins and 187 unique RBC membrane proteins.  Of the 23 fetal 
NRBC proteins, 10 proteins were predicted on plasma membrane, 5 were on 
plasma membrane/organelle and 8 proteins had unknown location but with 
predicted transmembrane domains (Table 5-1). 
 
Interpretation.  The number of identified membrane proteins with potential surface 
domain (54) in fetal NRBCs was much smaller than that of RBCs (202).  This was 
probably because only a small amount of fetal NRBCs (5×107) were available for 
this proteomic analysis, leading to an under-represented membrane proteome.  In 
contrast, RBCs are easily accessible and have been extensively studied, thereby 
leading to a much more comprehensive membrane proteome. 
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The common expression of major membrane proteins by fetal NRBCs and adult 
RBCs might elucidate that there was little success achieved in the attempt to 
generate antibody specific to fetal NRBCs or adult RBCs using a hybridoma 
technology (Alvarez et al., 1999), as only those antibodies against 
immunodominant epitopes tended to be generated with this approach (Groves et 
al., 2000). 
 
In this study, unique fetal NRBC membrane proteins were further validated and 
functionally annotated in on-going paragraphs (sections 5.3 and 5.4), whereas 
“unique RBC membrane proteins” were used only as additional information for 
antibody selection in the immunocytochemical screening study (Chapter 6), as 
they were less reliable as “unique RBC proteins”: some of these proteins might 
be also expressed on fetal NRBCs but failed to be identified from the proteomic 













Table 5-1 Potential surface markers expressed on fetal NRBCs 
 
No. Accession Number Protein Name Subcellular location 
1 IPI00022462 Transferrin receptor protein 1  Plasma membrane 
2 IPI00554481 
Solute carrier family 3 (activators of dibasic and 
neutral amino acid transport), member 2, isoform 
A 
Plasma membrane 
3 IPI00418660 Solute carrier family 22 member 11, isoform 2 Plasma membrane 
4 IPI00034208 BCG induced integral membrane protein BIGM103 Plasma membrane 
5 IPI00607576 Splice Isoform 1 of Protein C9orf5 Plasma membrane 
6 IPI00168981 Olfactory receptor 11H4 Plasma membrane 
7 IPI00396411 Cleft lip and palate transmembrane protein 1 Plasma membrane 
8 IPI00382815 Splice Isoform 2 of Protein GPR107 precursor Plasma membrane 
9 IPI00019472 Neutral amino acid transporter B Plasma membrane 
10 IPI00305252 Splice Isoform B of Chloride channel protein 6 Plasma membrane 
11 IPI00022246 Azurocidin precursor Plasma membrane /Extracellular/Cytoplasmic 
12 IPI00027180 CAAX prenyl protease 1 homolog Plasma/ER/Golgi 
membrane 
13 IPI00335277 Splice Isoform 2 of Synaptophysin-like protein Plasma/Vesicle membrane 
14 IPI00292532 Antibacterial protein FALL-39 precursor Plasma membrane /Extracellular 
15 IPI00553138 Vesicle-associated membrane protein 2 Plasma/Vesicle/Synapse /Mitochondrial membrane 
16 IPI00166079 Vitamin K epoxide reductase complex subunit 1-like protein 1 Unclassified 
17 IPI00604615 ALEX3 protein variant Unclassified 
18 IPI00031064 Hypothetical protein DKFZp586C1924 Unclassified 
19 IPI00639803 8 kDa protein Unclassified 
20 IPI00646289 25 kDa protein Unclassified 
21 IPI00176708 Hypothetical protein MGC14288 Unclassified 
22 IPI00394779 Splice Isoform 1 of Protein C20orf22 Unclassified 
23 IPI00295621 Hypothetical protein DKFZp564K247 Unclassified 
 
 
5.3 Validation of unique fetal NRBC membrane proteins 
While proteomic approaches are very powerful to discover potential markers, the 
identified markers usually have to be validated using conventional methods 
before they can be considered for further use.  Commonly used validation 
methods are antibody-based, such as enzyme-linked immunosorbent assay 
(ELISA), western blotting and immunocytochemistry.  ELISA and western blotting 
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analysis require a relatively large amount of fetal NRBC sample, whereas 
immunocytochemistry does not.  In this study, immunocytochemistry was chosen 
due to the sample limitation.  For some proteins, especially those to which no 
commercial antibody was available, RT-PCR was chosen to provide additional 




Aim.  To gain additional information about the gene expression of some identified 
proteins including those to which no commercial antibody was available. 
 
Investigation.  The RNA was isolated from fetal NRBCs with an RNeasy Mini Kit, 
and cDNA template was then synthesised using Sensiscript RT Kit and Oligo dT 
as primers (section 2.2.22).  PCR was performed with a PTC-200 Peltier Thermal 
Cycler.  Optimal annealing temperatures were determined for each gene.  Primer 
pairs used for the amplification for individual gene were listed in Table 2-1.  The 
gene expressions of 23 selected proteins were tested, which includes 11 unique 
fetal NRBC membrane proteins to which no commercial antibody was available 
as yet. 
 
Results.  Of the 23 selected proteins, the mRNA expression of all targets except 
olfactory receptor 11H4 was detected (Figure 5-1). Of these, 4 proteins were well-
known erythroid proteins (epsilon-globin, gamma-globin, Band 3, GAPDH); 15 
proteins were potentially unique fetal NRBC membrane proteins (BCG induced 
integral membrane protein BIGM103, chloride channel protein 6, azurocidin 
precursor, vitamin K epoxide reductase complex subunit 1-like protein 1, protein 
GPR107 precursor, neutral amino acid transporter B, solute carrier family 3 
(activators of dibasic and neutral amino acid transport), member 2, isoform A, 
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solute carrier family 22 member 11, isoform 2, antibacterial protein FALL-39 
precursor, vesicle-associated membrane protein 2, transferrin receptor protein 1, 
cleft lip and palate transmembrane protein 1, CAAX prenyl protease 1 homolog, 
synaptophysin-like protein and protein C9orf5); and the other three proteins 
(solute carrier family 43 member 3, vacuolar proton translocating ATPase 116 
kDa subunit a isoform 1, steroid dehydrogenase homolog) were common but 






















Figure 5-1 RT-PCR of the gene expression of twenty-three selected proteins 
The presence of all gene expressions except olfactory receptor 11H4 was 
detected.  The proteins were epsilon-globin, gamma-globin, Band 3, BCG 
induced integral membrane protein BIGM103, chloride channel protein 6, 
azurocidin precursor, vitamin K epoxide reductase complex subunit 1-like protein 
1, protein GPR107 precursor, neutral amino acid transporter B, GAPDH, solute 
carrier family 3 (activators of dibasic and neutral amino acid transport), member 
2, isoform A, solute carrier family 22 member 11, isoform 2, antibacterial protein 
FALL-39 precursor, vesicle-associated membrane protein 2, transferrin receptor 
protein 1, cleft lip and palate transmembrane protein 1, CAAX prenyl protease 1 
homolog, vacuolar proton translocating ATPase 116 kDa subunit a isoform 1, 
steroid dehydrogenase homolog, olfactory receptor 11H4, solute carrier family 43 
member 3, synaptophysin-like protein and protein C9orf5.  RT control: no RT 
enzyme was added during cDNA synthesis; PCR control: water rather than cDNA 




Interpretation.  As there was no commercially available antibody to some 
identified proteins and the generation of a new antibody required a relatively long 
period, the validation of these proteins therefore presented a challenge.  In this 
study, use of RT-PCR to detect the mRNA expression provided indirect proof of 




Aim.  To immunocytochemically detect the protein expression of four unique fetal 
NRBC membrane proteins to which antibodies were commercially available. 
 
Investigation.  Primary antibodies including anti-CD71, anti-azurocidin, anti-CLC6 
and anti-neutral amino acid transporter ASCT2 and anti-Band 3 were used for 
immunocytochemical stain of the protein expressions in fetal NRBCs and adult 
RBCs as described in section 2.2.23. 
 
Results.  The immunocytochemical staining on fetal NRBCs and adult RBCs were 
shown in Figure 5-2.  CD71 expression was found to be weak/undetectable on 
primitive fetal NRBCs but absent on adult RBCs.  While azurocidin was 
expressed strongly on all fetal NRBCs, it was located within nucleus and 
undetectable on the surface.  Immunocytochemistry using anti-chloride channel 
protein 6 and anti-neutral amino acid transporter showed no detectable staining 
on both fetal NRBCs and adult RBCs, which could be due to either the low 
expression of targeted antigens or lack of immunoreaction due to imcompatible 









Figure 5-2 Immunocytochemical staining on fetal NRBCs and adult RBCs 
(A) Band 3 is strongly expressed on fetal NRBCs (white arrowed) and RBC 
(yellow arrowed), (B) CD71 is expressed on some of fetal NRBCs but absent on 






Interpretation.  It has been reported that CD71 expression was strong in cord 
NRBCs, adult NRBCs and in second trimester NRBCs (Zheng et al., 1999) but  
weak/undetectable in first trimester fetal NRBCs (primitive fetal NRBCs) 
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(Choolani et al., 2003).  Our data provided the first independent evidence to 
confirm the early observation (Choolani et al, 2003).  Azurocidin, also termed 
heparin-binding protein or CAP37, was predominantly expressed in neutrophil 
granule, and with a minor part (~8%) on its plasma membrane (Tapper et al., 
2002).  The expression of this protein in erythroid cells has never been described.  
Thus, the finding of this protein in fetal NRBCs would help to understand the 
biological functions of this cell type.  Azurocidin has a role in white blood cell 
apoptosis upon heparin induction (Erduran et al., 1999; Manaster et al., 1996) 
and a similar possibility is expected in fetal NRBCs.  Indeed, it has been reported 
that in the enrichment of fetal NRBCs from maternal blood, the fetal NRBC 
detection rate was much lower when maternal blood was collected in tube with 
heparin anticoagulant than that collected in tube with EDTA anticoagulant 
(Brombacher et al., 2000), which could be presumably due to the cell loss caused 
by heparin induced fetal NRBC apoptosis. 
 
5.4 Functional annotation of unique fetal NRBC membrane 
proteins 
Many of the unique fetal NRBC proteins were annotated as molecule and ion 
transporters.  CD71, which is responsible for cellular iron uptake, is essential for 
definitive erythropoiesis and completely lost during reticulocyte maturation 
(Knowles et al., 1997).  However, it was found that the knock-out of CD71 gene 
only caused partially impaired primitive erythropoiesis (Levy et al., 1999).  
Together with our observation, it may suggest that some of primitive fetal NRBCs 
(CD71- NRBCs) have alternative ion uptake pathway.  BCG induced integral 
membrane protein BIGM103 is responsible for zinc uptake.  Zinc is an essential 
cofactor for hundreds of enzymes, and involved in protein, nucleic acid, 
carbohydrate, and lipid metabolism, as well as in the control of gene transcription, 
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growth, development, and differentiation (Taylor et al., 2003b).  The identification 
of zinc transporter might reflect the high enzyme activity required in at least some 
fetal NRBCs for their continuing remodelling in the circulation such as enucleation 
process (Kingsley et al., 2004).  Both Solute carrier family 1 and 3 (SLC1, 3) are 
sodium-dependent amino acid transport.  SLC1A5 (Neutral amino acid 
transporter B) has broad substrate specificity, a preference for zwitterionic amino 
acids.  It also acts as a cell surface receptor for feline endogenous virus RD114, 
baboon M7 endogenous virus and type D simian retroviruses (Rasko et al., 
1999).  SLC3A2 is the activator of dibasic and neutral amino acid transport and 
may have a role in cell differentiation (Lumadue et al., 1987).  Erythroblast amino 
acid transporter contributes to cell viability by providing precursors for intracellular 
biosynthesis (Young et al., 1983) and provide an efflux route for amino acids 
produced during reticulocyte maturation (Tucker et al., 1980).  Solute carrier 
family 22 member 11, also called organic anion transporter 4, mediates saturable 
uptake of estrone sulfate, dehydroepiandrosterone sulfate and related 
compounds (Cha et al., 2000).  Chloride channel protein 6 is voltage-gated ion 
channel which has several functions including the regulation of cell volume; 
membrane potential stabilisation, signal transduction and trans-epithelial 
transport (Schwartz et al., 1997).  As some of fetal NRBCs may not be a 
terminally differentiated cell type (Kingsley et al., 2004), thereby transcriptionally 
and translationally active at this stage, it was not surprised that many unique 
molecule and ion transporters were identified. 
 
Two G-protein-coupled receptors (GPCR) were uniquely identified in fetal 
NRBCs.  Olfactory receptors are expressed in sensory neurons of nasal 
epithelium, where they interact with odorant molecules to initiate a neuronal 
response that triggers the perception of a smell (Buck et al., 1991).  In erythroid 
cells, most olfactory receptor genes were inactive (Bulger et al., 2000), but the 
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expression of an olfactory receptor gene at all stages of erythroid development 
was also described (Feingold et al., 1999).  Protein GPR107 belongs to the 
LU7TM family (Lung seven transmembrane receptor), and has putative functions 
as calcium-ion binding, signal transducer, and phospholipase A2 activity. 
 
The proteins involved in protein synthesis, modification and transportation have 
also been identified in fetal NRBCs.  CAAX prenyl protease 1 homolog is 
responsible for the removal of the c-terminal three residues of farnesylated 
proteins.  Defects in this protein are the cause of mandibuloacral dysplasia with 
type B lipodystrophy (MADB) (Simha et al., 2003).  Synaptophysin-like protein 1  
and Vesicle-associated membrane protein 2 are involved in transporting proteins 
or vesicle to the target locations such as plasma membrane (Johnston et al., 
1989; Leube et al., 1987; Sudhof et al., 1989). 
 
An interesting finding was that an antimicrobial protein azurocidin, together with 
its two neutral serine protease family members: elastase and cathepsin G, was 
identified in fetal NRBCs.  Azurocidin binds heparin and functions to kill ingested 
bacteria and to regulate various physiological and pathological processes, such 
as inflammation (Campanelli et al., 1990; Pereira et al., 1990).  The finding of 
azurocidin in fetal NRBCs might confer this cell type a similar role of anti-bacteria 
during the early fetal development. 
 
Molecular functions of the rest 10 unique proteins are unknown.  Some of them 
were annotated as plasma membrane proteins and others with unknown location.  




The comparison of the two membrane proteomes revealed both similarity and 
difference in the surface membrane protein expression between fetal NRBCs and 
adult RBCs.  The major RBC surface proteins were found to be expressed in fetal 
NRBCs (section 5.2), and similar expression level was observed for at least the 
tested protein, Band 3 (section 5.3.2).  Moreover, the comparison yielded 23 
unique fetal NRBC surface proteins and 187 unique adult RBC surface proteins.  
While the unique RBC proteins were not further explored as discussed in section 
5.2, the unique fetal NRBC proteins were validated using RT-PCR or 
immunocytochemistry, and functionally annotated.  These unique fetal NRBC 
proteins are potential targets that could be used for the isolation of fetal NRBCs 
from maternal blood.  In addition, these proteins have been linked to many novel 
functions that were not described with adult RBCs, and thus their identifications 
could help us to understand the biology and/or physiology of fetal NRBCs. 
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Chapter 6 Immunocytochemical Screening of 
Surface Membrane Proteins on Fetal NRBCs and 
Adult RBCs and Sorting of These Cells Based on 
Potential Candidate Identified 
 
6.1 Introduction 
Immunocytochemical screening is an alternative and complementary approach to 
proteomics, and can be used to systematically characterise the surface 
membrane protein expression.  In this approach, commercially available 
antibodies against cell surface antigens were tested on their reactivity to fetal 
NRBCs and adult RBCs for the identification of potential markers.  The 
advantages of this approach include: (1) it requires only a small amount of 
sample (a few cells) and is technically simple, (2) it can be used for semi-
quantitative detection of differential protein expression, (3) it can detect some 
proteins (e.g. glycosylated proteins) that were probably missed out in proteomic 
analysis, and (4) the identified marker could be directly used to isolate fetal 
NRBCs from maternal blood by various immunoseparation techniques. 
 
Earlier, there were some attempts to search for a more specific antigen to fetal 
NRBCs (section 1.6.2), but none of them systematically compared the surface 
antigen expressions of primitive fetal NRBCs and adult RBCs.  In this study, 
unique antigen expression on fetal NRBCs or adult RBCs, and differential antigen 
expression between fetal NRBCs and adult RBCs were explored.  I tested 31 
commercially available antibodies that belonged to three categories: (1) 
antibodies that are known to target antigens on adult RBCs, (2) antibodies that 
potentially bind to surface antigens on NRBCs and (3) antibodies that are known 
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not to react with surface antigens on adult RBCs but known to react with some 
other blood cells and their progenitors.  In particular, my emphasis was to 
consider well-characterised cluster of differentiation (CD) antigens, as the 
expression of these antigens has been linked to cellular differentiation and 
changes of physiological conditions. 
 
6.2 Immunocytochemical screening of surface antigens on fetal 
NRBCs and adult RBCs 
 
Aim.  To identify the differential surface protein expression that could be 
potentially used to isolate fetal NRBCs from maternal blood. 
 
Investigation.  Antibody selection was based on the criteria described in section 
6.1.  Primary antibodies (all host in mouse except otherwise stated) against 
following human antigens were tested on fetal NRBCs and adult RBCs using 
immunocytochemistry (section 2.2.23): CD14, CD29, CD31, CD34, CD35, CD36, 
CD44, CD45, CD45RB, CD46, CD47, CD55, CD59, CD81, CD90, CD99, CD100, 
CD105, CD108, CD117 (host in rabbit), CD133, CD147, CD164, CD175s, 
CD222, CD233, CD235a, HLA-ABC, HLA-DR, E-Cadherin and Monocarboxylate 
transporter 1 (MCT1, host in rabbit).  The image intensities of differential 
expression were evaluated as described in section 2.2.24. 
 
Results.  A total of 31 antibodies were tested regarding their reactivity to fetal 
NRBCs and adult RBCs.  Of these targeting antigens, majority of them were 
expressed similarly on both fetal NRBCs and adult RBCs, but differential 
expression of three antigens were also identified (Table 6-1). 
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Table 6-1 Panel of antibodies tested and results for fetal NRBCs and adult 
RBCs 
 
No. Target antigen Binding to fetal NRBCs Binding to adult RBCs 
1 CD14 - - 
2 CD29 - - 
3 CD31 - - 
4 CD34 - - 
5 CD35 - - 
6 CD36 - - 
7 CD44 + + 
8 CD45 - - 
9 CD45RB - - 
10 CD46 - - 
11 CD47 ++ ++ 
12 CD55 + + 
13 CD59 + + 
14 CD81 - - 
15 CD90 - - 
16 CD99 - - 
17 CD100 - - 
18 CD105 - - 
19 CD108 - - 
20 CD117 - - 
21 CD133 - - 
22 CD147 ++ + 
23 CD164 ± - 
24 CD175s - - 
25 CD222 - - 
26 CD233 ++ ++ 
27 CD235a ++ ++ 
28 E-cadherin  - - 
29 HLA-ABC - - 
30 HLA-DR - - 
31 MCT1 ± - 
 
* Mean pixel intensity of negative control in immunocytochemical staining was 
187.3 AU, range 185.2-189.2, n=5; strong expression (++) was defined based on 
the mean pixel intensity ≤110 AU. 
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CD164 and MCT1 were expressed on 30-50% of fetal NRBCs but completely 
undetectable on adult RBCs.  CD147 was found to be expressed strongly on fetal 
NRBCs and weakly/undetectably on adult RBCs [mean pixel intensity 95.3 AU; 
range, 81.1-113.7; n=5; and 168.4 AU; range 156.2-176.6; n=5 respectively] 
(Figure 6-1), suggesting its potential use for improving current enrichment of fetal 
NRBCs from maternal blood. 
 
Figure 6-1 Differential expression of surface antigens between fetal NRBCs 
and adult RBCs 
(A) Internal control, (B) MCT1 staining: fetal NRBCs show MCT1+ or MCT1- 
whereas adult RBCs show MCT1-, (C) CD164 staining: fetal NRBCs show 
CD164+ or CD164- whereas adult RBCs show CD164-, (D-F) CD147 staining: 





Interpretation.  This study attempted to find the differential expression of surface 
antigens between first trimester primitive fetal NRBCs and adult RBCs, which 
could potentially be explored to improve current fetal NRBC enrichment protocols.  
Thirty-one antibodies were tested.  Most of the target antigens were expressed in 
similar patterns on both fetal NRBCs and adult RBCs.  CD35 and CD108 were 
known to express on adult RBCs (Reid et al., 2004) but were not detected by our 
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immunocytochemistry, which could be due to the low expression of these 
antigens beyond the detectable limit (≤1000 molecules per cell) of light 
microscopy (Barclay 1998).  Indeed, CD35 was expressed with only 100 to 800 
molecules per RBC (Rowe et al., 1997).  The copy number of CD108 (carrying 
JMH blood group antigen) per RBC has not been determined yet, probably due to 
the low copy number. 
 
While some of erythroid progenitor antigens such as E-cadherin (Armeanu et al., 
2000) and HLA-ABC (Robinson et al., 1981) were found to be absent on both of 
fetal NRBCs and adult RBCs, others including CD71 (Chapter 5) and CD164 
(Watt et al., 2000; Zannettino et al., 1998) were found to be weakly expressed on 
some of fetal NRBCs but with undetectable stain on adult RBCs. 
 
MCT1 belongs to monocarboxylate transporter family which consists of at least 
eight members.  MCT1 is the only form in human erythrocytes and mainly 
facilitates the transport of lactate across cell membrane.  Under physiologic 
conditions, the MCT1 was believed to mediate 90% of lactate transport in RBCs 
(Deuticke et al., 1982).  The inability to detect this antigen in adult RBCs may be 
due to a low level of expression of MCT1.  In fetal NRBCs, the MCT1 was found 
to be detectable in 30-50% of fetal NRBCs, indicating a possible more active 
glycolysis in these cells.  Together, the expression of MCT1, CD71 and CD164 in 
some of fetal NRBCs might suggest the presence of two distinct types of primitive 
fetal NRBCs. 
 
CD147 is expressed on erythrocyte lineage cells throughout erythroid 
development, and its presence is necessary for successful entry of RBCs into 
blood circulation (Coste et al., 2001).  CD147 has a homophilic counterreceptor 
binding activity (Yoshida et al., 2000) that can function as adhesion molecules.  
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Abundant expression of CD147 on fetal NRBCs may facilitate the entry of these 
cells into maternal circulation.  In addition, CD147 is a highly glycosylated protein, 
and its distinct expression level in fetal NRBCs and adult RBCs could serve as a 
potential marker that enabled the separation of fetal NRBCs from adult RBCs 
using lectin-affinity approach as demonstrated by Shinya et al. (2004). 
 
CD147 was suggested to be necessary for the translocation and/or correct 
localisation of lactate transporters MCT1 to plasma membrane (Kirk et al., 2000).  
Recent studies suggested that CD147 was an accessory protein that was closely 
associated with MCT transporters in the plasma membrane (Table 6-2).  As such, 
it was not surprising that both of the two antigens were found of relatively strong 
expression on fetal NRBCs, but with lower/undetectable expression level on adult 
RBCs.  However, current data also showed while CD147 was strongly expressed 
on all fetal NRBCs, MCT1 was only expressed on less than half of fetal NRBCs.  
Thus, it would be worthwhile to study their co-expression in fetal NRBCs and 
adult RBCs. However this was not explored as this thesis focused on biomarker 
discovery for cell sorting. 
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Figure 6-2 MCT1 and CD147 topology 
MCT1 is an integral membrane proteins consisting of 12 TMDs.  CD147, a 
membrane of immunoglobulin superfamily, has three glycosylation sites, and 
interact with MCT1 through an arginine residue within transmembrane segment 8 




The unique fetal NRBC markers including CD71, CD164 and MCT1 are 
expressed in some of fetal NRBCs, and thus are not ideal targets for fetal NRBC 
enrichment due to possible loss of target cells.  CD147 instead, with much higher 
level of expression in all fetal NRBCs as compared in adult RBCs, could be a 
useful marker for the separation of fetal NRBCs from adult RBCs.  This possibility 
was subsequently explored by using common fetal cell separation methods 
(immunomagnetic cell sorting (section 6.3) and fluorescence-activated cell sorting 
(section 6.4)) to separate fetal NRBCs from the model mixtures of NRBCs/RBCs. 
 
6.3 Immunomagnetic cell sorting using anti-CD147 
Aim.  The two major immunomagnetic cell sorting methods that are generally 
used to separate fetal NRBCs from maternal blood are immunomagnetic beads 
method (e.g. Dynabeads) and magnetic-activated cell sorting (MACS). In this 
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section, I tested the the potential of anti-CD147 for the separation of fetal NRBCs 
from adult RBCs by both Dynabeads and MACS techniques. 
 
6.3.1 Dynal system 
Investigation.  Pure fetal NRBCs and adult RBCs were obtained as described in 
section 2.2.5 and. 2.2.6 respectively.  Fetal NRBCs were mixed with adult RBCs 
in a 1:50 ratio.  The mixed cells (5×106) were labelled with anti-CD147 by addition 
of 1 µg monoclonal antibody into the cell suspension (50 µl) and incubated at 4°C 
for 30 min.  The other procedures were followed as described in section 2.2.25.1.  
The cells in positive and negative fractions were recovered to assess the 
effectiveness of CD147 for the cell separation fetal NRBCs from the mixture. 
 
Results.  The mean recovery of fetal NRBCs was 56.2% (range: 50-64.3%; n=5) 
and the mean purity after separation was 13.3% (range: 10.3-17.0%) which 
corresponded to a 92.6% (range: 88.8-94.8%) of RBC depletion (Table 6-2).  
 












1 50.0 2.0 16.2 48.0 
2 64.3 3.4 10.3 32.3 
3 62.5 1.5 17.0 36.0 
4 54.0 2.0 12.3 44.0 
5 52.8 2.0 10.5 45.2 
Mean 56.7* 2.18 13.3 41.1 
 
* (Mean recovery 95% CI, 48.9-64.5%) 
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6.3.2 Magnetic-activated cell sorting 
Investigation.  The cell mixtures (as in section 6.3.1) were labelled with anti-
CD147 by addition of 10 ng the antibody into the cell suspension (80 µl) and 
incubated at 4°C for 30 min.  The other procedures were followed as described in 
section 2.2.25.2.  The cells in positive and negative fractions were recovered to 
assess the effectiveness of CD147 for the cell separation fetal NRBCs from the 
mixture. 
 
Results.  The mean recovery of fetal NRBCs was 79.7% (range: 77-80.8%, n=5) 
and the mean purity after separation was 12.8% (range: 10.2-17.8%) which 
corresponded to an 89.2% (range: 85.8-92.6%) of RBC depletion (Table 6-3).  
Fetal NRBC loss was significantly lower (p<0.001) in MACS (14.0%) compared to 
that of Dynabeads separation (41.1%). 
 












1 80.0 5.0 17.8 15.0 
2 80.0 0.0 13.8 20.0 
3 77.0 8.0 11.5 15.0 
4 80.5 12.0 10.9 7.5 
5 80.8 6.8 10.2 12.4 
Mean 79.7* 6.4 12.8 14.0 
 
* (Mean recovery 95% CI, 77.7-81.5%) 
 
Interpretation.  Immunomagnetic cell sortings using anti-CD147 to separate fetal 
NRBCs from a mixture of fetal NRBCs and RBCs yielded relative high recovery 
rates (Dynabeads: 56.2%; MACS: 79.7%), whereby both methods depleted 
approximately 90% of RBCs.  The separation principles of these two techniques 
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are quite different.  Dynabeads have a physical size of 4.5 µm of diameter which 
is approximately the same diameter of RBCs.  The low density of CD147 antigen 
and the relatively smaller size of RBCs provide limited chances of binding the 
IgG-conjugated Dynabeads.  In contrast, such a high density of antigen and the 
larger size of fetal NRBCs (Figure 6-1) allowed stronger interaction with the IgG-
conjugated Dynabeads.  As a result, binding of NRBCs to the beads fetal NRBCs 
were separated from the mixtures.  However, the main drawback is that binding 
of fetal NRBCs to these large and heavy beads (with a diameter of 4.5 µm and a 
density of 1.5 g/cm3) may cause cell lysis during the separation process, one 
possible reason explaining the cell loss (41%).  This could be circumvented with 
the use of a slightly smaller Dynabeads in order to reduce cell loss but it might 
increase binding chances of RBCs as well. 
 
MACS cell sorting device has a high capability of recovering target cells even 
when there is low expression of target antigen.  Initial experiments showed no 
enrichment due to excess antibody used during incubation with almost 100% 
recovery of fetal NRBC and no depletion of RBCs.  Subsequent optimisation of 
antibody titre yielded very promising results: high recovery of fetal NRBCs and 
relatively high rates of RBC depletion.   
 
Both Dynal and MACS cell sorting are often used the separation of one cell 
population from another based on the unique antigen(s) expressed on one of the 
cells.  In our case, CD147 was expressed on both adult RBCs and fetal NRBCs 
but the expression levels were different.  Thus, the recovery rate and the purity 
are always to be tradeoff when this antigen is targeted for the cell sorting of adult 
RBCs and fetal NRBCs.  The higher recovery rate would be accompined with 
lower purity.  The other technique FACS is an ideal tool for the separatioin of one 
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cell population from another based on differential expression and thus was used 
for the cell sorting in the next section. 
 
6.4 Fluorescence-activated cell sorting with anti-CD147 
Aim.  FACS is one of the commonest techniques for isolation of fetal cells from 
maternal blood.  Compared to immunomagnetic cell sorting, FACS cell soting is 
based on differential antigen density, and generally gives higher purity of target 
cells, thereby enhancing FISH efficiency and easing the identification of target 
cells on slide.  Here, I tested the possible usefulness of CD147 for the separation 
of fetal NRBCs from adult RBCs by FACS sorting technique. 
 
Investigation.  Fetal NRBCs were mixed with adult RBCs in different ratios of 
NRBCs/RBCs: 30:70; 20:80; 10:90, 5:95 (1 set respectively), and 1:50 (5 sets).  
The mixed cells (106) were labelled with anti-CD147 conjugated with FITC by 
addition of 10 µg antibody into the cell suspension (100 µl) and incubated at 4°C 
for 30 min.  The cell mixtures were washed, and sorted by FACS as described in 
section 2.2.26.  The cells in positive (as shown in Figure 6-3, arrowed peak) and 
negative fractions were recovered to assess the effectiveness of CD147 for the 
cell separation of fetal NRBCs from the mixture. 
 
Results.  The separation of fetal NRBCs from adult RBCs was illustrated in Figure 
6-3.  Two distinct peaks were obtained in FACS based on fluorescence intensity.  
Cell population in “arrowed peak” was collected as positive fraction, and the rest 
was collected as negative fraction.  Wright stain of a set of initial mixture, positive 
cells and negative cells was shown in Figure 6-4.  Nearly pure cell population 
could be obtained after FACS sorting, suggesting that fetal NRBCs could be well 
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separated from adult RBCs by setting an appropriate gating (flurescence intensity 




Figure 6-3 Histograms of results from FACS cell sorting experiments 
FACS cell sorting of NRBC and RBC mixture with anti-CD147 and without anti-
CD147 (Control); the initial ratios of NRBC/RBC mixture are indicated in the 





Figure 6-4 Wright stain of cell samples before and after FACS sorting 
(A) initial mixture of fetal NRBCs and adult RBCs (10: 90), (B) Negative fraction 
from FACS sorting with anti-CD147 (FITC), (C) Positive fraction from FACS 




In order to compare the efficiency of FACS separation with immunomagnetic cell 
sorting, fetal NRBCs from five sets of NRBC/RBC (1:50) mixture were separated 
following the gating set as above.  The mean recovery of fetal NRBCs was 59.0% 
(range: 56.4-60.7%, n=5), which is comparable with Dynabeads sorting (56.2%) 
but lower than MACS sorting (79.9%) (Table 6-4).  The purity of fetal NRBCs after 
FACS separation was more than 99%, which was significantly higher that that of 
immunomagnetic cell sorting (Dynabeads and MACS sorting). 
 











1 60.7 <1.0 >99.0 39.3 
2 58.1 <1.0 >99.0 41.9 
3 56.4 <1.0 >99.0 43.6 
4 59.6 <1.0 >99.0 40.4 
5 60.4 <1.0 >99.0 39.6 
Mean 59.0* <1.0 >99.0 41.0 
 
* (Mean recovery 95% CI, 56.8-61.3%) 
 
Interpretation.  Although CD147 was found to be expressed on both cell types, 
the expression on fetal NRBCs was much stronger as compared to that on adult 
RBCs.  Thus, FACS that can efficiently separate cell populations based on the 
differential expression of their antigens should be an ideal technique for our 
purpose.  Theoretically, each CD147 molecule could bind one molecule of anti-
CD147 IgG conjugated with FITC.  Thus, when enough anti-CD147 (FITC) was 
added, the fluorescence intensity on fetal NRBCs would be in proportion to the 
density of surface antigen CD147, and hence stronger than that on adult RBCs.  
The successful separation of fetal NRBCs from adult RBCs could then be 
achieved according to their difference in fluorescence intensity. 
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In order to determine an appropriate gating, fetal NRBCs and adult RBCs were 
mixed in different ratios and sorted using FACS.  As shown in Figure 6-3 and 
Figure 6-4, fetal NRBCs were located in higher fluorescence intensity region, and 
could be separated from adult RBCs by an appropriate gating.  Furthermore, it 
was shown that FACS separation gave a comparable recovery (59.0%) as in 
immunomagnetic cell sorting, but had a significantly higher fetal NRBC purity 
(nearly 100%).  This suggested that the application of CD147 in FACS sorting 
could be very useful for the separation of fetal NRBCs from maternal blood. 
 
In conclusion, the usefulness of CD147 was experimentally demonstrated in the 
enrichment of fetal NRBCs from model mixture with an encouraging recovery of 
fetal NRBCs and depletion rate of adult RBCs, indicative of its potential use for 




From immunocytochemical screening of surface antigens on fetal NRBCs and 
adult RBCs, I have found three antigens (CD164, CD147, and MCT1) that were 
expressed differentially on fetal NRBCs and adult RBCs.  Erythroid progenitor 
antigens CD164 were expressed on some of fetal NRBCs, but almost 
undetectable on adult RBCs.  Similarly, MCT1 was expressed on some of fetal 
NRBCs but undetectable on adult RBCs.  CD147, on the other hand, was 
strongly expressed on all fetal NRBCs, and also expressed on adult RBCs but 
with lower and/or negligible level.  Interestingly, it has been suggested that 
CD147 was necessary for the translocation and/or correct localisation of MCT1 to 
plasma membrane, and in most cases closely interact with each other.  Data from 
this study indicated a similar “co-expression” in only some of human erythrocytes, 
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as MCT1 was undetectable on more than half of fetal NRBCs despite with high 
level expression of CD147 in fetal NRBCs. 
 
The usefulness of CD147 for immuno-cell separation was experimentally 
demonstrated in the enrichment of fetal NRBCs from model mixture.  Although 
different yields and purities were obtained from three types of separation 
techniques (Dynabeads, MACS and FACS), all of them are very encouraging and 
promising.  Thus, this study provided potentially useful markers that could be 
used for the development of an efficient enrichment protocol to isolate first 
trimester fetal NRBCs from maternal blood for early non-invasive prenatal 
diagnosis. 
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Chapter 7 General Discussion 
Current prenatal diagnosis involves invasive procedures which carry a small but 
definitive risk of fetal loss, and limits the uptake of at-risk pregnant women for 
prenatal diagnosis of chromosomal and monogenic disorders.  Over the last 20 
years there has been much interest in the development of non-invasive 
techniques.  Use of fetal nucleated erythroblasts (NRBCs) in maternal blood 
during early pregnancy (e.g. at first trimester) represents the state of art 
technique and offers great potential to replace existing methods.  However, 
challenges preventing this from becoming clinically applicable are the technical 
difficulties in isolating the very rare fetal cells, which is mainly due to the lack of a 
specific surface marker that could be used to isolate fetal NRBCs from maternal 
red blood cells (RBCs). 
 
7.1 Hypothesis 
The aim of this thesis was to examine whether there is/are difference(s) of the 
surface membrane protein expression between fetal NRBCs and adult RBCs.  My 
primary hypothesis is that there is/are difference(s) and that the difference(s) 
could be identified by systematically analysing their membrane proteins either by 
proteomic profiling or immunocytochemical screening.  In order to logically 
address this hypothesis, I have restated it as following:  
1. That the most comprehensive membrane protein profiles of fetal NRBCs 
and adult RBCs can be obtained by developing an efficient proteomic 
strategy for the membrane protein analysis. 
2. That it is possible to identify unique surface protein(s) on fetal NRBCs by 
comparing the two sets of membrane profiling data obtained by proteomic 
studies. 
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3. That differential expression of surface antigen(s) is/are present in primitive 
fetal NRBCs, and could be identified by immunocytochemical screening 
using commercially available antibodies. 
 
7.2 Research findings 
Development of an efficient proteomic strategy for the analysis of fetal NRBC 
membrane proteome.  As only a small number of fetal NRBCs could be 
recovered from one sample of termination of pregnancy (~106 cells per sample), 
an efficient proteomic method has to be used in order to maximise the recovery of 
the membrane proteome.  Current methods for protein sample preparation use 
detergents, chaotropes and organic acids for membrane protein extraction that 
require sample clean-up or pH adjustment, and are associated with significant 
sample loss.  As such, these methods are not suitable for membrane proteome 
analysis in a situation when a sample is limited.  In this study, I have developed a 
very efficient proteomic strategy for the analysis of membrane proteins from a 
small number of fetal NRBCs (5×107), that is, sequential use of two organic 
solvents MeOH and TFE to recover both hydrophilic and hydrophobic peptides, 
and identification of proteins using 2-D LC-MALDI-TOF/TOF-MS (Chapter 3).  
This method not only allowed us to present the first relatively comprehensive fetal 
NRBC membrane proteome (Chapter 4), but also is applicable to other similar 
situations where only a limited sample is available. 
 
Identification of differentially expressed membrane proteins between fetal NRBCs 
and adult RBCs.  In this thesis, twenty-three unique fetal NRBC membrane 
proteins were identified by proteomic strategy.  Of these, twenty-two proteins 
were validated by RT-PCR or immunocytochemistry (Chapter 5).  In addition, 
three differentially/uniquely expressed surface antigens were identified using 
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immunocytochemical screening (Chapter 6).  Of these potentially useful markers, 
the most promising target CD147 was tested and demonstrated to be very useful 
in the separation of fetal NRBCs from the model mixture of fetal NRBCs and adult 
RBCs by using both immunomagnetic cell sorting (MACS and Dynal system) and 
fluorescence-activated cell sorting (FACS) techniques (Chapter 6). 
 
7.3 Implications and limitations of this research 
Implications.  Early non-invasive prenatal diagnosis using fetal cells in maternal 
blood is hampered by the difficulty in enrichment of these rare cells from maternal 
blood.  This is due to the lack of unique/specific surface antigens that could be 
used to efficiently separate primitive fetal NRBCs from adult RBCs.  Current 
separation techniques including density gradient centrifugation and selective RBC 
lysis are accompanied with significant cell loss and adversely affect fetal NRBC 
morphology, rendering the overall sensitivity and specificity of enrichment of fetal 
NRBCs from maternal blood as yet to be clinically useful. 
 
This study offered markers (e.g. CD147) that could be used to effectively 
separate fetal NRBCs from adult RBCs by commonly used techniques 
(Dynabeads, MACS and FACS).  These markers, therefore, could be potentially 
useful for the development of an optimal protocol for the separation of fetal 
NRBCs from maternal blood by modifying or replacing the density gradient 
centrifugation and/or selective RBC lysis, thereby minimising fetal NRBC loss and 
improving the overall efficiency of the enrichment of fetal NRBCs from maternal 
blood. 
 
Limitations.  The proteomic study of fetal NRBCs was limited by the small amount 
of sample available from trophoblast villi obtained at elective termination of 
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pregnancy.  Duplicate or triplicate of LC-MS/MS experiment and/or study of 
glycoproteins simultaneously, if more sample available, would not only increase 
overall membrane protein identification, but also could provide more information 
(e.g. relative abundance) that helps to yield more likely protein targets for further 
investigation.  Fetal NRBC number could be increased if more invasive 
techniques such as direct intracardiac puncture were performed under ultrasound 
guidance immediately before termination of pregnancy.  However, this procedure 
is not under routine practice in Singapore. 
 
The second limitation is that there is no commercially available antibody to many 
of the unique proteins identified from our proteomic study.  As such, antibodies 
have to be generated and assessed for their reactivity to fetal NRBCs and adult 
RBCs, which is time-consuming and very costly. 
 
Third, immunochemical screening is an alternative and complementary to 
proteomic analysis, which allowed us to identify differential expression and 
unique protein targets that were probably missed out in proteomic study.  
However, due to constraints of cost and the availability of antibody for 
immunocytochemical stain, only those more likely to show up difference between 
fetal NRBCs and adult RBCs were tested, which could result in inability to identify 
some differentially/uniquely expressed surface proteins. 
 
7.4 Directions of future study 
Investigation of identified targets.  In this thesis, potential markers have been 
identified.  It would be therefore logical to extend this study by exploring the 
usefulness of the identified markers, which can include: (1) development of an 
optimal enriment protocol for isolating fetal NRBCs from maternal blood by using 
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the identified surface marker CD147.  CD147 has been demonstrated to be very 
useful for the separation of fetal NRBCs from adult RBCs in a model mixture 
using both immunomagnetic cell sorting (MACS, Dynabeads) and fluorescence-
activated cell sorting (FACS) techniques.  I envisage that the use of CD147 for 
fetal NRBC enrichment would be able to enhance the recovery of these cells from 
maternal blood; (2) investigation of other markers.  As three antigens (CD71, 
CD164 and MCT1) were found to be expressed in some of fetal NRBCs but 
undectable on adult RBCs, use of one of them for fetal NRBC separation would 
result in a loss of some target cells.  However, use of a combination of them for 
fetal NRBC separation might be able to minimise fetal NRBC loss, and is thus 
worthwhile to be investigated.  In addition, for many potential markers, there is no 
commercially available antibody.  Thus there is a need to generate antibodies 
and to assess their usefulness for the separation of fetal NRBCs from adult 
RBCs.  Antibodies to the most promising potential maker(s) could then be tested 
in the separation of fetal NRBCs from maternal blood. 
 
Exploration of new surface marker:  As only limited sample was available for my 
study, some proteins (in particular glycosylated proteins) could be missed out 
despite the use of a sensitive, high throughput proteomic strategy.  The recently 
developed antibody array (Sigma-Aldrich) could test more than 725 protein 
targets in a single assay, and it is suitable for cell assay.  Another antibody array 
GlycoChip (Glycomind) that specifically designed for studying glycoprotein could 
also be used to detect the difference of protein glycosylation between fetal 
NRBCs and adult RBCs.  These newly developed techniques are high 
throughput, fast, reliable, and more importantly require a relatively small amount 
of sample.  Thus, these techniques have their place for the identification of new 




Fetal primitive erythroblasts (NRBCs) in the maternal blood provide an ideal 
source of fetal genetic material for early non-invasive prenatal diagnosis.  
However, these cells are rare and it is technically challenging in recovering them 
from maternal blood due to the lack of a specific surface marker that could be 
used to separate them from adult RBCs. 
 
In this thesis, I have studied the membrane protein expressions of fetal NRBCs 
and adult RBCs using proteomic profiling and immunocytochemical screening, in 
order to identify differentially/uniquely expressed surface membrane proteins.  I 
have shown that both approaches yielded potentially useful markers that can be 
used to differentiate fetal NRBCs from adult RBCs.  Most of these markers were 
validated by RT-PCR and immunocytochemistry.  Moreover, one of identified 
markers (CD147) has been tested and demonstrated to be very useful in the 
isolation of fetal NRBCs from the model mixture by both immunomagnetic cell 
sorting and fluorescence-activated cell sorting.  While this was adequate for the 
purposes of this thesis, it is not yet to apply it to isolate fetal NRBCs from clinical 
samples.  This is because that the usefulness of this marker for clinical 
application can only be concluded when well-designed clinical trials with an 
optimised protocol and a large sample size are conducted.  The effort from our 
group, which applies the identified marker for the enrichment of fetal NRBCs from 
clinical samples, is currently on-going and an efficient enrichment protocol is 
anticipated. 
 
In conclusion, I have achieved the primary aim of this thesis: to identify 
differentially/uniquely expressed membrane proteins in fetal NRBCs and adult 
RBCs.  I envisage that after all the potential targets found in our study have been 
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further investigated, an optimal enriching protocol based on targeting identified 
markers could be developed to isolate fetal NRBCs from maternal blood for early 
non-invasive prenatal diagnosis. 
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Appendix table 1   Total proteins identified from extended LC elution gradient (60 min) from MeOH-based extraction and digestion method 









1 Spectrin, alpha, erythrocytic 1 IPI00641363 279501.69 4.95 0 83 192 
2 Spectrin, alpha, erythrocytic 1 (elliptocytosis 2) IPI00220741 280883.88 4.98 0 83 192 
3 Spectrin beta isoform a IPI00216704 267589.56 5.24 0 71 212 
4 Ankyrin 1 isoform 1 IPI00216697 206136.92 5.65 0 52 196 
5 Band 3 anion transport protein IPI00022361 101727.41 5.08 11 35 200 
6 Flotillin-2 IPI00029625 41659.24 5.23 0 18 224 
7 Splice Isoform Short of Erythrocyte membrane protein band 4.2 IPI00028614 76793.61 8.27 0 19 150 
8 55 kDa erythrocyte membrane protein IPI00215610 52263.65 6.91 0 16 210 
9 Splice Isoform 4 of Protein 4.1 IPI00218699 66357.31 6.81 0 18 164 
10 Solute carrier family 2, facilitated glucose transporter member 1 IPI00220194 54082.52 8.93 12 16 164 
11 Flotillin-1 IPI00027438 47325.62 7.08 0 11 176 
12 Erythrocyte band 7 integral membrane protein IPI00219682 31579.70 7.90 1 10 142 
13 Alpha 2 globin variant IPI00410714 15270.94 8.72 0 6 215 
14 Beta-globin gene from a thalassemia patient, complete cds IPI00382950 18918.59 6.28 0 8 150 
15 Splice Isoform XB of Plasma membrane calcium-transporting ATPase 4 IPI00217169 133845.70 6.04 8 9 148 
16 Aquaporin-1 IPI00024689 28377.02 7.15 6 6 179 
17 Calpain-5 IPI00742984 73122.66 7.57 0 10 126 
18 Complement component (3b/4b) receptor 1, including Knops blood group IPI00640083 223560.88 6.57 1 9 120 
19 Hemoglobin delta chain IPI00473011 15914.25 7.97 0 6 121 
20 Splice Isoform Glycophorin D of Glycophorin C IPI00218128 11491.61 4.76 1 3 255 
21 Kell blood group glycoprotein IPI00220459 82770.92 8.09 1 7 147 
22 Hypothetical protein IPI00456429 14718.96 9.87 0 4 159 
23 Calnexin precursor IPI00020984 67525.85 4.47 1 5 109 
24 Multidrug resistance-associated protein 4 IPI00006675 149445.70 8.48 11 5 124 
25 Splice Isoform 2 of Cell division control protein 42 homolog IPI00016786 21245.02 6.15 0 5 103 
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26 ATP-binding cassette half-transporter IPI00465442 99649.17 9.26 9 7 124 
27 Acetylcholinesterase precursor/ACHE protein IPI00220026  69665.78 6.45 0 8 82 
28 Splice Isoform B of Ras-related C3 botulinum toxin substrate 1 IPI00219675 23452.31 8.87 0 7 85 
29 Rhesus blood group-associated glycoprotein IPI00024094 44169.66 6.19 12 4 128 
30 Splice Isoform 2 of Neutral alpha-glucosidase AB precursor IPI00011454 109369.04 5.82 1 7 92 
31 Probable endonuclease KIAA0830 precursor IPI00001952 54981.26 5.55 3 5 100 
32 Ras-related protein Rap-2b IPI00018364 20491.21 4.73 0 6 105 
33 Equilibrative nucleoside transporter 1 IPI00550382 58924.58 8.49 11 5 78 
34 Splice Isoform 2 of Disheveled associated activator of morphogenesis 1 IPI00337801 122229.07 6.81 0 5 84 
35 Erythroblast membrane-associated protein IPI00647116 42800.59 8.93 1 4 111 
36 Ras-related protein Rab-10 IPI00016513 22526.59 8.59 0 4 89 
37 Protein FAM38A IPI00006093 232892.56 6.51 25 7 64 
38 Solute carrier family 40 IPI00005547 62473.32 6.08 10 2 151 
39 Semaphorin 7A precursor IPI00025257 74776.17 7.57 0 4 89 
40 Ras-related protein Rab-21 IPI00007755 24201.21 8.16 0 3 100 
41 Glycophorin A precursor IPI00298800 16263.40 5.47 1 2 150 
42 Splice Isoform Long of Dematin IPI00292290 45486.22 8.94 0 4 101 
43 Hypothetical protein DKFZp686P17114 IPI00478210 202466.06 6.21 0 4 75 
44 Splice Isoform 3 of Alpha adducin IPI00220158 84250.40 5.67 0 4 89 
45 Splice Isoform 1 of Duffy antigen/chemokine receptor IPI00215964 35654.63 5.84 7 2 126 
46 Urea transporter, erythrocyte IPI00298337 48309.66 6.11 8 2 141 
47 Rhesus blood group, CcEe antigens, isoform 1 IPI00465155 45421.20 9.40 12 4 66 
48 NADH-cytochrome b5 reductase IPI00328415 34081.68 7.31 0 4 72 
49 Splice Isoform Alpha-S1 of Guanine nucleotide-binding protein G(s) IPI00219835 44238.32 5.92 0 5 64 
50 Hypothetical protein DKFZp564D0478 IPI00030236 21164.34 6.28 3 2 159 
51 Phosphatidylinositol 4-kinase type II IPI00020124 53988.61 8.51 0 2 106 
52 Splice Isoform 2 of Syntaxin-7 IPI00552913 27383.66 5.02 0 3 100 
53 Actin, cytoplasmic 2 IPI00021440 41765.79 5.31 0 3 81 
54 Stromal cell-derived receptor-1 alpha IPI00011578 31271.86 6.40 1 3 97 
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55 28 kDa protein IPI00069985 28213.33 8.52 1 2 127 
56 Polyposis locus protein 1 IPI00024670 21118.89 8.25 2 4 63 
57 Similar to mouse 1500009M05Rik protein IPI00166865 15268.45 9.66 1 2 99 
58 Vesicle-associated membrane protein-associated protein A isoform 1 IPI00374657 32592.62 9.03 1 3 72 
59 Splice Isoform Short of Intercellular adhesion molecule-4 precursor IPI00396335 25914.66 10.19 0 3 87 
60 Splice Isoform 1 of Choline transporter-like protein 2 IPI00549521 80098.56 8.93 11 3 84 
61 CD59 glycoprotein precursor IPI00011302 14167.79 6.02 0 2 113 
62 Ras-related protein Rab-8A IPI00028481 23653.19 9.15 0 3 60 
63 RAP1A, member of RAS oncogene family IPI00640287 20939.72 6.38 0 2 104 
64 Zinc transporter 1 IPI00002483 55292.08 6.02 6 2 77 
65 Splice Isoform 2 of Zinc finger DHHC domain containing protein 3 IPI00216069 34147.21 8.54 4 1 134 
66 Splice Isoform H14 of Myeloperoxidase precursor IPI00236554 73806.61 9.30 0 4 34 
67 Splice Isoform 1 of Beta adducin IPI00019904 80803.43 5.67 0 3 57 
68 Thioredoxin domain containing protein 4 precursor IPI00401264 46941.40 5.09 0 1 122 
69 Acyl-Coa synthetase long-chain family member 6 isoform A IPI00296333 80477.23 6.79 1 3 58 
70 N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D IPI00419930 45565.47 5.80 0 2 67 
71 Solute carrier family 2, facilitated glucose transporter member 4 IPI00027281 54752.36 6.47 12 2 74 
72 Calreticulin precursor IPI00020599 48111.82 4.29 0 2 83 
73 Mesenchymal stem cell protein DSCD75 IPI00550002 23849.87 9.71 1 1 110 
74 Similar to Ras-related protein Rab-5C IPI00016339 31028.31 8.48 0 2 74 
75 Glyceraldehyde-3-phosphate dehydrogenase, liver IPI00219018 35899.36 8.58 0 2 60 
76 DKFZP564J0863 protein IPI00550523 60503.42 5.43 2 2 62 
77 Splice Isoform 1 of Choline transporter-like protein 1 IPI00221393 73253.26 8.93 9 2 63 
78 Chromosome 9 open reading frame 19 IPI00479010 14204.11 9.55 0 1 101 
79 Splice Isoform CD44 of CD44 antigen precursor IPI00305064 81503.40 5.13 1 1 100 
80 Lutheran blood group glycoprotein isoform 2 precursor IPI00554618 63653.97 5.74 1 2 64 
81 Splice Isoform 2 of Complement decay-accelerating factor precursor IPI00292069 41373.58 7.79 0 2 65 
82 Ras-related protein Ral-A IPI00217519 23551.97 6.66 0 1 96 
83 78 kDa glucose-regulated protein precursor IPI00003362 72288.43 5.07 0 2 59 
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84 Suppressor of actin 1 IPI00022275 66908.01 6.66 2 2 53 
85 Transforming protein RhoA IPI00027500 21754.07 5.83 0 1 88 
86 Ras-related protein Rab-35 IPI00300096 23010.77 8.52 0 1 85 
87 Vesicular integral-membrane protein VIP36 precursor IPI00009950 40203.10 6.46 1 2 48 
88 Splice Isoform OA3-323 of Leukocyte surface antigen CD47 precursor IPI00374740 35190.74 6.82 6 2 52 
89 Flavin reductase IPI00219910 22579.64 7.12 0 2 44 
90 Hypothetical protein FLJ14347 IPI00022300 28266.57 8.70 1 2 45 
91 Splice Isoform Short of Lymphocyte function-associated antigen 3 precursor IPI00219549 26643.16 5.85 2 1 78 
92 Solute carrier family 12 member 5 IPI00301180 123415.32 5.91 12 1 78 
93 Myeloblastin precursor IPI00027409 27789.27 8.72 0 2 43 
94 Splice Isoform 1 of Vacuolar proton translocating ATPase 116 kDa subunit a isoform 1 IPI00552514 96350.11 6.02 7 1 74 
95 Splice Isoform 1 of Solute carrier family 2 (facilitated glucose transporter member 14 IPI00152505 56283.47 8.00 10 1 73 
96 Hypothetical protein MGC13057 IPI00031140 10963.21 4.84 0 1 70 
97 Guanine nucleotide binding protein IPI00639998 16396.27 9.27 0 1 70 
98 ABC transporter ABCA7 IPI00293895 234275.16 6.85 11 2 40 
99 Splice Isoform 3 of Cyclin fold protein 1 IPI00413625 33224.14 7.62 0 1 69 
100 Reticulon 3 isoform a variant IPI00555783 28803.32 8.88 3 2 36 
101 Protein kinase C substrate 80K-H isoform 1 IPI00419384 59387.82 4.33 0 1 65 
102 Protein disulfide-isomerase A3 precursor IPI00025252 56746.75 5.98 0 2 39 
103 Splice Isoform 1 of Disheveled associated activator of morphogenesis 2 IPI00514893 123420.36 6.36 0 1 64 
104 Guanine nucleotide binding protein, q polypeptide IPI00288947 42115.31 5.48 0 2 39 
105 UDP-glucose:glycoprotein glucosyltransferase 1 Precursor IPI00619903 174867.02 5.40 1 2 38 
106 Endoplasmin precursor IPI00027230 92411.34 4.76 0 1 63 
107 EVIN2 IPI00302538 81589.02 9.49 8 1 62 
108 Cathepsin G precursor IPI00028064 28819.07 11.19 0 1 61 
109 Surfeit 4 IPI00399142 21115.80 8.88 2 1 60 
110 ARFRP2 protein IPI00005163 22843.55 5.41 0 1 60 
111 Splice Isoform Short of Sodium/potassium-transporting ATPase alpha-1 chain precusor IPI00414005 74092.64 5.73 4 1 59 
112 Galphai2 protein IPI00465121 41521.62 5.66 0 2 32 
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113 17 kDa protein IPI00642218 16710.62 6.49 3 1 58 
114 Phospholipid scramblase 1 IPI00005181 35025.85 4.83 0 1 57 
115 Splice Isoform Delta of Poliovirus receptor related protein 1 precursor IPI00003648 57122.48 5.77 2 2 29 
116 Microsomal glutathione S-transferase 3 IPI00639812 18404.62 9.99 3 1 56 
117 Casein kinase I gamma 1 isoform IPI00465058 50312.43 8.91 0 1 56 
118 Protein BAT5 IPI00033075 63072.05 8.40 2 1 56 
119 Splice Isoform 2 of ADP-ribosyl cyclase 1 IPI00395006 13779.04 9.01 1 1 56 
120 Guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 2 IPI00003348 37176.02 5.60 0 1 54 
121 Hypothetical protein 327024.1 IPI00178934 44565.75 7.24 1 1 53 
122 Splice Isoform 1 of Multiple inositol polyphosphate phosphatase 1 precursor IPI00293748 55016.08 7.93 0 1 52 
123 Phospholipid scramblase 4 IPI00016776 36939.60 5.53 0 1 51 
124 Intermediate conductance calcium-activated potassium channel protein 4 IPI00032466 47664.55 9.87 5 1 51 
125 Signal peptidase complex subunit 1 IPI00219755 11797.11 9.33 2 1 50 
126 Growth-inhibiting protein 12 IPI00646848 78334.00 8.54 0 1 52 
127 FCGR3A protein IPI00639988 29038.68 8.20 0 1 48 
128 Epidermal growth factor receptor pathway substrate 15 IPI00385325 83602.79 4.56 0 1 48 
129 Thioredoxin domain containing protein 1 precursor IPI00395887 31770.80 4.92 3 1 48 
130 101 kDa protein IPI00514990 101264.14 6.17 8 1 48 
131 Transmembrane protein Tmp21 precursor IPI00028055 24960.02 6.97 2 1 48 
132 ATP-binding cassette, sub-family C, member 1 isoform 6 IPI00008463 166576.64 7.27 15 1 47 
133 Leukocyte elastase precursor IPI00027769 28499.79 9.71 1 1 44 
134 Histidine decarboxylase IPI00290368 74092.53 8.30 0 1 44 
135 Splice Isoform 2 of Large neutral amino acids transporter small subunit 3 IPI00479732 61011.13 8.26 11 1 43 
136 Splice Isoform 2 of Transmembrane protein 55B IPI00332278 30165.25 9.29 2 1 43 
137 SPATS2 protein IPI00329345 59507.56 9.01 0 1 41 
138 Ras-related protein Rab-7 IPI00016342 23474.84 6.40 0 1 40 
139 Membrane protein IPI00026111 21161.16 9.77 2 1 40 
140 Protein transport protein SEC61 gamma subunit IPI00006072 7736.17 10.01 1 1 39 
141 Solute carrier family 43, membrane 3 IPI00301100 54494.25 8.71 11 1 38 
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Appendix table 2   Comprehensive membrane protein list summarised from various studies on human adult RBCs 
(Adjacent proteins in Italic were identified from same peptide but in different studies, and were counted as one protein) 
No. Protein Name Accession Number TMD Subcellular localisation 
1 101 kDa protein IPI00514990 8 Integral membrane protein 
2 17 kDa protein IPI00642218 3 Integral membrane protein 
3 22 kDa protein IPI00478755 0 Plasma membrane 
4 27 kDa protein IPI00641837 3 Integral membrane protein 
5 28 kDa protein IPI00069985 1 Integral membrane protein 
6 55 kDa erythrocyte membrane protein IPI00215610 0 Membrane associated protein 
7 64 kDa protein IPI00479914 0 Membrane; Cytoplasmic 
8 ABC transporter ABCA7 IPI00293895 11 Integral membrane protein 
9 Acetylcholinesterase precursor/ACHE protein IPI00220026 0 Membrane; Extracellular 
10 Splice isoform 1 of P22303 Acetylcholinesterase precursor IPI00026103 0 Integral membrane protein 
11 Acyl-Coa synthetase long-chain family member 6 isoform A IPI00296333 1 Membrane 
Splice isoform 1 of P35611 Alpha adducin IPI00019901 0 Membrane; Cytoskeleton 
Adducin subunit (alpha), erythrocyte Gi12644231 0 Membrane; Cytoskeleton 12 
Adducin 1 (alpha) isoform c Gi7710117 0 Membrane; Cytoskeleton 
13 Splice Isoform 3 of Alpha adducin IPI00220158 0 Membrane; Cytoskeleton 
Splice isoform 1,3 of Beta adducin IPI00019904 0 Membrane; Cytoskeleton 14 Beta adducin P35612  0 Membrane; Cytoskeleton 
15 Adipocyte plasma membrane-associated protein, Low molecular weight phosphotyrosine protein phosphatase IPI00031131 1 Membrane associated protein 
16 Splice Isoform 2 of ADP-ribosyl cyclase 1 IPI00395006 1 Integral membrane protein 
17 Splice isoform APP770 of P05067 Amyloid beta A4 protein precursor IPI00006608 1 Type I membrane protein 
Ankyrin 1 isoform 1 IPI00216697 0 Membrane; Cytoskeleton 
Similar to ankyrin 1 Gi13645508 0 Membrane; Cytoskeleton 18 
Ankyrin 1 P16157 0 Membrane; Cytoskeleton 
Ankyrin 1, splice form 2 Gi105337 0 Membrane; Cytoskeleton 19 Ankyrin 1, isoform 2, erythrocytic Gi10947042 0 Membrane; Cytoskeleton 
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20 Annexin A11 protein IPI00001856 1 Membrane; Cytoskeleton 
21 Annexin I             IPI00218918 0 Membrane associated protein 
22 Annexin VII isoform 2  IPI00002460 0 Integral membrane protein 
23 ANXA4 protein IPI00221225 0 Membrane; Cytoskeleton 
24 Apolipoprotein E precursor            IPI00021842 0 Extracellular binding RBCs 
25 Aquaporin 1 IPI00024689 6 Integral membrane protein 
26 Aquaporin 1 splice variant 2 IPI00428490 1 Integral membrane protein 
ATP-binding cassette half-transporter IPI00465442 9 Integral membrane protein; Inner 
mitochondrial 27 
ATP-binding cassette, sub-family B, member 6, mitochondrial precursor IPI00014555 9 Mitochondrial membrane 
28 ATP-binding cassette, subfamily C, member 6 Gi6715561 12 Integral membrane protein 
29 ATP-binding cassette, sub-family C, member 1 isoform 6 IPI00008463 15 Integral membrane protein 
30 ATP-binding cassette, sub-family G, member 2 IPI00298214 6 integral membrane protein 
31 Band 3 anion transport protein IPI00022361 11 integral membrane protein 
32 Splice Isoform 2 or 1 of P35613 Basigin precursor IPI00019906 2 Type I membrane protein 
33 C4B1 IPI00418163 0 Extracellular protein 
34 Calcium and integrin-binding protein 1 IPI00018451 0 Membrane associated protein 
35 Calcium binding protein 39                 IPI00032561 0 Integral membrane protein 
36 Calnexin precursor IPI00020984 1 Integral membrane protein; ER 
37 Calreticulin precursor IPI00020599 0 ER; Extracellular; Cytosolic protein 
38 Carnitine O-palmitoyltransferase I, mitochondrial liver isoform IPI00032038 2 Mitochondrial outer membrane. 
39 Cathepsin G precursor IPI00028064 0 Extracellular binding RBC 
CD44 antigen IPI00297160 1 Type I membrane protein 
Cell surface glycoprotein CD44 Gi7512338 1 Integral membrane protein 40 
Splice Isoform CD44 of CD44 antigen precursor IPI00305064 1 Integral membrane protein 
41 CD59 glycoprotein precursor IPI00011302 0 Membrane associated protein 
42 Splice Isoform 2 of P60953 Cell division control protein 42 homolog IPI00016786 0 Membrane associated protein 
43 Channel-like integral membrane protein 1314306 3 Integral membrane protein 
44 Chloride intracellular channel protein 3   IPI00000692 0 Integral membrane protein 
45 Splice Isoform 1 of Choline transporter-like protein 1 IPI00221393 9 Integral membrane protein 
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46 Splice Isoform 1 of Choline transporter-like protein 2 IPI00549521 11 Integral membrane protein 
47 CGI-26 protein IPI00219677 0 Extracellular protein 
48 Clathrin coat assembly protein AP180  IPI00006612 0 Membrane associated protein 
49 Clusterin precursor                                                   IPI00291262 0 Extracellular binding RBC 
Splice Isoform 1 of P08174 Complement decay-accelerating factor 
precursor IPI00216550 0 Membrane associated protein 50 
Splice Isoform 2 of Complement decay-accelerating factor precursor IPI00292069 0 Integral membrane protein 
51 Complement C3b                               IPI00164623 0 Extracellular binding RBC 
Complement component (3b/4b) receptor 1, including Knops blood group 
system (Complement receptor 1) IPI00640083 1 Integral membrane protein 
Complement receptor 1 IPI00412546 1 Integral membrane protein 52 
Complement receptor type 1 precursor IPI00018287 1 Type I membrane protein 
53 Cop-coated vesicle membrane protein p24 precursor IPI00016608 2 Integral membrane protein 
54 Copine III IPI00024403 0 Membrane associated protein 
55 Splice Isoform 4 of Q04656 Copper-transporting ATPase 1 IPI00028610 7 Golgi; Plasma membrane 
Splice Isoform CNPI of 2',3'-cyclic-nucleotide 3'-phosphodiesterase IPI00220993 0 Membrane associated protein 56 2',3'-cyclic-nucleotide 3'-phosphodiesterase Gi7435185 0 Membrane associated protein 
57 Cytochrome b5 reductase membrane-bound isoform IPI00328415 0 Membrane associated protein 
58 Splice Isoform 2 or 1 of  Q9H3Z4 DNAJ homolog subfamily C member 5 IPI00023780 1 Membrane associated protein 
59 DC-TM4F2 protein IPI00165394 4 Integral membrane protein 
Splice Isoform Long of Dematin IPI00292290 0 Membrane associated protein 
Dematin 52 kDa subunit Gi4503581 0 Membrane associated protein 
Dematin (Erythrocyte membrane protein band 4,9) Q08495 0 Membrane associated protein 60 
Splice Isoform Short of Q08495 Dematin IPI00216633 0 Integral membrane protein 
61 DKFZP564J0863 protein IPI00550523 2 Unclassified 
62 Down syndrome cell adhesion molecule 2 IPI00154755 1 Type I membrane protein 
Splice Isoform 1 of Duffy antigen/chemokine receptor IPI00215964 7 Integral membrane protein 63 Splice Isoform 2 of Q16570 Duffy antigen/chemokine receptor IPI00002940 7 Integral membrane protein 
Duodenal cytochrome b sequence coverage:10% IPI00432050 1 Integral membrane protein 64 Duodenal cytochrome b Gi13376257 6 Integral membrane protein 
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65 Ecto-ADP-ribosyltransferase 4 precursor IPI00004065 0 Integral membrane protein 
66 Endoplasmin precursor IPI00027230 0 Membrane; ER 
67 Alpha enolase IPI00215736 0 Cytosolic; Plasma membrane 
68 ENSEMBL:ENSP00000309219 Tax_Id=9606 IPI00156774 0 Membrane associated protein 
69 Eosinophil granule major basic protein precursor IPI00010341 0 Extracellular protein 
70 Equilibrative nucleoside transporter 1 IPI00550382 11 Integral membrane protein 
71 Erythroblast membrane-associated protein IPI00647116 1 Integral membrane protein 
72 Erythroid membrane-associated protein IPI00044556 2 Membrane associated protein 
Erythrocyte membrane protein band 4.2 (pallidin) P16452 0 Membrane associated protein 
Splice Isoform Short of Erythrocyte membrane protein band 4.2 IPI00028614 0 Membrane associated protein 73 
Erythrocyte membrane protein band 4.2 IPI00028120 0 Membrane associated protein 
74 EVIN2 IPI00302538 8 Integral membrane protein 
75 Similar to expressed sequence AA536743 IPI00216890 2 Integral membrane protein 
76 Splice Isoform 1 Of Fibronectin precursor       IPI00022418 0 Integral membrane protein 
77 Flotillin-1 IPI00027438 0 Membrane associated protein 
Flotillin-2 IPI00029625 0 Membrane associated protein 78 Similar to flotillin 2 IPI00386741 0 Membrane associated protein 
79 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2       IPI00221205 1 Integral membrane protein; Golgi 
80 Galectin-3                   IPI00465431 0 Extracellular binding RBC 
81 Splice isoform Long of O00182 Galectin-9 IPI00010477 0 Extracellular protein 
82 Gene rich cluster, C3f gene IPI00306419 7 Unclassified 
Glycophorin A precursor IPI00298800 2 Type I membrane protein 83 Similar to glycophorin A Gi13529077 2 Type I membrane protein 
84 Glycophorin A Gi106140 2 Type I membrane protein 
85 Glycophorin Erik I-IV precursor IPI00384414 1 Integral membrane protein 
Glycophorin C, isoform 1 Gi4504229 1 Integral membrane protein 
Splice Isoform Glycophorin C of P04921 Glycophorin C IPI00026299 1 Integral membrane protein 86 
Splice Isoform Glycophorin D of Glycophorin C IPI00218128 1 Integral membrane protein 
87 Gp25L2 protein IPI00023542 2 Integral membrane protein 
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88 Guanine nucleotide binding protein IPI00639998 0 Extrinsic plasma membrane 
89 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 IPI00220578 0 Inner surface of plasma membrane 
90 Guanine nucleotide binding protein (G protein), q polypeptide IPI00288947 0 Inner surface of plasma membrane  
91 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-5 (like) 
subunit IPI00000060 0 Inner surface of plasma membrane  
92 Guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 1 IPI00026268 0 Inner surface of plasma membrane  
93 Guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 2 IPI00003348 0 Inner surface of plasma membrane  
94 Guanine nucleotide-binding protein, alpha-13 subunit IPI00290928 0 Inner surface of plasma membrane  
95 Guanine nucleotide-binding protein, alpha-14 subunit IPI00000695 0 Inner surface of plasma membrane  
Splice Isoform Alpha-S1 of Guanine nucleotide-binding protein G(s) IPI00219835 0 Membrane associated protein 96 Guanine nucleotide-binding protein G(S), alpha subunit P04895 0 Membrane associated protein 
97 Splice Isoform Alpha-S2 of Guanine nucleotide-binding protein G(s) IPI00025899 0 Inner surface of plasma membrane 
98 HGTD-P Gi9295192 1 Integral membrane protein 
99 Hypothetical protein XP_092517 gi18552304 1 Unclassified 
100 High mobility group protein 1 - AMIGO2 protein IPI00219096 0 Integral membrane protein 
101 Hypothetical protein IPI00029002 4 Integral membrane protein 
102 Hypothetical protein IPI00031697 5 Unclassified 
103 Hypothetical protein         IPI00385392 0 Integral membrane protein 
104 Hypothetical protein CGI-109 precursor   IPI00032825 1 Integral membrane protein 
105 Hypothetical protein DKFZp564J0863 IPI00383828 2 Unclassified 
106 Hypothetical protein 327024.1 IPI00178934 1 Integral membrane protein 
107 Hypothetical protein DKFZp564D0478 IPI00030236 3 Integral membrane protein 
108 Hypothetical protein DKFZp564E227 IPI00100199 6 Integral membrane protein 
109 Hypothetical protein DKFZp686P17114 IPI00478210 0 Membrane; Cytoskeleton 
110 Hypothetical protein DKFZp762A227 IPI00032013 11 Integral membrane protein 
111 Hypothetical protein FLJ14347 IPI00022300 1 Unclassified 
112 Hypothetical protein FLJ16766          IPI00442030 7 Integral membrane protein 
113 Hypothetical protein FLJ31842 IPI00043429 6 Integral membrane protein 
114 Hypothetical protein FLJ40269 IPI00167359 2 Integral membrane protein 
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115 Hypothetical protein MGC34680 IPI00171004 12 Integral membrane protein 
116 Hypothetical protein ORF9 precursor          IPI00003441 1 Integral membrane protein 
117 Hypothetical protein PSEC0098 IPI00171421 1 Unclassified 
118 Ig gamma-1 chain C region       IPI00332161 0 Extracellular binding RBC 
119 Ig kappa chain C region IPI00385058 0 Extracellular binding RBC 
120 Ig heavy chain V-V region Gi87863 0 Extracellular binding RBC 
121 Integrin beta-2 precursor P05107 1 Integral membrane protein 
Splice Isoform Long of Intercellular adhesion molecule-4 precursor IPI00000118 1 Integral membrane protein 122 Splice Isoform Short of Intercellular adhesion molecule-4 precursor IPI00396335 0 Plasma membrane 
123 B-CAM protein Gi2134798 1 Integral membrane protein 
124 Intermediate conductance calcium-activated potassium channel protein 4 IPI00032466 5 Integral membrane protein 
125 Ion transporter protein IPI00415077 9 Integral membrane protein 
126 Junctional adhesion molecule 1 precursor IPI00001754 2 Type I membrane protein 
127 JWA protein regulates intracellular concentrations of taurine and glutamate IPI00007426 3 Integral membrane protein 
128 Kell blood group glycoprotein IPI00220459 1 Integral membrane protein 
129 KIAA0830 protein IPI00001952 3 Integral membrane protein 
130 KIAA0851 protein IPI00022275 2 Membrane associated protein 
131 KIAA1363 protein IPI00002230 1 Membrane associated protein 
132 KIAA1617 protein IPI00010970 0 Integral membrane protein 
133 Lactotransferrin precursor       IPI00298860 0 Extracellular binding RBC 
134 LanC-like protein 1 IPI00005724 0 Integral membrane protein 
135 Leukemia inhibitory factor receptor P42702 1 Integral membrane protein 
136 Leukocyte elastase precursor IPI00027769 1 Extracellular protein 
Splice Isoform OA3-293 of Leukocyte surface antigen CD47 precursor IPI00216514 0 Integral membrane protein 137 Splice Isoform OA3-323 of Leukocyte surface antigen CD47 precursor IPI00374740 6 Integral membrane protein 
138 LFA-3 IPI00000059 2 Integral membrane protein 
139 LGALS3 protein IPI00219220 0 Integral membrane protein 
140 Long-chain-fatty-acid--CoA ligase 3 IPI00031397 1 Type III membrane protein 
141 Splice Isoform Short of Q9UKU0 Long-chain-fatty-acid--CoA ligase 6 IPI00218718 0 Type III membrane protein 
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142 Low affinity immunoglobulin gamma Fc region receptor III-B precursor IPI00023858 1 Integral membrane protein 
Lutheran blood group glycoprotein precursor IPI00002406 1 Type I membrane protein 
Lutheran blood group IPI00328869 1 Integral membrane protein 143 
Lutheran blood group glycoprotein isoform 2 precursor IPI00554618 1 Integral membrane protein 
144 Similar to Lutheran blood group Gi18589892 0 Integral membrane protein 
145 Splice Isoform Short of Lymphocyte function-associated antigen 3 precursor IPI00219549 2 Integral membrane protein 
146 Lysozyme C precursor IPI00019038 0 Extracellular protein 
147 Membrane associated progesterone receptor component   2 IPI00005202 1 Integral membrane protein 
148 Membrane protein IPI00026111 2 Unclassified 
149 Membrane transport protein XK IPI00020896 9 Integral membrane protein 
150 Mesenchymal stem cell protein DSCD75 IPI00010292 1 Unclassified 
151 Microsomal glutathione S-transferase 3 IPI00639812 3 Integral membrane protein 
152 Moesin IPI00219365 0 Membrane; Cytoskeleton 
153 Monocarboxylate transporter 1 IPI00024650 11 Integral membrane protein 
154 Splice Isoform Delexon-17 of P33527 Multidrug resistance-associated protein 1 IPI00008338 16 Integral membrane protein 
155 Multidrug resistance-associated protein 4 IPI00006675 11 Integral membrane protein 
156 Multidrug resistance-associated protein 5 IPI00385383 11 Integral membrane protein 
157 Myeloblastin precursor IPI00027409 0 Extracellular protein 
158 Splice Isoform 1 of Q92542 Nicastrin precursor IPI00021983 0 Type I membrane protein 
159 Neuropathy target esterase IPI00217600 1 Unclassified 
160 Splice Isoform 2 of Q14697 Neutral alpha-glucosidase AB precursor IPI00011454 1 ER and Golgi 
161 Splice Isoform 2 of Large neutral amino acids transporter small subunit 3 IPI00479732 11 Integral membrane protein 
162 Novel protein IPI00513701 3 Integral membrane protein 
163 Splice Isoform 1 of Q16563 Pantophysin IPI00009507 3 Integral membrane protein 
164 PB39 IPI00021075 12 Integral membrane protein 
165 Phosphatidylinositol 4-kinase type II IPI00020124 0 Integral membrane protein 
Phosphatidylinositol-4-phosphate 5-kinase type II alpha IPI00009688 0 Integral membrane protein 166 Phosphatidylinositol-4-phosphate 5 kinase, type III Gi1730569 0 Integral membrane protein 
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167 Splice Isoform 1 Of Phosphofurin acidic cluster sorting protein 1    IPI00376229 0 Membrane associated protein 
168 Phospholipid scramblase 1 IPI00005181 0 Type II membrane protein 
169 Phospholipid scramblase 4 IPI00016776 0 Type II membrane protein 
170 PICALM protein             IPI00472438 0 Membrane associated protein 
171 Splice isoform B of P20020 Plasma membrane calcium-transporting ATPase 1 IPI00021695 7 Integral membrane protein 
Splice Isoform XB of Plasma membrane calcium-transporting ATPase 4 IPI00217169 8 Integral membrane protein 
177 Splice isoform XD of P23634 Plasma membrane calcium-transporting 
ATPase 4 IPI00012490 8 Integral membrane protein 
178 Splice Isoform Delta of Poliovirus receptor related protein 1 precursor IPI00003648 2 Integral membrane protein; Cell junction 
179 Polyposis locus protein 1 IPI00024670 2 Integral membrane protein 
180 Potassium channel subfamily K member 5 IPI00029507 6 Integral membrane protein 
181 Presenilin-associated protein Gi6409316 2 Integral membrane protein 
182 Prolactin        IPI00022974 0 Extracellular binding RBC 
Splice Isoform 1 of Protein 4.1 IPI00003921 0 Membrane; Cytoskeleton 
Protein 4.1 P11171  Membrane; Cytoskeleton 183 
Protein band 4.1, erythrocytic Gi14916944 0 Membrane; Cytoskeleton 
Splice Isoform 4 of P11171 Protein 4.1 IPI00218699 0 Membrane; Cytoskeleton 184 Protein band 4.1 (elliptocytosis 1, RH-linked) Gi4758274 0 Membrane; Cytoskeleton 
185 Splice Isoform 2 of P11171 Protein 4.1 IPI00218697 0 Membrane; Cytoskeleton 
186 Band 4.1-like protein 4A IPI00030794 0 Membrane; Cytoskeleton 
187 Erythroid protein 4.1 isoform B Gi182074 0 Membrane; Cytoskeleton 
188 Protein BAT5 (HLA-B-associated transcript 5) IPI00033075 2 Integral membrane protein 
189 Protein disulfide-isomerase A2 precursor             IPI00011571 0 Membrane associated protein 
190 Protein disulfide-isomerase precursor IPI00010796 0 ER; Extracellular region 
191 Protein FAM38A IPI00006093 25 Membrane associated protein 
192 Protein transport protein SEC61 gamma subunit IPI00006072 1 Integral membrane protein 
193 PREDICTED: similar to RAB1B, member RAS oncogene family subset 
match by rab-10 and 8A IPI00374519 0 Membrane associated protein 
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194 Ras-related C3 botulinum toxin substrate 4 IPI00001352 0 Membrane associated protein 
195 Ras-related protein Rab-10 IPI00016513 0 Membrane associated protein 
196 Ras-related protein Rab-14 IPI00291928 0 Membrane associated protein 
197 Ras-related protein Rab-2A IPI00031169 0 Membrane associated protein 
198 Ras-related protein Rab-21 IPI00007755 0 Membrane associated protein 
199 Splice Isoform 1 of P62820 Ras-related protein Rab-1A IPI00005719 0 Membrane associated protein 
200 Ras-related protein Rab-33B IPI00021475 0 Membrane associated protein 
Ras-related protein Rab-35 IPI00300096 0 Membrane associated protein 201 RAB 35, RAS oncogene family Gi5803135 0 Membrane associated protein 
202 Ras-related protein Rab-5B IPI00017344 0 Membrane associated protein 
203 Ras-related protein Rab-5C IPI00016339 0 Membrane associated protein 
204 Ras-related protein Rab-7b IPI00016342 0 Membrane associated protein 
205 Ras-related protein Rab-8A IPI00028481 0 Membrane; Cytosolic protein 
206 Ras-related protein Rab-8B IPI00024282 0 Membrane; Cytosolic protein 
207 Ras-related protein Ral-A IPI00217519 0 Membrane; Cytosolic protein 
Ras-related protein Rap-1A IPI00019345 0 Membrane associated protein 208 RAP1A, member of RAS oncogene family Gi4506413 0 Membrane associated protein 
Ras-related protein Rap-1B IPI00015148 0 Membrane associated protein 209 RAP1B Gi7661678 0 Membrane associated protein 
Ras-related protein Rap-2b IPI00018364 0 Membrane associated protein 210 RAP2B, member of RAS oncogene family Gi11433346 0 Membrane associated protein 
211 Splice Isoform 1 of P59190 Ras-related protein Rab-15 IPI00394882 0 Membrane associated protein 
Ras-related C3 botulinum toxin substrate 1 P15154 0 Membrane associated protein 212 Splice isoform A of P15154 Ras-related C3 botulinum toxin substrate 1 IPI00010271 0 Membrane associated protein 
213 Splice Isoform B of Ras-related C3 botulinum toxin substrate 1 IPI00219675 0 Membrane associated protein 
214 Similar to RAS-related protein RAL-A Gi14740792 0 Membrane associated protein 
215 Similar to RAS-related protein RAB-15 Gi18596861 0 Membrane associated protein 
216 RECS1 protein homolog IPI00290452 7 Integral membrane protein 
217 Splice Isoform 2 Of Reticulon 4 IPI00298289 1 Integral membrane protein 
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Reticulon protein 3 IPI00028946 3 Integral membrane protein 
Reticulon 3 isoform a variant IPI00555783 3 Integral membrane protein 
RTN3-A1 IPI00398795 3 Integral membrane protein 218 
PREDICTED: similar to Reticulon protein 3 IPI00177423 1 Integral membrane protein 
219 Rh blood CE group antigen polypeptide IPI00039665 12 Integral membrane protein 
RhD protein IPI00329565 10 Integral membrane protein 
Rhesus blood group D antigen IPI00478119 10 Integral membrane protein 220 
Rh blood D group antigen polypeptide 10800054 10 Integral membrane protein 
221 Rhesus D category VI type III protein Gi2765839 12 Integral membrane protein 
222 Rhesus blood group-associated glycoprotein IPI00024094 11 Integral membrane protein 
223 Rhesus blood group, CcEe antigens, isoform 1 IPI00465155 12 Integral membrane protein 
224 Splice Isoform RHVIII of P18577 Blood group Rh(CE) polypeptide IPI00221017 10 Integral membrane protein 
225 Hypothetical protein FLJ45640 (Rhesus blood group, CcEe antigens) IPI00444375 10 Integral membrane protein 
226 Similar to RIKEN cDNA 1500009M05 gene IPI00166865 1 Unclassified 
227 PREDICTED: similar to RIKEN cDNA C730027E14              IPI00373867 1 Integral membrane protein 
228 Secretory carrier-associated membrane protein   4 IPI00056310 4 Integral membrane protein 
229 Semaphorin 7A precursor IPI00025257 0 Integral membrane protein 
230 Serum albumin precursor IPI00022434 0 Extracellular protein 
231 Signal peptidase complex subunit 1 IPI00219755 2 Integral membrane protein 
232 Alpha-2,8-sialyltransferase 8C Q64689 1 Inner cell membrane 
233 Similar to SWAP-70 IPI00307200 0 Membrane associated protein 
234 Splice Isoform 2 of Sodium channel protein type I alpha subunit IPI00216029 19 Integral membrane protein 
235 Splice Isoform Long of P05023 Sodium/potassium-transporting ATPase 
alpha-1 chain precursor IPI00006482 10 
Integral membrane protein 
236 Sodium/potassium-transporting ATPase alpha-2 chain precursor IPI00003021 8 Integral membrane protein 
237 Splice Isoform Short of Sodium/potassium-transporting ATPase alpha-1 
chain precursor IPI00414005 4 
Integral membrane protein 
238 Solute carrier family 1 (glutamate transporter), member 7       IPI00100081 7 Integral membrane protein 
239 Solute carrier family 12 member 5 IPI00301180 12 Integral membrane protein 
240 solute carrier family 19 member 1 isoform b IPI00299186 9 Integral membrane protein 
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241 Solute carrier family 2, facilitated glucose transporter, member 3 or 14 IPI00003909 10 Integral membrane protein 
242 Solute carrier family 2, facilitated glucose transporter, member 4 IPI00027281 12 Integral membrane protein 
Solute carrier family 2, facilitated glucose transporter, member 1 IPI00220194 12 Integral membrane protein 
Glucose transporter type I P11166 12 Integral membrane protein 243 
Glucose transporter glycoprotein Gi3387905 8 Integral membrane protein 
244 Splice Isoform 1 of Q9Y666 Solute carrier family 12 member 7 IPI00008616 11 Integral membrane protein 
245 Solute carrier family 27 (fatty acid transporter), member 4          IPI00021089 2 Integral membrane protein 
246 Solute carrier family29 (nucleoside transporters), member 1 IPI00412547 11 Integral membrane protein 
247 Solute carrier family 40, member 1 IPI00005547 10 Integral membrane protein 
248 Solute carrier family 43, member 3 IPI00301100 11 Integral membrane protein 
249 Spectrin alpha chain, erythrocyte IPI00220741 0 Membrane, cytoskeleton 
250 Spectrin, alpha, erythrocytic 1 IPI00641363 0 Membrane, cytoskeleton 
Spectrin beta isoform a IPI00216704 0 Membrane, cytoskeleton 251 Splice Isoform 1 2 of P11277 Spectrin beta chain, erythrocyte IPI00004501 0 Membrane, cytoskeleton 
252 Splice Isoform 1 of Q9H254 Spectrin beta chain, brain 3 IPI00018829 0 Membrane, cytoskeleton 
253 Splice Isoform Long of Q01082 Spectrin beta chain, brain 1 IPI00005614 0 Membrane, cytoskeleton 
254 Stomatin                           IPI00377081 1 Membrane, cytoskeleton 
Stomatin isoform a IPI00219682 1 Integral membrane protein 255 Erythrocyte band 7 integral membrane protein (stomatin) (protein 7.2B) P27105 1 Integral membrane protein 
Stromal cell-derived receptor-1 alpha IPI00011578 1 Integral membrane protein 256 Stromal cell-derived receptor-1 beta IPI00018311 1 Integral membrane protein 
257 Surfeit 4 IPI00399142 2 Integral membrane protein 
258 Splice Isoform SNAP-23a of Synaptosomal-associated protein 23 IPI00010438 0 Membrane associated protein 
259 Syntaxin 4 IPI00029730 1 Type IV membrane protein 
Syntaxin 7 IPI00289876 1 Type IV membrane protein 260 Splice Isoform 2 of Syntaxin-7 IPI00552913 0 Membrane; Cytosolic protein 
261 Splice Isoform I of P14209 T-cell surface glycoprotein E2 precursor IPI00253036 2 Integral membrane protein 
262 TGF-beta receptor type I precursor P36897 2 Integral membrane protein 
263 Thioredoxin domain containing protein 1 precursor  IPI00395887 3 Integral membrane protein 
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264 Thioredoxin-like protein KIAA1162 precursor IPI00100247 1 Type I membrane protein 
265 Thrombospondin 1 precursor, glycoprotein IV IPI00296099 0 Extracellular region 
266 Splice Isoform 1 Of Thyrotropin receptor precursor         IPI00028642 0 Integral membrane protein 
267 Titin IPI00179357 0 Cytoskeleton 
268 Titin isoform novex-1 IPI00375498 0 Cytoskeleton 
269 TPM1 protein IPI00384369 0 Cytoskeleton 
270 TPR repeat containing protein   IPI00007052 1 Integral membrane protein 
271 Transforming protein RhoA IPI00027500 0 Cytoskeleton 
272 Splice Isoform 2B of P01116 Transforming protein p21 IPI00423570 0 Membrane associated protein 
273 Translocon-associated protein, delta subunit precursor IPI00019385 0 ER membrane 
274 Transmembrane protein 24 IPI00394781 1 Integral membrane protein 
275 Transmembrane protein Tmp21 precursor IPI00028055 2 Type I membrane protein 
276 Splice Isoform 2 of Transmembrane protein 55B IPI00332278 2 Integral membrane protein 
277 Triadin IPI00220272 1 Integral membrane protein 
Tropomodulin 1 IPI00002375 0 Cytoskeleton 
Tropomodulin Gi4507553 0 Cytoskeleton 278 
Tropomodulin P28289 0 Cytoskeleton 
Splice Isoform 1 of P09493 Tropomyosin 1 alpha chain      IPI00014581 0 Cytoskeleton 279 Tropomyosin, cytoskeletal type P12324 0 Cytoskeleton 
Splice isoform 2 of P06753 Tropomyosin alpha 3 chain IPI00218319 0 Cytoskeleton 
Tropomyosin 3, cytoskeletal Gi136096 0 Cytoskeleton 280 
Similar to Tropomyosin Gi18590249 0 Cytoskeleton 
Splice Isoform 1 of P07226 Tropomyosin alpha 4 chain IPI00010779 0 Cytoskeleton 281 Similar to Tropomyosin 4 Gi14729747 0 Cytoskeleton 
282 Tropomyosin isoform Gi1082876 0 Cytoskeleton 
283 Tropomyosin chain (smooth muscle) Gi136100 0 Cytoskeleton 
284 UDP-glucose:glycoprotein glucosyltransferase 1precursor          IPI00024466 1 Integral membrane protein 
285 Uncharacterised hematopoietic stem/progenitor cells protein MDS032       IPI00020515 1 Type II membrane protein 
286 UPF0198 protein CGI-141 IPI00007061 3 Integral membrane protein 
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287 Urea transporter, erythrocyte IPI00298337 8 Integral membrane protein 
288 Vacuolar ATP synthase 16 kDa proteolipid subunit IPI00018855 4 Integral membrane protein 
289 Splice Isoform 1 of Vacuolar proton translocating ATPase 116 kDa 
subunit a isoform 1 IPI00552514 7 Integral membrane protein 
290 Vesicle trafficking protein SEC22b IPI00006865 1 Type IV membrane protein 
291 Vesicle-associated membrane protein-associated protein A isoform 2 IPI00170692 1 Type IV membrane protein 
292 Vesicle-associated membrane protein-associated protein A isoform 1 IPI00374657 1 Membrane; Cytoskeleton 
293 Splice Isoform 1 of O95292 Vesicle-associated membrane protein-
associated protein B/C IPI00006211 1 Type IV membrane protein 
294 Vesicle-associated membrane protein 2 GI7657675 1 Type IV membrane protein 
295 Vesicular integral-membrane protein VIP36 precursor IPI00009950 1 Type I membrane protein 
296 WNT-3 proto-oncogene protein [precursor] P56703  1 Integral membrane protein 
297 Splice Isoform 2 of Zinc finger DHHC domain containing protein 3 IPI00216069 4 Integral membrane protein 
298 Zinc transporter 1 IPI00002483 6 Integral membrane protein 











Appendix table 3   Comprehensive RBC membrane proteins with potential surface domain(s) 
(Adjacent proteins in Italic were identified from same peptide but in different studies, and were counted as one protein) 
No. Protein Name Accession Number TMD Subcellular localisation 
1 101 kDa protein IPI00514990 8 Integral membrane protein 
2 17 kDa protein IPI00642218 3 Integral membrane protein 
3 22 kDa protein IPI00478755 0 Plasma membrane 
4 27 kDa protein IPI00641837 3 Integral membrane protein 
5 28 kDa protein IPI00069985 1 Integral membrane protein 
6 ABC transporter ABCA7 IPI00293895 11 Integral membrane protein 
7 Acetylcholinesterase precursor/ACHE protein IPI00220026 0 Membrane; extracellular 
8 Splice Isoform 1 of P22303 Acetylcholinesterase precursor IPI00026103 0 Integral membrane protein 
9 Acyl-Coa synthetase long-chain family member 6 isoform A IPI00296333 1 Membrane 
10 Adipocyte plasma membrane-associated protein, Low molecular weight phosphotyrosine protein phosphatase IPI00031131 1 Membrane associated protein 
11 Splice Isoform 2 of ADP-ribosyl cyclase 1 IPI00395006 1 Integral membrane protein 
12 Splice Isoform APP770 of P05067 Amyloid beta A4 protein precursor IPI00006608 1 Type I membrane protein 
13 Annexin A11 protein IPI00001856 1 Membrane associated protein 
14 Apolipoprotein E precursor            IPI00021842 0 Extracellular binding RBC 
15 Aquaporin 1 IPI00024689 6 Integral membrane protein 
16 Aquaporin 1 splice variant 2 IPI00428490 1 Integral MP 
ATP-binding cassette half-transporter IPI00465442 9 Integral membrane protein; Inner 
mitochondrial 17 
ATP-binding cassette, sub-family B, member 6, mitochondrial precursor IPI00014555 9 Mitochondrial membrane 
18 ATP-binding cassette, subfamily C, member 6 Gi6715561 12 Integral membrane protein 
19 ATP-binding cassette, sub-family C, member 1 isoform 6 IPI00008463 15 Integral membrane protein 
20 ATP-binding cassette, sub-family G, member 2 IPI00298214 6 Integral membrane protein 
21 Band 3 anion transport protein IPI00022361 11 Integral membrane protein 
22 Splice isoform 2 or 1 of P35613 Basigin precursor IPI00019906 2 Type I membrane protein 
23 C4B1 IPI00418163 0 Extracellular 
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24 Calnexin precursor IPI00020984 1 Type I membrane protein 
25 Calreticulin precursor IPI00020599 0 ER; Extracellular; Cytosolic protein 
26 Carnitine O-palmitoyltransferase I, mitochondrial liver isoform IPI00032038 2 Mitochondrial outer membrane. 
27 Cathepsin G precursor IPI00028064 0 Extracellular binding RBC 
CD44 antigen IPI00297160 1 Type I membrane protein 
Cell surface glycoprotein CD44 Gi7512338 1 Integral membrane protein 28 
Splice Isoform CD44 of CD44 antigen precursor IPI00305064 1 Integral membrane protein 
29 CD59 glycoprotein precursor IPI00011302 0 Membrane associated protein 
30 Channel-like integral membrane protein Gi1314306 3 Integral membrane protein 
31 Splice Isoform 1 of Choline transporter-like protein 1 IPI00221393 9 Integral membrane protein 
32 Splice Isoform 1 of Choline transporter-like protein 2 IPI00549521 11 Integral membrane protein 
33 CGI-26 protein IPI00219677 0 Extracellular 
34 Clusterin precursor                                                   IPI00291262 0 Extracellular binding RBC 
Splice Isoform 1 of P08174 Complement decay-accelerating factor 
precursor IPI00216550 0 Membrane associated protein 35 
Splice Isoform 2 of Complement decay-accelerating factor precursor IPI00292069 0 Membrane associated protein 
36 Complement C3b                               IPI00164623 0 Extracellular binding RBC 
Complement component (3b/4b) receptor 1, incl. Knops blood group IPI00640083 1 Integral membrane protein 
Complement receptor 1 IPI00412546 1 Integral membrane protein 37 
Complement receptor type 1 precursor IPI00018287 1 Type I membrane protein 
38 Cop-coated vesicle membrane protein p24 precursor IPI00016608 2 Integral membrane protein 
39 Splice Isoform 4 of Q04656 Copper-transporting ATPase   1 IPI00028610 7 Golgi, Plasma membrane 
40 Splice Isoform 2 or 1 of  Q9H3Z4 DNAJ homolog subfamily C member 5 IPI00023780 1 Membrane associated protein 
41 DC-TM4F2 protein IPI00165394 4 Integral membrane protein 
42 DKFZP564J0863 protein IPI00550523 2 Unclassified 
43 Down syndrome cell adhesion molecule 2 IPI00154755 1 Type I membrane protein 
Splice Isoform 1 of Duffy antigen/chemokine receptor IPI00215964 7 Integral membrane protein 44 Splice Isoform 2 of Q16570 Duffy antigen/chemokine receptor IPI00002940 7 Integral membrane protein 
Duodenal cytochrome b sequence coverage:10% IPI00432050 1 Integral membrane protein 45 Duodenal cytochrome b Gi13376257 6 Integral membrane protein 
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46 Ecto-ADP-ribosyltransferase 4 precursor IPI00004065 0 Integral membrane protein 
47 Eosinophil granule major basic protein precursor IPI00010341 0 Extracellular 
48 Equilibrative nucleoside transporter 1 IPI00550382 11 Integral membrane protein 
49 Erythroblast membrane-associated protein IPI00647116 1 Integral membrane protein 
50 Erythroid membrane-associated protein IPI00044556 2 Membrane associated protein 
51 EVIN2 IPI00302538 8 Integral membrane protein 
52 Similar to expressed sequence AA536743 IPI00216890 2 Integral membrane protein 
53 Splice Isoform 1 Of Fibronectin precursor       IPI00022418 0 Integral membrane protein; Extracellular 
54 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2       IPI00221205 1 Integral membrane protein; Golgi 
55 Galectin-3                   IPI00465431 0 Extracellular binding RBC 
56 Splice Isoform Long of O00182 Galectin-9 IPI00010477 0 Extracellular 
57 gene rich cluster, C3f gene IPI00306419 7 Unclassified 
Glycophorin A precursor IPI00298800 2 Type I membrane protein 58 Similar to Glycophorin A Gi13529077 2 Type I membrane protein 
59 Glycophorin A Gi106140 2 Type I membrane protein 
60 Glycophorin Erik I-IV precursor IPI00384414 1 Integral membrane protein 
Glycophorin C, isoform 1 Gi4504229 1 Integral membrane protein 
Splice Isoform Glycophorin C of P04921 Glycophorin C IPI00026299 1 Integral membrane protein 61 
Splice Isoform Glycophorin D of Glycophorin C IPI00218128 1 Integral membrane protein 
62 Gp25L2 protein IPI00023542 2 Integral membrane protein 
63 HGTD-P Gi9295192 1 Integral membrane protein 
64 Hypothetical protein XP_092517 gi18552304 1 Integral membrane protein 
65 Hypothetical protein IPI00029002 4 Integral membrane protein 
66 Hypothetical protein IPI00031697 5 Unclassified 
67 Hypothetical protein CGI-109 precursor   IPI00032825 1 Integral membrane protein 
68 Hypothetical protein DKFZp564J0863 IPI00383828 2 Unclassified 
69 Hypothetical protein 327024.1 IPI00178934 1 Integral membrane protein 
70 Hypothetical protein DKFZp564D0478 IPI00030236 3 Integral membrane protein 
71 Hypothetical protein DKFZp564E227 IPI00100199 6 Integral membrane protein 
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72 Hypothetical protein DKFZp762A227 IPI00032013 11 Integral membrane protein 
73 Hypothetical protein FLJ14347 IPI00022300 1 Unclassified 
74 Hypothetical protein FLJ16766          IPI00442030 7 Integral membrane protein 
75 Hypothetical protein FLJ31842 IPI00043429 6 Integral membrane protein 
76 Hypothetical protein FLJ40269 IPI00167359 2 Integral membrane protein 
77 Hypothetical protein MGC34680 IPI00171004 12 Integral membrane protein 
78 Hypothetical protein ORF9 precursor          IPI00003441 1 Integral membrane protein 
79 Hypothetical protein PSEC0098 IPI00171421 1 Unclassified 
80 Ig gamma-1 chain C region       IPI00332161 0 Extracellular binding RBC 
81 Ig kappa chain C region IPI00385058 0 Extracellular binding RBC 
82 Ig heavy chain V-V region Gi87863 0 Extracellular 
83 Integrin beta-2 precursor P05107 1 Integral membrane protein 
Splice Isoform Long of Intercellular adhesion molecule-4 precursor IPI00000118 1 Integral membrane protein 84 Splice Isoform Short of Intercellular adhesion molecule-4 precursor IPI00396335 0 Membrane 
85 B-CAM protein Gi2134798 1 Integral membrane protein 
86 Intermediate conductance calcium-activated potassium channel protein 4 IPI00032466 5 Integral membrane protein 
87 Ion transporter protein IPI00415077 9 Integral membrane protein 
88 Junctional adhesion molecule 1 precursor IPI00001754 2 Type I membrane protein 
89 JWA protein regulates intracellular concentrations of taurine and glutamate IPI00007426 3 Integral membrane protein 
90 Kell blood group glycoprotein IPI00220459 1 Integral membrane protein 
91 KIAA0830 protein IPI00001952 3 Integral membrane protein 
92 KIAA0851 protein IPI00022275 2 Integral membrane protein 
93 KIAA1363 protein IPI00002230 1 Integral membrane protein 
94 Lactotransferrin precursor       IPI00298860 0 Extracellular binding RBC 
95 Leukemia inhibitory factor receptor P42702 1 Integral membrane protein 
96 Leukocyte elastase precursor IPI00027769 1 Extracellular 
Splice Isoform OA3-293 of Leukocyte surface antigen CD47 precursor IPI00216514 0 Integral membrane protein 97 Splice Isoform OA3-323 of Leukocyte surface antigen CD47 precursor IPI00374740 6 Integral membrane protein 
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98 LFA-3 IPI00000059 2 Integral membrane protein 
99 Long-chain-fatty-acid--CoA ligase 3 IPI00031397 1 Type III membrane protein 
100 Splice Isoform Short of Q9UKU0 Long-chain-fatty-acid--CoA ligase 6 IPI00218718 0 Type III membrane protein 
101 Low affinity immunoglobulin gamma Fc region receptor III-B precursor IPI00023858 1 Integral membrane protein 
Lutheran blood group glycoprotein precursor IPI00002406 1 Type I membrane protein 
Lutheran blood group IPI00328869 1 Integral membrane protein 102 
Lutheran blood group glycoprotein isoform 2 precursor IPI00554618 1 Integral membrane protein 
103 Similar to Lutheran blood group Gi18589892 0 Integral membrane protein 
104 Splice Isoform Short of Lymphocyte function-associated antigen 3 precursor IPI00219549 2 Integral membrane protein 
105 Lysozyme C precursor IPI00019038 0 Extracellular 
106 Membrane associated progesterone receptor component   2 IPI00005202 1 Integral membrane protein 
107 Membrane protein IPI00026111 2 Unclassified 
108 Membrane transport protein XK IPI00020896 9 Integral membrane protein 
109 Mesenchymal stem cell protein DSCD75 IPI00010292 1 Unclassified 
110 Microsomal glutathione S-transferase 3 IPI00639812 3 Integral membrane protein; Microsome 
111 Monocarboxylate transporter 1 IPI00024650 11 Integral membrane protein 
112 Splice Isoform Delexon-17 of P33527 Multidrug resistance-associated protein 1 IPI00008338 16 Integral membrane protein 
113 Multidrug resistance-associated protein 4 IPI00006675 11 Integral membrane protein 
114 Multidrug resistance-associated protein 5 IPI00385383 11 Integral membrane protein 
115 Myeloblastin precursor IPI00027409 0 Extracellular 
116 Splice isoform 1 of Q92542 Nicastrin precursor IPI00021983 0 Type I membrane protein 
117 Neuropathy target esterase IPI00217600 1 Unclassified 
118 Splice Isoform 2 of Q14697 Neutral alpha-glucosidase AB precursor IPI00011454 1 ER; Golgi 
119 Splice Isoform 2 of Large neutral amino acids transporter small subunit 3 IPI00479732 11 Integral membrane protein 
120 Novel protein IPI00513701 3 Integral membrane protein 
121 Splice isoform 1 of Q16563 Pantophysin IPI00009507 3 Integral membrane protein 
122 PB39 IPI00021075 12 Integral membrane protein 
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123 Phosphatidylinositol 4-kinase type II IPI00020124 0 Integral membrane protein 
Phosphatidylinositol-4-phosphate 5-kinase type II alpha IPI00009688 0 Integral membrane protein 124 Phosphatidylinositol-4-phosphate 5 kinase, type III Gi1730569 0 Integral membrane protein 
125 Phospholipid scramblase 1 IPI00005181 0 Type II membrane protein 
126 Phospholipid scramblase 4 IPI00016776 0 Type II membrane protein 
127 Splice Isoform B of P20020 Plasma membrane calcium-transporting ATPase 1 IPI00021695 7 Integral membrane protein 
Splice Isoform XB of Plasma membrane calcium-transporting ATPase 4 IPI00217169 8 Integral membrane protein 
128 Splice Isoform XD of P23634 Plasma membrane calcium-transporting 
ATPase 4 IPI00012490 8 Integral membrane protein 
129 Splice Isoform Delta of Poliovirus receptor related protein 1 precursor IPI00003648 2 Integral membrane protein 
130 Polyposis locus protein 1 IPI00024670 2 Integral membrane protein 
131 Potassium channel subfamily K member 5 IPI00029507 6 Integral membrane protein 
132 Presenilin-associated protein Gi6409316 2 Integral membrane protein 
133 Prolactin        IPI00022974 0 Extracellular binding RBC 
134 Protein BAT5 IPI00033075 2 Integral membrane protein 
135 Protein disulfide-isomerase precursor IPI00010796 0 ER lumen, extracellular region 
136 Protein FAM38A IPI00006093 25 Unclassified 
137 Protein transport protein SEC61 gamma subunit IPI00006072 1 Integral membrane protein 
138 RECS1 protein homolog IPI00290452 7 Integral membrane protein 
Reticulon protein 3 IPI00028946 3 Integral membrane protein 
Reticulon 3 isoform a variant IPI00555783 3 Membrane; Extracellular 
RTN3-A1 IPI00398795 3 Integral membrane protein 139 
PREDICTED: similar to Reticulon protein 3 IPI00177423 1 Integral membrane protein 
140 Splice Isoform 2 Of Reticulon 4 IPI00298289 1 Integral membrane protein 
141 Rh blood CE group antigen polypeptide IPI00039665 12 Integral membrane protein 
RhD protein IPI00329565 10 Integral membrane protein 
Rhesus blood group D antigen IPI00478119 10 Integral membrane protein 142 
Rh blood D group antigen polypeptide Gi10800054 10 Integral membrane protein 
143 Rhesus D category VI type III protein Gi2765839 12 Integral membrane protein 
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144 Rhesus blood group-associated glycoprotein IPI00024094 11 Integral membrane protein 
145 Rhesus blood group, CcEe antigens, isoform 1 IPI00465155 12 Integral membrane protein 
146 Splice Isoform RHVIII of P18577 Blood group Rh(CE) polypeptide IPI00221017 10 Integral membrane protein 
147 Hypothetical protein FLJ45640 (Rhesus blood group, CcEe antigens) IPI00444375 10 Integral membrane protein 
148 Similar to RIKEN cDNA 1500009M05 gene IPI00166865 1 Unclassified 
149 PREDICTED: similar to RIKEN cDNA C730027E14              IPI00373867 1 Integral membrane protein 
150 Secretory carrier-associated membrane protein   4 IPI00056310 4 Integral membrane protein 
151 Semaphorin 7A precursor IPI00025257 0 Integral membrane protein 
152 Serum albumin precursor IPI00022434 0 Extracellular 
153 Signal peptidase complex subunit 1 IPI00219755 2 Integral membrane protein 
154 Alpha-2,8-sialyltransferase 8C Q64689 1 Inner cell membrane 
155 Splice Isoform 2 of Sodium channel protein type I alpha subunit IPI00216029 19 Integral membrane protein 
156 Splice Isoform of Sodium/potassium-transporting ATPase alpha-1 chain  IPI00006482 10 Integral membrane protein 
157 Sodium/potassium-transporting ATPase alpha-2 chain precursor IPI00003021 8 Integral membrane protein 
158 Splice Isoform Short of Sodium/potassium-transporting ATPase alpha-1 
chain precursor IPI00414005 4 Integral membrane protein 
159 Solute carrier family 1 (glutamate transporter), member 7       IPI00100081 7 Integral membrane protein 
160 Solute carrier family 12 member 5 IPI00301180 12 Integral membrane protein 
161 solute carrier family 19 member 1 isoform b IPI00299186 9 Integral membrane protein 
162 Solute carrier family 2, facilitated glucose transporter, member 3, or 14 IPI00003909 10 Integral membrane protein 
163 Solute carrier family 2, facilitated glucose transporter, member 4 IPI00027281 12 Integral membrane protein 
Solute carrier family 2, facilitated glucose transporter, member 1 IPI00220194 12 Integral membrane protein 
Glucose transporter type I GiP11166 12 Integral membrane protein 164 
Glucose transporter glycoprotein Gi3387905 8 Integral membrane protein 
165 Splice Isoform 1 of Q9Y666 Solute carrier family 12 member 7 IPI00008616 11 Integral membrane protein 
166 Solute carrier family 27 (fatty acid transporter), member 4          IPI00021089 2 Integral membrane protein 
167 Solute carrier family29 (nucleoside transporters), member 1 IPI00412547 11 Integral membrane protein 
168 Solute carrier family 40, member 1 IPI00005547 10 Integral membrane protein 
169 Solute carrier family 43, member 3 IPI00301100 11 Integral membrane protein 
170 Stomatin                           IPI00377081 1 Cytoskeleton 
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Stomatin isoform a IPI00219682 1 Integral membrane protein 171 Erythrocyte band 7 integral membrane protein (stomatin) (protein 7.2B) P27105  Integral membrane protein 
Stromal cell-derived receptor-1 alpha IPI00011578 1 Extracellular; Integral membrane protein 172 
Stromal cell-derived receptor-1 beta IPI00018311 1 Extracellular; Integral membrane protein 
173 Surfeit 4 IPI00399142 2 Integral membrane protein; ER 
membrane 
174 Syntaxin 4 IPI00029730 1 Type IV membrane protein 
Syntaxin 7 IPI00289876 1 Type IV membrane protein 175 Splice Isoform 2 of Syntaxin-7 IPI00552913 0 Membrane; Cytoplasmic 
176 Splice Isoform I of P14209 T-cell surface glycoprotein E2 precursor IPI00253036 2 Integral membrane protein 
177 TGF-beta receptor type I precursor P36897 2 Integral membrane protein 
178 Thioredoxin domain containing protein 1 precursor  Protein disulfide-isomerase A6 precursor  IPI00395887 3 ER lumen 
179 Thioredoxin-like protein KIAA1162 precursor IPI00100247 1 Type I membrane protein 
180 Thrombospondin 1 precursor, glycoprotein IV, also in mature RBCs IPI00296099 0 Extracellular region 
181 Splice Isoform 1 Of Thyrotropin receptor precursor         IPI00028642 0 Integral membrane protein 
182 TPR repeat containing protein   IPI00007052 1 Integral membrane protein 
183 Transmembrane protein 24 IPI00394781 1 Integral membrane protein 
184 Transmembrane protein Tmp21 precursor IPI00028055 2 Type I membrane protein 
185 Splice Isoform 2 of Transmembrane protein 55B IPI00332278 2 Integral membrane protein 
186 Triadin IPI00220272 1 Integral membrane protein 
187 UDP-glucose:glycoprotein glucosyltransferase 1precursor          IPI00024466 1 Integral membrane protein 
188 Uncharacterised hematopoietic stem/progenitor cells protein MDS032       IPI00020515 1 Type II membrane protein 
189 UPF0198 protein CGI-141 IPI00007061 3 Integral membrane protein 
190 Urea transporter, erythrocyte IPI00298337 8 Integral membrane protein 
191 Vacuolar ATP synthase 16 kDa proteolipid subunit IPI00018855 4 Integral membrane protein 
192 Splice Isoform 1 of Vacuolar proton translocating ATPase 116 kDa 
subunit a isoform 1 IPI00552514 7 Integral membrane protein 
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193 Vesicle trafficking protein SEC22b IPI00006865 1 Type IV membrane protein 
194 Vesicle-associated membrane protein-associated protein A isoform 2 IPI00170692 1 Type IV membrane protein 
195 Vesicle-associated membrane protein-associated protein A isoform 1 IPI00374657 1 Membrane; Cytoskeleton 
196 Splice Isoform 1 of O95292 Vesicle-associated membrane protein 
associated protein B/C IPI00006211 1 Type IV membrane protein 
197 Vesicle-associated membrane protein 2 Gi7657675 1 Type IV membrane protein 
198 Vesicular integral-membrane protein VIP36 precursor IPI00009950 1 Type I membrane protein 
199 WNT-3 proto-oncogene protein [precursor] P56703  1 Integral membrane protein 
200 Splice Isoform 2 of Zinc finger DHHC domain containing protein 3 IPI00216069 4 Integral membrane protein 
201 Zinc transporter 1 IPI00002483 6 Integral membrane protein 











Appendix table 4   Total proteins identified from fetal NRBC membrane 
(PM: Plasma membrane; MIM: mitochondrial inner membrane; MOM: mitochondrial outer membane; IMP: integral membrane proteins) 
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1 Band 3 anion transport protein IPI00022361 101727.41 5.08 11 15 149 13 178 PM 
2 Histone H4 IPI00453473 11229.34 11.36 0 12 122 11 116 Nuclear 
3 Ankyrin 1 isoform 1 IPI00216697 206136.92 5.65 0 9 104 6 81 PM 
4 Hemoglobin epsilon chain IPI00217471 16061.43 8.68 0 5 164 6 170 Cytosolic 
5 Histone H2B.n IPI00152785 13766.52 10.32 0 6 146 9 128 Nuclear 
6 ADP/ATP translocase 3 IPI00291467 32714.15 9.76 2 7 101 5 102 MIM; PM 
7 Ferritin light chain IPI00375676 28399.25 6 0 4 134 3 104 Cytosolic  
8 Solute carrier family 2, facilitated glucose transporter member 1 IPI00220194 54082.52 8.93 12 6 83 8 92 PM 
9 Transferrin receptor protein 1 IPI00022462 84847.95 6.18 1 5 96 1 55 PM 
10 
Ubiquinol-cytochrome-c reductase complex core protein 2, 
mitochondrial precursor IPI00305383 48412.88 8.74 0 4 129 2 127 MIM 
11 Microsomal glutathione S-transferase 3 IPI00639812 18404.62 9.99 3 4 117 4 91 
Microsome 
membrane; ER 
12 Calnexin precursor IPI00020984 67525.85 4.47 1 5 103 4 89 ER membrane 
13 25 kDa protein IPI00646289 25141.15 8.93 1 4 113 3 77 Unclassified 
14 
Splice Isoform Short of Erythrocyte membrane protein  
band 4.2 IPI00028614 76793.61 8.27 0 4 100 4 89 PM 
15 Histone H2A.z IPI00218448 13413.51 10.58 0 4 87 4 83 Nuclear 
16 H3 histone, family 3B IPI00219038 15318.50 11.27 0 5 85 6 147 Nuclear 
17 Splice Isoform B of Phosphate carrier protein IPI00215777 39932.64 9.43 2 4 111 1 41 MIM 
18 Hypothetical protein IPI00646240 7390.90 9.86 0 3 112 4 88 Nuclear 




20 Splice Isoform H14 of Myeloperoxidase precursor IPI00236554 73806.61 9.3 0 4 79 8 77 
Lysosome; 
Nuclear  
21 40S ribosomal protein S7 IPI00013415 22113.26 10.09 0 3 100 6 89 Ribosomal 
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22 Ribosomal protein L5 variant IPI00647085 34340.69 9.73 0 3 131 5 72 Ribosomal 
23 Fibrillarin IPI00025039 33763.42 10.18 0 3 94 6 72 Nuclear  
24 
NADH-ubiquinone oxidoreductase 39 kDa subunit, mitochondrial 
precursor IPI00003968 42482.57 9.81 0 3 100 2 91 Mitochondrial 
25 PREDICTED: similar to ribosomal protein L18a IPI00176629 20753.89 10.73 0 4 71 4 49 Ribosomal 
26 60S ribosomal protein L26 IPI00027270 17247.53 10.55 0 3 84 1 44 Ribosomal 
27 H2B/t variant IPI00454695 21458.16 10.71 0 3 84 4 83 Nuclear 
28 Coproporphyrinogen III oxidase, mitochondrial precursor IPI00093057 50119.97 8.59 0 4 56 4 59 Mitochondrial 
29 Splice isoform short of Heterogenous nuclear ribonucleoprotein U IPI00386491 88890.16 5.6 0 3 86 6 123 Nuclear 
30 Cytochrome c oxidase polypeptide Va, mitochondrial precursor IPI00025086 16763.72 6.3 0 2 85 2 56 MIM 
31 Lamin B receptor variant IPI00645733 70651.06 9.41 8 3 89 3 67 
Nuclear inner 
membrane. 




33 HNRPC protein IPI00552125 27804.46 4.55 0 2 80 1 59 Nuclear 
34 
Solute carrier family 3 (activators of dibasic and neutral amino acid 
transport), member 1 IPI00554481 71079.20 4.84 1 2 85 4 64 PM 
35 ATP-binding cassette half-transporter IPI00465442 99649.17 9.26 9 4 52 2 59 PM 
36 Equilibrative nucleoside transporter 1 IPI00550382 58924.58 8.49 11 2 79 2 52 PM 
37 Mitochondrial 2-oxoglutarate/malate carrier protein IPI00219729 33908.81 9.92 0 2 84 1 61 MIM 
38 Nucleolar protein Nop56 IPI00411937 66194.78 9.21 0 2 86 3 61 Nuclear 
39 Cytochrome c1, heme protein, mitochondrial precursor IPI00029264 35367.00 9.15 0 2 110 1 75 
Mitochondrial 
membrane 
40 60S ribosomal protein L27 IPI00219155 15656.71 10.56 0 2 68 3 63 Ribosomal 
41 Spectrin beta isoform a IPI00216704 267589.56 5.24 0 2 90 5 62 PM 
42 Ribosomal protein L27a IPI00456758 16468.03 11 0 2 76 2 93 Ribosomal 
43 Leukocyte elastase precursor IPI00027769 28499.79 9.71 1 1 123 1 101 PM 
44 Splice isoform 2 of Reticulon 4 IPI00298289 40292.95 4.71 2 1 117 1 52 ER membrane 
45 60S ribosomal protein L3 IPI00550021 45948.72 10.19 0 2 73 6 96 Ribosomal 
46 Membrane protein IPI00026111 21161.16 9.77 2 1 110 1 65 Unclassified 
47 40S ribosomal protein S4, X isoform IPI00217030 29448.01 10.16 0 2 73 2 56 Ribosomal 
48 H2A histone family, member Y isoform 1 IPI00148096 39159.18 9.83 0 1 103 3 97 Nuclear 
49 Ubiquinol-cytochrome c reductase complex 14 kDa protein IPI00220416 13390.94 8.75 0 2 59 3 81 MIM 
 239 
 Appendix table 4.  Continued          
50 CAAX prenyl protease 1 homolog IPI00027180 54777.53 7.12 7 1 97 1 93 
ER/Golgi; PM 
membrane;  
51 Splice Isoform 2 of Heat shock cognate 71 kDa protein IPI00037070 53887.70 5.74 0 2 51 2 46 
Cytosolic; 
Nuclear 
52 18 kDa protein IPI00514123 17639.75 10.86 0 2 61 3 58 Ribosomal 
53 Membrane associated progesterone receptor component 2 IPI00005202 23803.73 4.76 1 1 94 1 44 
Microsome 
membrane 
54 Splice Isoform 2 of 40S ribosomal protein S24 IPI00219486 15059.24 10.89 0 1 91 1 79 Ribosomal 
55 Growth-inhibiting protein 12 IPI00646848 78334.00 8.54 0 1 91 1 84 PM 
56 Thioredoxin domain containing protein 1 precursor IPI00395887 31770.80 4.92 3 1 85 1 65 ER membrane 
57 ATP synthase beta chain, mitochondrial precursor IPI00303476 56524.60 5.26 0 1 82 1 49 MOM 
58 
Ubiquinol-cytochrome c reductase complex ubiquinone-binding 
protein QP-C IPI00024742 9769.08 10.08 0 1 82 1 42 MIM 
59 60S ribosomal protein L28 IPI00182533 15606.63 12.02 0 1 81 1 74 Ribosomal 
60 
Ubiquinol-cytochrome-c reductase complex core protein I, 
mitochondrial precursor IPI00013847 52585.42 5.94 0 2 48 4 58 MIM 
61 RAB14, member RAS oncogene family IPI00646415 20396.31 5.94 0 1 78 1 38 Universal 
62 Novel protein IPI00640179 11673.18 10.21 0 1 74 1 69 Unclassified 




64 Eosinophil peroxidase precursor IPI00006690 80989.13 10.31 0 2 38 2 41 
Lysosome; 
Nuclear ;  
65 Thioredoxin-like protein KIAA1162 precursor IPI00100247 38927.68 4.31 1 1 70 1 90 PM 
66 Splice Isoform short of Splicing factor, proline-and glutamine-rich IPI00216613 72217.75 9.26 0 1 68 1 72 Nuclear 
67 
Splice Isoform 4 of Plasminogen activator inhibitor 1 RNA-binding 
protein IPI00412714 42401.27 8.42 0 1 66 2 49 Unclassified 
68 ATP synthase g chain, mitochondrial IPI00027448 11421.24 9.65 0 1 62 1 58 Mitochondrial 
69 Cytochrome c IPI00465315 11610.09 9.59 0 1 62 1 38 MIM 
70 GSTK1 protein IPI00440703 31545.51 8.85 0 1 61 1 75 Mitochondrion 
71 Kell blood group glycoprotein IPI00220459 82770.92 8.09 1 1 53 2 93 PM 
72 50 kDa protein IPI00396485 50138.50 7.26 0 1 69 1 54 
Nuclear; 
Cytosolic 
73 Histone H1x IPI00021924 22473.53 10.76 0 1 52 1 79 Nuclear 
74 DEK protein IPI00020021 42647.92 8.69 0 1 49 3 53 Nuclear 
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75 
Splice isoform 1 of Vacuolar proton translocating ATPase 116 kDa 
subunit a isoform 1 IPI00552514 96350.11 6.02 7 1 47 1 54 
Vesicle 
membrane; PM  
76 Olfactory receptor 11H4 IPI00168981 36861.19 9.05 7 1 47 1 39 PM 
77 Solute carrier family 43, member 3 IPI00301100 54494.25 8.71 11 1 47 1 54 ER; PM  
78 ATP-binding cassette sub-family D member 3 IPI00002372 75427.57 9.41 3 1 44 2 64 
Perixisome 
membrane 
79 PRA1 family protein 3 IPI00007426 21600.41 9.77 3 1 43 1 49 ER Membrane 
80 Suppressor of actin 1 IPI00022275 66908.01 6.66 2 1 45 1 39 
ER membrane; 
Golgi 
81 HSPC051 IPI00100810 14391.31 10.96 0 1 41 1 40 
Mitochondrial 
membrane 
82 Ribosomal protein S29 isoform 2 IPI00639942 8081.99 10.08 0 1 39 1 39 Ribosomal 
83 H2A histone family, member J, isoform 2 IPI00220855 14010.93 10.9 0 7 132   Nuclear 
84 Histone H2A.q IPI00339274 13848.80 10.9 0 7 121   Nuclear 
85 ADP/ATP translocase 2 IPI00007188 32743.13 9.76 2 7 101   MIM 
86 
ATP-binding cassette sub-family B member 10, mitochondrial 
precursor IPI00015826 79048.95 9.91 5 5 72   MIM 
87 B-cell receptor-associated protein BAP37 IPI00027252 33275.92 9.83 0 5 56   
Mitochondrial 
membrane 
88 HP1-BP74 IPI00549250 61169.27 9.69 0 3 111   Nuclear 
89 SAM50-like protein CGI-51 IPI00412713 51929.30 6.44 0 3 93   MOM 
90 40S ribosomal protein S8 IPI00216587 24059.12 10.32 0 4 88   Ribosomal 
91 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 67 
kDa subunit precursor IPI00025874 68526.81 5.96 1 3 93   ER membrane 
92 Tubulin beta-2 chain IPI00011654 49638.97 4.78 0 3 95   Cytosolic 
93 Splice Isoform 3 of Mitochondrial inner membrane protein IPI00470829 79977.51 6.31 0 3 69   MIM 
94 Protoporphyrinogen oxidase IPI00031357 50733.65 8.44 0 3 81   Mitochondrial 
95 
Splice Isoform 2 of Voltage-dependent anion-selective channel 
protein 3 IPI00294779 30770.33 8.85 0 2 100   MOM 
96 
Splice Isoform 2 of Voltage-dependent anion-selective channel 
protein 2 IPI00216024 35111.16 5.87 0 2 117   MOM 
97 PREDICTED: similar to ribosomal protein S3a IPI00472119 29951.83 9.78 0 3 64   Ribosomal 
98 ATP synthase alpha chain, mitochondrial precursor IPI00440493 59713.59 9.16 0 3 69   MOM 
99 Splice Isoform 2 of Protein 4.1 IPI00218697 93181.33 5.41 0 3 58   PM 
100 16 kDa protein IPI00334432 15532.11 8.76 0 3 144   Cytosolic 
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101 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b 
isoform 2 IPI00456746 17451.13 9.36 0 2 95   Mitochondrial 
102 Heterogeneous nuclear ribonucleoprotein M isoform b IPI00383296 73572.36 8.94 0 2 109   Nuclear 
103 Mitochondrial substrate carrier family protein IPI00383240 29874.04 9.66 0 3 59   MIM 
104 ATP synthase, H+ transporting, subunit f isoform 2a variant IPI00220300 10910.70 9.7 1 2 103   Mitochondrial 
105 Splice Isoform 2 of Retinol dehydrogenase 11 IPI00339385 33981.68 8.95 0 2 101   ER membrane 
106 Probable DNA dC->dU editing enzyme APOBEC-3C IPI00555878 22810.96 7.52 0 2 79   Unclassified 
107 
Similar to Cytochrome b5 outer mitochondrial membrane isoform 
precursor IPI00641334 14163.00 5.06 0 2 86   MOM 




109 OTTHUMP00000028841 IPI00478327 22617.43 10.43 0 2 96   Ribosomal 
110 Hypothetical protein FLJ35097 IPI00554589 48583.91 8.96 0 1 133   Mitochondrial 
111 Transmembrane protein 14C IPI00009346 11556.97 9.87 4 2 93   
ER/Golgi 
membrane 
112 Tricarboxylate transport protein, mitochondrial precursor IPI00639810 35972.12 10.12 0 3 60   MIM 
113 
NADH-ubiquinone oxidoreductase 30 kDa subunit, mitochondrial 
precursor IPI00025796 30222.71 6.99 0 2 74   MIM 
114 60S ribosomal protein L10 IPI00554723 24429.82 10.11 0 2 65   Ribosomal 
115 21 kDa protein IPI00398234 20886.74 9.46 0 2 60   Ribosomal 
116 50 kDa protein IPI00180730 50121.92 9.06 0 2 79   Ribosomal 
117 Rhesus blood group, CcEe antigens, isoform 1 IPI00465155 45421.20 9.4 12 2 61   PM 
118 Mitochondrial carrier homolog 2 IPI00003833 33308.86 8.25 0 2 55   MIM 
119 HLA-B associated transcript 1 variant IPI00641829 48987.98 5.51 0 2 55   Nuclear 
120 
Splice Isoform Heart of ATP synthase gamma chain, mitochondrial 
precursor IPI00395769 32860.24 9.31 0 2 55   MIM 
121 40S ribosomal protein S11 IPI00025091 18418.99 10.31 0 2 60   Ribosomal 
122 10 kDa protein IPI00186338 9733.91 5.81 0 1 90   Nuclear 
123 17 kDa protein IPI00642218 16710.62 6.49 3 1 92   ER membrane 
124 Mitochondrial transmembrane GTPase FZO-2 IPI00293073 86938.53 5.99 0 2 61   
Mitochondrial 
membrane 
125 Cytochrome c oxidase subunit 2 IPI00017510 25548.21 4.67 2 1 90   MIM 
126 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d 
isoform b IPI00456049 15763.17 6.6 0 2 57   Mitochondrial 
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127 Myeloblastin precursor IPI00027409 27789.27 8.72 0 2 52   PM; Cytosolic 
128 Steroid dehydrogenase homolog IPI00007676 34328.24 9.34 3 1 87   Unclassified 
129 15 kDa protein IPI00477513 15095.99 7.9 0 4 134   Cytosolic 
130 40S ribosomal protein S26 IPI00186712 12876.04 11.01 0 1 87   Ribosomal 
131 SM-11044 binding protein IPI00644458 29918.72 5.52 1 2 48   
Endosome 
membrane 
132 Voltage-dependent anion-selective channel protein 1 IPI00216308 30622.53 8.63 0 2 50   MOM; PM 
133 Ras-related protein Rab-7 IPI00016342 23474.84 6.4 0 1 79   
Endosome; 
Golgi membrane 
134 Splice Isoform GN-1S of Glycogenin-1 IPI00216115 29070.36 4.73 0 1 78   Cytosolic  
135 Optic atrophy 1 isoform 5 IPI00107750 113445.91 7.63 0 2 43   Mitochondrial 
136 40S ribosomal protein S16 IPI00221092 16304.00 10.21 0 1 75   Ribosomal 
137 KIAA0102 protein IPI00452747 14159.28 7.85 1 2 38   
ER/Microsome 
membrane 
138 Protein expressed in T-cells and eosinophils in atopic dermatitis IPI00172656 52590.54 5.46 0 1 73   Cytosolic 
139 Azurocidin precursor IPI00022246 26868.65 9.75 0 1 75   PM; Cytosolic  
140 Pre-mRNA processing splicing factor 8 IPI00007928 273426.56 8.95 0 2 40   Nuclear 
141 Protein IPI00411968 17775.75 9.13 0 1 64   Nuclear 
142 Vitamin K epoxide reductase complex subunit 1-like protein 1 IPI00166079 19822.68 9.28 2 1 73   Unclassified 
143 
CDNA FLJ90376 fis, clone NT2RP2004794, highly similar to 
Butyrate- induced transcript 1 IPI00385976 21254.36 9.74 4 1 72   ER membrane 
144 60S ribosomal protein L15 IPI00470528 24000.04 11.62 0 2 43   Ribosomal 
145 Sodium/potassium-transporting ATPase beta-3 chain IPI00008167 31492.09 8.58 1 1 71   PM 
146 55 kDa erythrocyte membrane protein IPI00215610 52263.65 6.91 0 1 70   PM 
147 
Splice isoform XB of Plasma membrane calcium-transporting 
ATPase 4 IPI00217169 133845.70 6.04 8 2 41   PM 
148 Heterogeneous nuclear ribonucleoprotein L isoform b IPI00465225 50528.51 7.22 0 1 70   Nuclear 
149 12 kDa protein IPI00644559 12027.62 6.81 0 1 70   
Mitochondrial 
 
150 NADH dehydrogenase IPI00643646 52526.70 7.21 0 1 69   Mitochondrial 
151 PREDICTED: similar to hypothetical protein IPI00455976 27850.92 10.36 0 1 69   Ribosomal 
152 Ras-related protein Rab-5A IPI00023510 23643.82 8.32 0 1 69   
Golgi 
membrane;  
153 Neutral amino acid transporter B IPI00019472 56576.27 5.34 9 1 68   PM 
154 Splice isoform 2 of Protein GPR107 precursor IPI00382815 61936.41 6.72 7 1 68   PM 
 243 
 
Appendix table 4.  Continued 
         
155 High mobility group protein 2 IPI00219097 23887.68 7.77 0 1 67   Nuclear 
156 PREDICTED: similar to RPL7L1 protein IPI00455892 59708.63 8.4 0 2 36   Ribosomal 








159 ATP synthase F0 subunit 6 IPI00549893 24735.88 10.09 6 1 65   MIM 
160 
Thyroid hormone receptor-associated protein complex 150 kDa 
component IPI00104050 108629.04 10.16 0 1 65   Nuclear 
161 Phosphatidylserine synthase 1 IPI00010746 55491.10 8.71 9 2 33   
Mitochondrial 
membrane 
162 Splice Isoform 2 of Synaptophysin-like protein IPI00335277 26394.49 6.79 3 1 64   
Vesicle 
membrane; PM 
163 Ras-related protein Rab-21 IPI00007755 24201.21 8.16 0 1 62   
Endosome; 
Golgi membrane 
164 Splice Isoform 2 of DNA-dependent protein kinase catalytic subunit IPI00376215 465202.00 6.81 0 1 64   Nuclear 
165 
Splice Isoform 2 of Translocon-associated protein alpha subunit 
precursor IPI00449669 29355.03 4.52 1 1 63   ER membrane 
166 SLC27A2 protein IPI00447606 64574.28 8.73 1 1 61   
ER/peroxisome 
membrane 
167 PREDICTED: similar to ribosomal protein S2 IPI00165486 29940.93 10.01 0 1 61   Ribosomal 
168 Hypothetical protein DKFZp586C1924 IPI00031064 21513.48 9.36 2 1 61   Unclassified 
169 Hypothetical protein DKFZp686L18234 IPI00414000 37566.79 9.45 0 1 59   Unclassified 
170 Synaptosomal-associated protein 29 IPI00032831 28952.59 5.56 0 1 59   
PM; 
Synaptosome 
171 60S ribosomal protein L9 IPI00031691 21849.80 9.96 0 1 58   Ribosomal 
172 Zn-finger, RING domain containing protein IPI00414712 35574.19 8.54 6 1 57   
Microsomal 
membrane 




174 13 kDa protein IPI00374249 12579.21 10.85 0 1 57   Ribosomal 
175 
Splice Isoform 2 of NADH-ubiquinone oxidoreductase 51 kDa 
subunit, mitochondrial precursor IPI00221298 49836.33 8.51 0 1 56   MIM 
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176 Hypothetical protein FLJ14938 IPI00024642 55838.31 4.76 0 1 56   Unclassified 
177 FLJ00144 protein IPI00383085 28437.22 5.75 0 1 54   Unclassified 
178 Prohibitin IPI00017334 29785.90 5.57 0 1 54   
mitochondrial 
membrane 
179 Aquaporin 1 splice variant 2 IPI00428490 14913.58 5.48 1 1 53   PM 
180 BCG induced integral membrane protein BIGM103 IPI00034208 49598.38 5.71 7 1 53   PM 
181 48 kDa protein IPI00471915 47536.39 11.07 0 2 52   Ribosomal 
182 Hypothetical protein FLJ90397 IPI00171459 36994.10 8.88 0 1 52   Unclassified 
183 FLJ12442 protein IPI00100938 54142.43 6.47 0 1 52   Cytosolic 
184 Actin, cytoplasmic 1 IPI00021439 41709.73 5.29 0 1 52   Cytosolic 
185 RCC2 protein IPI00465044 56049.20 9.02 0 1 51   Nuclear 
186 Calreticulin precursor IPI00020599 48111.82 4.29 0 1 52   Cytosolic 
187 Similar to Translocon-associated protein, delta subunit precursor IPI00644824 13270.66 6.48 1 1 51   ER membrane 
188 Proliferation-associated 2G4, 38kDa IPI00299000 43785.20 6.13 0 1 50   Nuclear 




190 Ubiquitin-specific protease 31 IPI00328815 118956.15 5.75 1 1 48   Nuclear 
191 Der1-like domain containing protein IPI00643745 21238.77 9.69 4 1 48   ER membrane 
192 Phytanoyl-coa hydroxylase IPI00514332 34049.12 9.02 0 1 49   Peroxisome 
193 130 kDa leucine-rich protein IPI00329745 158825.66 5.91 0 1 48   
Nuclear; 
Cytosolic 
194 Hypothetical protein FLJ13940 IPI00017454 27533.68 7.71 0 1 47   Cytosolic 
195 ATP synthase e chain, mitochondrial IPI00218848 7797.28 9.34 1 1 47   
Mitochondrial 
membrane 
196 PREDICTED: similar to dJ753D5.2 IPI00397441 13749.95 9.36 0 1 47   Ribosomal 
197 Erythrocyte band 7 integral membrane protein IPI00219682 31579.70 7.9 1 1 47   PM 
198 Hypothetical protein MGC14288 IPI00176708 6595.25 9.58 1 1 46   Unclassified 
199 Peroxisomal membrane protein 2 IPI00221002 22106.98 10.58 4 1 46   
Peroxisome 
membrane 
200 ALEX3 protein variant IPI00604615 42443.90 8.75 1 1 46   Unclassified  




202 Mitochondrial aspartate-glutamate carrier protein IPI00007084 74256.70 8.79 0 1 45   MIM; PM 
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203 NADH dehydrogenase subunit 5 IPI00221391 66968.42 9.14 15 1 45   MIM 
204 Isoform 2 of Solute carrier family 22, member 11 IPI00418660 48269.11 8.88 6 1 44   PM 
205 Splice isoform Glycophorin D of Glycophorin C IPI00218128 11491.61 4.76 1 1 44   PM 
206 Isocitrate dehydrogenase [NADP], mitochondrial precursor IPI00011107 50876.86 8.88 0 1 44   Mitochondrial 
207 Novel protein IPI00513768 52673.49 9.76 0 1 43   Unclassified 
208 Heparan sulfate 2-O-sulfotransferase 1 IPI00549891 41844.40 8.83 0 1 43   
Nuclear; Golgi; 
IMP 
209 9 kDa protein IPI00376529 9459.86 6.75 1 1 43   
Mitochondrial 
membrane 
210 NADH-ubiquinone oxidoreductase B15 subunit IPI00220059 15068.03 9.85 1 1 42   MIM 
211 Metaxin 1 IPI00013678 51444.59 9.8 1 1 42   MOM; IMP 
212 Guanine nucleotide-binding protein, alpha-13 subunit IPI00290928 44021.66 8.11 0 1 42   PM 
213 13kDa differentiation-associated protein IPI00604532 17073.62 9.63 0 1 42   Mitochondrial 
214 
Full-length cDNA clone CS0DC006YH13 of Neuroblastoma of Homo 
sapiens IPI00009247 8609.50 9.94 1 1 41   Mitochondrial 
215 Splice isoform 1 of Heterogeneous nuclear ribonucleoprotein D0 IPI00028888 38410.30 7.62 0 1 41   Nuclear 
216 Hypothetical protein FLJ32830 IPI00065287 65726.57 9.35 0 1 41   Unclassified 
217 Protein p65 IPI00014168 68575.97 9.67 0 1 41   Nuclear 
218 46 kDa protein IPI00335130 46266.42 7.28 0 1 41   Unclassified 
219 Cleft lip and palate transmembrane protein 1 IPI00396411 76048.46 5.88 5 1 40   PM 
220 Splice isoform 1 of Protein C9orf5 IPI00607576 100881.01 9.03 14 1 40   PM 
221 Novel protein IPI00642244 109351.93 7.94 0 1 40   ER 
222 Mitochondrial ribosomal protein L41 IPI00217553 15372.99 9.58 0 1 40   Ribosomal 
223 Splice isoform B of Chloride channel protein 6 IPI00305252 35910.30 8.03 3 1 41   PM 
224 Splice isoform 1 of Protein C20orf22 IPI00394779 45068.18 8.87 1 1 40   Unclassified 
225 Kelch domain containing protein 1 IPI00383231 46661.73 5.67 0 1 39   
Nuclear; 
Cytosolic 
226 P450-like protein IPI00419579 52399.01 5.84 0 1 39   Cytosolic 
227 Histone H2A.o IPI00216457 13955.85 10.9 0   7 125 Nuclear 
228 Histone H1.2 IPI00217465 21220.71 10.94 0   6 111 Nuclear 
229 Histone H1.4 IPI00217467 21720.96 11.03 0   5 113 Nuclear 
230 Histone H1.5 IPI00217468 22435.43 10.91 0   5 112 Nuclear 
231 Ubiquitin and ribosomal protein S27a IPI00179330 17893.44 9.65 0   5 159 Ribosomal 
232 Histone H1.3 IPI00217466 22205.28 11.02 0   5 103 Nuclear 
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233 Histone H2A IPI00031562 14112.93 11.05 0   7 121 Nuclear 
234 Histone H2B.j IPI00303133 13752.50 10.32 0   9 128 Nuclear 
235 Histone H1.1 IPI00217469 21697.83 10.99 0   4 112 Nuclear 
236 Ribosomal protein S8 IPI00645201 21866.01 10.37 0   4 104 Ribosomal 
237 Hemoglobin gamma-2 chain IPI00554676 15985.25 6.71 0   4 146 Cytosolic 
238 Alpha 2 globin variant IPI00410714 15270.94 8.72 0   5 106 Cytosolic 
239 Hemogen IPI00464963 55278.74 4.82 0   4 101 
Golgi;  
Nuclear 
240 60S ribosomal protein L19 IPI00025329 23451.25 11.48 0   4 89 Ribosomal 
241 HNRPR protein IPI00644055 71170.40 8.23 0   4 73 Nuclear 
242 Ribosomal protein L10 variant IPI00641164 24526.87 10.11 0   5 67 Ribosomal 
243 60S ribosomal protein L17 IPI00413324 21252.29 10.18 0   3 71 Ribosomal 




Splice Isoform 2 of Bromodomain adjacent to zinc finger domain 
protein 1B IPI00216695 170340.38 8.7 0   4 55 Nuclear 
246 ATP synthase, H+ transporting, mitochondrial F0 complex IPI00220487 18479.50 5.21 0   3 90 MIM 
247 25 kDa protein IPI00413986 24735.28 9.8 0   2 81 Ribosomal 
248 Novel protein similar to histone 2, H3c IPI00455457 15420.55 11.27 0   3 47 Nuclear 
249 PREDICTED: similar to 60S ribosomal protein L32 IPI00455900 52270.86 10.1 0   1 118 Ribosomal 
250 Splice Isoform 2 of Syntaxin-7 IPI00552913 27383.66 5.02 0   2 66 
Endosome 
membrane 
251 60S ribosomal protein L35 IPI00412607 14411.52 11.04 0   1 108 Ribosomal 
252 OTTHUMP00000016319 IPI00176681 12179.15 9.3 0   2 76 MOM 
253 50 kDa protein IPI00174849 49540.60 4.75 0   2 80 Mitochondrial 
254 Cytochrome c oxidase polypeptide VIb IPI00216085 10054.68 6.78 0   2 75 
Mitochondrial 
Membrane; 
255 Hypothetical protein DKFZp564K247 IPI00295621 10137.19 9.52 2   1 100 IMP 
256 ATP-dependent RNA helicase DDX18 IPI00301323 75359.44 9.52 0   2 60 Nuclear 
257 Splice Isoform 2 of U1 small nuclear ribonucleoprotein 70 kDa IPI00219483 50587.32 9.9 0   2 53 Nuclear 
258 Histone H1.0 IPI00550239 20719.15 10.84 0   1 91 Nuclear 
259 PREDICTED: similar to 60S ribosomal protein L21 IPI00374234 10973.01 10.97 0   2 51 Ribosomal 
260 18 kDa protein IPI00176755 17696.17 10.44 0   2 44 Ribosomal 
261 
SWI/SNF related matrix associated actin dependent regulator of 
chromatin subfamily A me IPI00297211 121828.36 8.27 0   1 81 Nuclear 
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262 Beta-globin gene from a thalassaemia patient, complete cds IPI00382950 18918.59 6.28 0   2 50 Cytosolic 
263 Hemoglobin delta chain IPI00473011 15914.25 7.97 0   2 50 Cytosolic 
264 CAG-ISL 7 IPI00069693 23417.02 10.94 0   2 45 Ribosomal 
265 Hypothetical protein FLJ32119 IPI00065554 62438.95 9.43 0   1 73 Cytosolic 
266 Splice Isoform 2 of H/ACA ribonucleoprotein complex subunit 1 IPI00607820 20821.40 10.45 0   1 71 Nuclear 
267 60S ribosomal protein L7 IPI00030179 29207.20 10.66 0   2 102 Ribosomal 
268 60S ribosomal protein L22 IPI00219153 14646.76 9.22 0   1 70 Ribosomal 
269 HEAT repeat containing protein IPI00549664 105626.65 9.45 0   1 69 Nuclear 
270 Ribosomal protein L15 IPI00375511 24071.05 11.62 0   2 36 Ribosomal 




272 PREDICTED: similar to 40S ribosomal protein S16 IPI00397701 16401.85 10.05 0   1 64 Ribosomal 
273 NADH-ubiquinone oxidoreductase MWFE subunit IPI00005695 8067.13 8.93 1   1 64 
Mitochondrial 
Membrane  
274 Splice Isoform 2 of Chromodomain helicase-DNA-binding protein 4 IPI00455210 220694.56 5.7 0   1 64 Nuclear 
275 NADH-ubiquinone oxidoreductase 15 kDa subunit IPI00220063 12378.35 9.29 0   1 63 
Mitochondrial 
Membrane  
276 High mobility group protein 4 IPI00217477 22834.40 8.5 0   2 31 Nuclear 
277 NADH dehydrogenase IPI00604684 30141.58 6.25 0   1 60 Mitochondrial 
278 Stromal cell-derived receptor-1 beta IPI00018311 44359.50 8.11 1   1 59 PM 
279 EH-domain containing protein 3 IPI00021458 61857.09 6.06 0   1 57 Nuclear 
280 Protein C10orf70 IPI00020510 12191.20 9.19 1   1 56 Mitochondrial 
281 Splice Isoform 2 of Putative RNA-binding protein Luc7-like 2 IPI00216804 46396.71 10.1 0   1 56 Nuclear 
282 Antibacterial protein FALL-39 precursor IPI00292532 19578.27 9.48 1   1 55 PM  
283 Flap endonuclease-1 IPI00026215 42566.10 8.8 0   2 27 Nuclear 
284 Hypothetical protein FLJ31842 IPI00043429 30020.92 9.4 6   1 54 PM 
285 40S ribosomal protein S15 IPI00216153 16898.13 10.39 0   2 27 Ribosomal 
286 Hypothetical protein FLJ14347 IPI00022300 28266.57 8.7 1   1 53 Unclassified 
287 NADH-ubiquinone oxidoreductase B22 subunit IPI00255052 21685.80 8.59 0   1 54 
Mitochondrial 
Membrane 
288 Splice Isoform 2 of N-acylneuraminate cytidylyltransferase IPI00479958 29543.15 8.59 0   1 52 Unclassified  
289 
NADH-ubiquinone oxidoreductase 23 kDa subunit, mitochondrial 
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290 Dihydroorotate dehydrogenase isoform 2 precursor IPI00607764 22006.30 9.27 1   1 50 MIM 





292 NLN protein IPI00025564 70259.06 8.42 0   1 50 Mitochondrial 
293 Splice Isoform 2 of Myb-binding protein 1A IPI00607584 149273.88 9.34 0   1 49 
Nucleus; 
Cytosolic 
294 Splice Isoform A of Band 4.1-like protein 3 IPI00032230 120603.14 5.09 0   1 48 
PM protein; 
Cytoskeleton 
295 65 kDa protein IPI00478631 64667.14 9.8 0   1 47 Nuclear 
296 ATPase subunit 8 IPI00641145 7972.15 9.93 1   1 47 
Mitochondrial 
membrane 
297 58 kDa protein IPI00556310 57968.46 10.11 0   1 47 Ribosomal 
298 Hypothetical protein DKFZp313B047 IPI00013452 170483.09 7.02 0   1 45 Cytosolic 
299 
Splice Isoform 1 of Voltage-dependent anion-selective channel 
protein 3 IPI00031804 30639.28 8.85 0   1 46 MOM 
300 8 kDa protein IPI00639803 8078.35 9.01 2   1 45 Unclassified 
301 TUBA6 protein IPI00166768 36624.66 8.2 0   1 45 Cytosolic  
302 Splice Isoform long of Dematin IPI00292290 45486.22 8.94 0   1 45 
PM; 
Cytoskeleton 
303 40S ribosomal protein S19 IPI00215780 15919.49 10.31 0   1 44 Ribosomal 
304 Stomatin IPI00377081 13466.03 7.82 1   1 43 PM 
305 ATP synthase, H+ transporting, mitochondrial F1 complex IPI00549805 59771.60 9.07 0   1 42 MIM 
306 Sec61 alpha 1 subunit IPI00218466 52230.51 8.3 10   1 41 ER membrane 
307 Ferritin heavy chain IPI00419501 25207.52 6.33 0   1 41 PM 
308 Vesicular integral-membrane protein VIP36 precursor IPI00009950 40203.10 6.46 1   1 41 
ER membrane; 
Golgi 
309 Cell death-regulatory protein GRIM19 IPI00219685 25804.38 9.82 1   1 40 MIM 
310 40S ribosomal protein S9 IPI00221088 22446.51 10.66 0   1 40 Ribosomal 
311 Pol protein IPI00386255 97621.79 8.89 0   1 39 Cytosolic 
312 Similar to Telomeric repeat binding factor 2 IPI00216552 32277.72 9.6 0   1 37 Nuclear 
313 Ras-related protein Rap-1A IPI00019345 20973.71 6.38 0   1 36 Unclassified 
314 NDUFC2 protein IPI00555919 14164.40 9.04 1   1 36 MIM 
315 Serine/threonine kinase 22B (Spermiogenesis associated) IPI00289715 40971.18 8.95 0     1 36 Cytosolic 
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No. Protein Description 
Accession 
No. TMD Sub-cellular localisation 
1 Membrane associated progesterone receptor component 2 IPI00005202 1 Microsome membrane; Plasma membrane 
2 PRA1 family protein 3 IPI00007426 3 ER Membrane; Plasma membrane 
3 Steroid dehydrogenase homolog IPI00007676 3 Unclassified 
4 Vesicular integral-membrane protein VIP36 precursor IPI00009950 1 ER/Golgi membrane; Plasma membrane 
5 Stromal cell-derived receptor-1 beta IPI00018311 1 Plasma membrane 
6 Neutral amino acid transporter B IPI00019472 9 Plasma membrane 
7 Calnexin precursor IPI00020984 1 ER membrane; Plasma membrane 
8 Azurocidin precursor IPI00022246 0 Plasma membrane 
9 Suppressor of actin 1 IPI00022275 2 ER/Golgi membrane; Plasma membrane 
10 Hypothetical protein FLJ14347 IPI00022300 1 Unclassified 
11 Band 3 anion transport protein IPI00022361 11 Plasma membrane 
12 Transferrin receptor protein 1 IPI00022462 1 Plasma membrane 
13 Membrane protein IPI00026111 2 Unclassified 
14 CAAX prenyl protease 1 homolog IPI00027180 7 ER/Golgi membrane; Plasma membrane 
15 Leukocyte elastase precursor IPI00027769 1 Plasma membrane 
16 Cathepsin G precursor IPI00028064 0 Plasma Membrane 
17 Hypothetical protein DKFZp586C1924 IPI00031064 2 Unclassified 
18 BCG induced integral membrane protein BIGM103 IPI00034208 7 Plasma membrane 
19 Hypothetical protein FLJ31842 IPI00043429 6 Plasma membrane 
20 Thioredoxin-like protein KIAA1162 precursor IPI00100247 1 Plasma membrane 
21 Vitamin K epoxide reductase complex subunit 1-like protein 1 IPI00166079 2 Unclassified 
22 Olfactory receptor 11H4 IPI00168981 7 Plasma membrane 
23 Hypothetical protein MGC14288 IPI00176708 1 Unclassified 
24 Splice Isoform XB of Plasma membrane calcium-transporting ATPase 4 IPI00217169 8 Plasma membrane 
25 Splice Isoform Glycophorin D of Glycophorin C IPI00218128 1 Plasma membrane 
26 Erythrocyte band 7 integral membrane protein IPI00219682 1 Plasma membrane 
27 Solute carrier family 2, facilitated glucose transporter member 1 IPI00220194 12 Plasma membrane 
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28 Kell blood group glycoprotein IPI00220459 1 Plasma membrane 
29 Antibacterial protein FALL-39 precursor IPI00292532 1 Plasma membrane 
30 Hypothetical protein DKFZp564K247 IPI00295621 2 Unclassified 
31 Splice Isoform 2 of Reticulon 4 IPI00298289 2 ER membrane; Plasma membrane 
32 Solute carrier family 43, member 3 IPI00301100 11 ER membrane; Plasma membrane 
33 Splice Isoform B of Chloride channel protein 6 IPI00305252 3 Plasma membrane 
34 Splice Isoform 2 of Synaptophysin-like protein IPI00335277 3 Vesicle membrane; Plasma membrane 
35 Stomatin IPI00377081 1 Plasma membrane 
36 Splice Isoform 2 of Protein GPR107 precursor IPI00382815 7 Plasma membrane 
37 Splice Isoform 1 of Protein C20orf22 IPI00394779 1 Unclassified 
38 Thioredoxin domain containing protein 1 precursor IPI00395887 3 ER membrane; Plasma membrane 
39 Cleft lip and palate transmembrane protein 1 IPI00396411 5 Plasma membrane 
40 Isoform 2 of Solute carrier family 22, member 11 IPI00418660 6 Plasma membrane 
41 Aquaporin 1 splice variant 2 IPI00428490 1 Plasma membrane 
42 Rhesus blood group, CcEe antigens, isoform 1 IPI00465155 12 Plasma membrane 
43 ATP-binding cassette half-transporter IPI00465442 9 Plasma membrane 
44 Equilibrative nucleoside transporter 1 IPI00550382 11 Plasma membrane 
45 
Splice Isoform 1 of Vacuolar proton translocating ATPase 116 kDa subunit a 
isoform 1 IPI00552514 7 Vesicle membrane; Plasma membrane  
46 Splice Isoform 2 of Syntaxin-7 IPI00552913 0 Endosome membrane; Plasma membrane 
47 Vesicle-associated membrane protein 2 IPI00553138 1 
Vesicle membrane; Integral membrane protein; 
Synapse; Mitochondria 
48 
Solute carrier family 3 (activators of dibasic and neutral amino acid 
transport), member 2 IPI00554481 1 Plasma membrane 
49 ALEX3 protein variant IPI00604615 1 Unclassified  
50 Splice Isoform 1 of Protein C9orf5 IPI00607576 14 Plasma membrane 
51 8 kDa protein IPI00639803 2 Unclassified 
52 Microsomal glutathione S-transferase 3 IPI00639812 3 ER/Microsome membrane; Plasma membrane 
53 17 kDa protein IPI00642218 3 ER membrane; Plasma membrane 
54 25 kDa protein IPI00646289 1 Unclassified 
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